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ABSTRACT
Matthew A. Psioda: Statistical Methods for Bayesian Clinical Trial Design and DNA Methylation
Deconvolution
(Under the direction of Joseph Ibrahim and Wei Sun)
We consider the Bayesian clinical trial design problem in situations where a historical trial is
available to inform the design and analysis of a future trial. Currently the FDA requires that
all proposed designs exhibit reasonable type I error control. Traditionally, frequentist type I error
control has been required. This is currently the case in the Center for Drug Evaluation and Research
but no longer in the Center for Devices and Radiological Health. The requirement that a design
exhibit frequentist type I error control necessitates that all prior information be discarded. We
propose several Bayesian solutions that balance the need to control type I errors with the desire to
utilize high quality prior information.
For scenarios where the historical trial informs the parameter being tested, we propose Bayesian
versions of the type I error rate and power that are defined with respect to the posterior distribution
for the parameters given the historical data and conditional on the respective hypothesis being true.
We demonstrate that in designs that control the Bayesian type I error rate, meaningful amounts of
prior information can be borrowed but that the size of the new trial must be relatively large to justify
borrowing a large amount of historical information. We tailor our design methodology for survival
applications using proportional hazards and cure rate models. We also develop Bayesian adaptive
designs for large cardiovascular outcomes trials (CVOTs) which incorporate control information
from a historical CVOT conducted in a similar patient population. We propose an all-or-nothing
adaptive design utilizing the power prior as well as a dynamic borrowing adaptive design utilizing
a novel extension of the joint power prior.
Separately, we present a statistical deconvolution method for DNA methylation data from
bisulfite sequencing experiments. We propose a joint model for methylation data from a set of
iii
heterogeneous tissue samples and another set of reference tissue samples. Unlike other methylation
deconvolution methods, our method allows one to estimate the heterogeneous tissue composition
and provides improved estimates of cell type-specific methylation levels through the process of de-
convolution. We demonstrate our method using data from DNA mixture tissues and simulation
studies.
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CHAPTER 1: INTRODUCTION
In this dissertation we present research on two important but otherwise unrelated topics. The
first topic, which is treated with the most depth, is the problem of Bayesian clinical trial design in
situations where a previously completed clinical trial (i.e. a historical trial) is available to inform
the design and analysis of a future trial. The traditional frequentist approach to clinical trial design
requires that the type I error rate be controlled for every possible null value of the parameters.
However, such control is impossible if one wishes to incorporate any subjective prior information.
We propose several Bayesian design solutions that balance the need to control type I errors with
the desire to utilize high quality prior information for the purpose of decreasing the size or duration
of a future trial.
In Chapters 3 and 4 we propose and apply Bayesian versions of the type I error rate and sta-
tistical power in the design of superiority trials for time-to-event data. These Bayesian operational
characteristics are defined with respect to the posterior distribution for the parameters given the
historical trial data and conditional on the respective hypothesis being true. Chapter 3 focuses
on design (i.e. sample size determination) for time-to-event trials where a proportional hazards
assumption is tenable. Chapter 4 focuses on designs for time-to-event trials where a fraction of the
studied population is “cured” (i.e. immune to having the event).
In Chapter 5 we consider the design of large cardiovascular outcomes trials (CVOTs) utilizing
data from control subjects from a previously completed CVOT (i.e. a historical CVOT). Borrowing
information only through the control arm presents unique challenges. The benefit of randomization
in the new trial is essentially lost and it becomes important to adjust for prognostic factors to help
ensure subjects in the two trials are exchangeable. We develop two Bayesian adaptive designs to
address a potential lack of exchangeability: an all-or-nothing borrowing approach using the basic
power prior (Ibrahim and Chen, 2000) and an adaptive borrowing approach using a novel restricted
maximal borrowing power prior which is a special case of the joint power prior (Ibrahim and Chen,
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2000).
In Chapter 6 we switch our focus to the second topic: statistical deconvolution of DNA methy-
lation levels. In this chapter we present a deconvolution method for DNA methylation data from
bisulfite sequencing experiments. We propose a joint model for methylation data from a set of
heterogeneous tissue samples and a set of reference tissue samples. Unlike other deconvolution
methods, our methods allows one to estimate the heterogeneous tissue composition and provides
improved estimates of cell type-specific methylation levels through the process of deconvolution.
Our method allows one to assess methylation at the cell type level whereas commonly used reference-
free methods do not. We demonstrate our method using real data from DNA mixture experiments
and from simulation studies.
2
CHAPTER 2: LITERATURE REVIEW
2.1 Bayesian Clinical Trial Design
There is a growing demand for principled ways to incorporate knowledge from previously com-
pleted clinical trials in the design and analysis of future trials. Regulatory authorities, such as the
Food and Drug Administration (FDA), are increasingly embracing Bayesian methodology for this
purpose. For example, in 2010 the FDA issued guidance on using Bayesian methods in medical
device clinical trials (Food and Drug Administration, 2010). Recently, additional guidance has
been issued that discusses using Bayesian methods to extrapolate information from adult trials
to pediatric populations (Food and Drug Administration, 2016). At the Center for Devices and
Radiological Health, companies are encouraged to take advantage of good prior information on the
safety and effectiveness of their investigational devices through formal Bayesian analysis (Pennello
and Thompson, 2007). The FDA sees great promise in using Bayesian methods for incorporation
of prior information as well as for conducting adaptive trials (Campbell, 2011).
There is an extensive literature on Bayesian sample size determination methods. Details in
book format can be found in Spiegelhalter et al. (2004). Somewhat outdated reviews are given by
Adcock (1997) and Pezeshk (2003). Brief summaries of more recent work focusing on traditional
Bayesian operating characteristics are as follows:
Wang and Gelfand (2002) formalized a general Bayesian framework that can be used to calculate
the required sample size such that certain characteristics of the posterior meet a specified criteria
based on an assumed sampling model for the data, sampling prior for the parameters, and fitting
prior for the analysis. An example criterion is the average posterior variance criterion (APVC).
For this criterion, one seeks a sample size n such that E
[
var
(
h(θ)
∣∣yn)] ≤  for some chosen  > 0,
where h(θ) is some functional of interest and yn is the data comprised of n observations. The
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expectation is with respect to the prior predictive distribution for the data defined by the sampling
model for the data and sampling prior for the parameters. The authors present two sample size
determination examples. One is based on a survival model with censoring and the other is based on
a logistic regression model. This simulation-based framework has been widely adopted for Bayesian
sample size determination.
Pham-Gia and Turkkan (2003) present a computationally-intensive method to calculate the
exact sample size required so that the expected length of the highest posterior density (HPD)
interval for the difference in two binomial proportions is sufficiently small. M’Lan et al. (2008)
investigate binomial sample size determination using generalized versions of the average length
and average coverage criteria, median length and median coverage criteria, and the worst outcome
criterion (Joseph et al., 1995). They compare sample sizes derived from highest posterior density
intervals and equal-tailed credible intervals. In some cases, they develop closed-form sample size
formulas.
De Santis (2004) considers the problem of choosing the sample size for testing hypotheses using
Bayes factors. The predictive criterion proposed for determining the sample size is maximizing the
probability of obtaining substantial evidence in favor of the true hypotheses (or, equivalently min-
imizing the probabilities of having either misleading or weak evidence). The method is developed
for the normally distributed data and applied to the design of a bladder cancer clinical trial.
Inoue et al. (2005) explore parallels between Bayesian and frequentist methods for determining
sample size. The authors provide a simple but general framework for investigating the relation-
ship between the two approaches, based on identifying mappings to connect the Bayesian and
frequentist inputs necessary to obtain the same sample size. They highlight a somewhat surpris-
ing “approximate functional correspondence” between power-based and information-based optimal
sample sizes.
De Santis (2006) presents a robust Bayesian approach to the sample size determination problem
based on the lower bound, upper bound, and range of posterior quantities of interest. These
characteristics (e.g. the lower bound) are obtained by varying the prior over a class of distributions.
Specifically, the authors aim to select an appropriate sample size that guarantees the researcher
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will observe a small value of the range and either a sufficiently large lower bound or a sufficiently
small upper bound for the posterior quantity of interest.
Clarke and Yuan (2006) give asymptotic expressions for the expected value (under a fixed pa-
rameter) of certain types of functionals of the posterior density. They obtain simple inequalities
which can be solved to give minimal sample sizes needed for various estimation goals. The au-
thors verify that the asymptotic bounds give good approximations to the expected values of the
functionals they approximate.
De Santis (2007) presents a general sample size determination method with a goal of choosing
the minimal sample size that guarantees probabilistic control on the performance of quantities that
are derived from the posterior distribution and used for inference. The author illustrates how the
class of power priors (Ibrahim and Chen, 2000) can be fruitfully employed to deal with lack of
homogeneity between historical data and observations of the upcoming experiment. The authors
discuss the need for discounting prior information and evaluating the effect of heterogeneity on the
optimal sample size. Some of the most popular Bayesian operational characteristics are reviewed
and their use is illustrated in several examples.
Brutti et al. (2008) consider determination of a sample size that guarantees a large posterior
probability that an unknown parameter of interest (e.g. a treatment effect) is greater than a chosen
threshold. The authors argue that a straightforward sample size criterion is to select the minimal
number of observations so that the predictive probability of a successful trial is sufficiently large.
In the paper the authors address sensitivity to prior assumptions by proposing a robust version
of the sample size criterion. Specically, instead of using a single prior distribution, the authors
consider a class of plausible priors for the parameter of interest. Robust sample sizes are then
selected by looking at the predictive distribution of the lower bound of the posterior probability
that the unknown parameter is greater than a chosen threshold. The authors consider classes of
-contamination priors (Berger and Berliner, 1986) for the flexibility and mathematical tractability.
Most of the aforementioned works have focused on computing sample size based on “traditional”
Bayesian operating characteristics (i.e. the APVC). As noted above, regulatory bodies such as the
FDA require evaluation of type I error rates and power as part of a study design proposal so it
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is natural to plan a Bayesian clinical trial where the prior is calibrated to ensure adequate type
I error control and power. The idea that these operating characteristics should be considered for
Bayesian clinical trial designs is not new (Rubin et al., 1984; Box, 1980). A variety of authors have
approached Bayesian sample size determination from the perspective of statistical power and type
I error rates with some attempting to incorporate subjective prior information in the design. Brief
summaries of selected works are as follows:
Spiegelhalter and Freedman (1986) develop sample size determination method which takes into
account prior clinical opinion about the treatment difference. This method adopts the point of
clinical equivalence (determined by interviewing the study participants) as the null hypothesis.
Decision rules at the end of the study are based on whether the interval estimate of the treatment
difference includes the null hypothesis. The prior distribution is used to predict the probabilities
of making the decisions to select one of the two treatments or to reserve final judgment. The
authors advocate that the sample size be chosen to control the predicted probability of reserving
final judgment. An example is presented using normally distributed data from a cancer clinical
trial.
Brown et al. (1987) present a sample size determination method that uses the results of a
historical study to predict the outcome of a subsequent trial in a setting where the response is binary.
The author’s method can be easily generalized to other two-sample cases for which power can be
calculated in closed-form (e.g. exponential survival), and to one-sample cases such as demonstrating
a minimal response rate. Bayesian methods are used to obtain a posterior distribution based on
an analysis of the historical study and this posterior is used as the “state of knowledge” for the
parameters of interest. The probability that the future study will demonstrate treatment superiority
is obtained by using the posterior distribution to compute the average power over the parameter
space.
Weiss (1997) presents an approach to sample size determination that aims to make it a priori
probable that the Bayes factor will be greater than a given cut-off of prespecified size. Similar
to Brown et al. (1987), the approach permits the propagation of uncertainty in quantities which
are unknown (i.e. the true effect size) and permits the computation of power and type I error
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rates either conditionally (i.e. conditional on the effect size being larger than a certain value) or
unconditionally (based on the prior distribution for the effect size). The approach is illustrated for
a one-sided and for a two-sided alternative hypothesis for continuous data with a normal prior.
Chen et al. (2011) develop a sample size determination method specifically for the design of
non-inferiority clinical trials using subject-level historical control data. The authors compare a
hierarchical modeling approach for information borrowing (which necessitates multiple historical
studies) with the power prior approach of Ibrahim and Chen (2000). The authors consider use
of the basic power prior which fixes the amount of information borrowed a priori as well as the
normalized power prior (Duan, 2005; Duan et al., 2006) which attempts to dynamically adjust the
amount of information borrowed from the historical study based on the level of agreement between
the two data sets. We note that the historical studies only provide information on the control group
in the case study and the type I error and power are computed under the implicit assumption that
the generative model for the new study data is consistent with the historical data. Hence the type I
error control demonstrated by the method is not as stringent as traditional frequentist type I error
control. The normalized power prior is a special case of the joint power prior proposed by Ibrahim
and Chen (2000) and it was developed to address some shortcomings of the joint power prior that
were described in Duan (2005).
Hobbs et al. (2011) propose the commensurate power prior which is another extension of the
normalized power prior (Duan, 2005; Duan et al., 2006). The commensurate power prior is quite
different from the normalized power prior in that it does not assume a common parameter in the
models for the historical and new study. Instead the new study parameter is assumed to be normally
distributed about the historical study parameter. The precision parameter in the normal component
of the commensurate power prior is called the commensurability parameter and this parameter is
incorporated into the prior for the parameter that controls the amount of information borrowed (i.e.
the power on the historical study likelihood). The authors compare the frequentist performance
of several informative prior choices using simulations and present an example using a colon cancer
trial that illustrates the adaptive borrowing approach in the case of a linear model. In general the
method does not lead to frequentist type I error control. However, the authors further compare
calibrated versions of their commensurate power prior and other informative priors (including the
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normalized power prior) where all methods control the type I error rate at the nominal level. The
power function with the largest area under the curve was based on the author’s commensurate
power prior. One draw back of the authors approach is that is requires normally distributed data
to apply without approximation. Hobbs et al. (2012) propose extensions to the commensurate
power prior and evaluate the frequentist and Bayesian properties using general and generalized
linear mixed regression models. The authors provide an example analysis of a colon cancer trial
comparing time-to-disease progression using a Weibull regression model. Use of the commensurate
power prior (as well as the normalized power prior and joint power prior) are closely related to
meta-analysis. Determining a sample size for a future study using these meta-analytic priors is
challenging due to the computational burden of fitting models with them. A complete review of
the basic power prior and its generalizations can be found in Ibrahim et al. (2015).
Ibrahim et al. (2012b) develop a Bayesian meta-analysis framework using survival regression
models to assess whether the size of a clinical development program is adequate to evaluate a partic-
ular safety endpoint. Their sample size determination methodology for meta-analysis clinical trial
design focuses on controlling the type I error rate and providing adequate statistical power. Using
the partial borrowing power prior (i.e. the basic power prior where not all parameters are shared
between the new and historical study), the authors incorporate the historical survival meta-data
into the statistical design. The authors develop a simulation-based algorithm for estimating relevant
operational characteristics of the Bayesian meta-analysis trial design. The proposed methodology
is applied to the design of a phase 2/3 development program including a non-inferiority clinical trial
for CV risk assessment in type II diabetes mellitus (T2DM). In Chen et al. (2014a) this methodol-
ogy is extended to a group sequential clinical trial design framework. In both papers the authors
show that minimal information can be borrowed without inflating the type I error rate (e.g. that
one can borrow ≤ 2% of the available information). The version of type I error rate that the
authors attempt to control is essentially the same as in Chen et al. (2011) with the only difference
being that information is being borrowed on the parameter being tested. This key difference makes
information borrowing essentially impossible.
Chen et al. (2014b) propose a Bayesian approach for the design of superiority clinical trials
using recurrent events frailty regression models. Historical recurrent events data from an already
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completed trial are incorporated into the design via the partial borrowing power prior. The authors
develop a simulation-based algorithm for computing various design quantities such as the type I
error rate and power. Similar to Ibrahim et al. (2012b) and Chen et al. (2014a), the results
demonstrate that little information can be borrowed if the design is required to control type I error
in a traditional sense.
2.2 Bayesian Analysis of Proportional Hazards and Cure Rate Models
Bayesian analysis of proportional hazards and cure rate models has been considered by many
authors. We briefly review the relevant literature in this section. A definitive text on Bayesian
survival analysis was provided by Ibrahim et al. (2001b). This text includes extensive discussion
on Bayesian analysis of proportional hazards models as well as cure rate models.
Bayesian analysis of the Cox partial likelihood (Cox, 1975) dates back to the work of Kalbfleisch
(1978) who was the first to give a fully Bayesian justification. A definitive work on Bayesian
justifications of the partial likelihood was given by Sinha et al. (2003). Therein the authors establish
new (both naive and formal) Bayesian justifications for the Cox partial likelihood and its various
modifications. The authors consider cases with time-dependent covariates, time-varying regression
parameters, continuous time survival data, and grouped survival data. In addition, the authors
present a Bayesian justification of a modified partial likelihood for handling ties.
Ibrahim and Chen (1998) propose a class of informative prior distributions for a proportional
hazards model. A novel construction of the prior is developed based on the notion of the availability
of historical data and using the power prior. This work discussed using the power prior several years
before the work of Ibrahim and Chen (2000), wherein the power prior was formalized. The authors
took a semi-parametric approach for modeling the baseline hazard which has become standard for
Bayesian proportional hazards models. They also developed an efficient Gibbs sampling framework
for model fitting.
Cure rate models date back to Berkson and Gage (1952) where the mixture cure rate model
was formalized. The authors develop a simple mixture model for survival data where an unknown
fraction of subjects are “cured” and the remaining complement have survival times governed by an
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exponential survival distribution. The class of promotion time cure rate models are an important
subclass of mixture cure rate models. The promotion time cure rate model was originally proposed
by Yakovlev et al. (1993). These models have a natural biological motivation based on a latent
competing risk framework where metastasis competent tumor cells (that survive treatment) define
the competing risks.
Bayesian analysis of promotion time cure rate models was considered first by Chen et al. (1999).
The authors provide a thorough discussion of the natural motivation and interpretation of the
model and derive several novel properties of it. In particular, the authors show that the model has
a proportional hazards structure on the marginal subhazard when the cured fraction is modeled
as a function of covariates. They also establish a mathematical connection with the standard
mixture cure rate model. They discuss prior elicitation in some detail and propose classes of
non-informative and informative prior distributions (the power prior being among them). Several
theoretical properties of the proposed priors and resulting posteriors are derived.
Ibrahim et al. (2001a) extend the Bayesian version of the promotion time cure rate model given
in Chen et al. (1999). Specifically, the authors propose a semi-parametric cure rate model with
a smoothing parameter that controls the degree of parametricity in the right tail of the survival
distribution. The authors argue that such a parameter is important for these models and can
influence posterior estimates. Several novel properties of the proposed model are derived and a
class of informative priors based on historical data is proposed (i.e. the power prior). A case study
involving a melanoma clinical trial is discussed in detail to demonstrate the proposed methodology.
Chen et al. (2002a) provide an interesting comparison of several Bayesian models for time-to-
event data. They consider a piecewise exponential baseline hazard proportional hazards model, a
fully parametric cure rate model, and a semi-parametric cure rate model. For each model, they
derive the likelihood function and examine some of its properties for carrying out Bayesian inference
with non-informative priors. They also examine model identifiably issues and give conditions which
guarantee identifiably. The authors compare the performance of the models based on the conditional
predictive ordinate (CPO) which is defined using the posterior predictive distribution for each data
point based on the posterior with that data point left out. The authors perform a detailed case
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study using the E1690 clinical trial (Kirkwood et al., 2000).
Ibrahim et al. (2012a) consider a joint analysis of the E1684 clinical trial (Kirkwood et al.,
1996) and the E1690 clinical trial (Kirkwood et al., 2000) using cure rate models and the power
prior. This was an interesting application of Bayesian methods to synthesize information from two
clinical trials but it did not address how to design a future trial given information from a previously
completed clinical trial.
2.3 DNA Methylation Deconvolution
The concept of DNA methylation deconvolution arises in two types of studies. In studies aimed
at identifying associations between DNA methylation and phenotypes of interest (e.g. comparing
diseased cases and healthy controls), researchers generally measure methylation levels using het-
erogeneous tissue samples, such as blood, which can be collected easily. The tissue samples are
heterogeneous in the sense that they are comprised of several (possibly many) functionally distinct
cell types with each having a potentially distinct DNA methylation signature that may or may not
be associated with the disease phenotype. For example, blood contains many different types of
white blood cells, including neutrophils, basophils, eosinophils, lymphocytes, and monocytes. In
addition to white blood cells, organs such as the liver can contribute significantly to the circulating
pool of DNA in blood (Lo et al., 1998). Presumably, each cell type represented in a heterogeneous
tissue contributes DNA for the methylation measurement in accordance with its relative abun-
dance in the tissue sample. If the cell types comprising a set of heterogeneous tissue samples have
functionally different methylation signatures, as they do in blood (Reinius et al., 2012; Houseman
et al., 2012), it is critically important to control for cell type composition in analyses that attempt
to establish associations between tissue-level methylation and phenotypes of interest. This fact is
increasingly appreciated and it has been argued that many purported associations between age and
DNA methylation can be attributed to tissue composition bias that was poorly addressed in the
analysis (Jaffe and Irizarry, 2014).
In studies aimed at identifying associations between tissue composition and phenotypes of in-
terest, DNA methylation can be used to facilitate estimation of heterogeneous tissue composition.
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In this setting, the DNA methylation levels of the constituent cell types are not of direct interest.
Rather, the cell type-specific DNA methylation levels simply offer a means to estimate the het-
erogeneous tissue’s composition. For example, Sun et al. (2015) performed a tissue composition
study in hepatocellular carcinoma (HCC) and observed increased levels of liver DNA in plasma
from cancer patients compared to healthy controls. Tissue composition studies require estimates
for the DNA methylation levels of the constituent cell types. These estimates typically comes from
reference tissue samples that are comprised predominately of one cell type though they are gener-
ally not perfectly homogeneous (Reinius et al. (2012), supplemental table 2). The reference tissues
are constructed through a procedure such as fluorescence activated cell sorting (FACS), which can
be laborious. As a result, reference tissues often have few replicates (biological or technical). In
the case of bisulfite sequencing data, there are often no replicates of any kind.
Broadly speaking, one may define DNA methylation deconvolution as the process of estimating
cell type-specific methylation levels and/or heterogeneous tissue composition using DNA methyla-
tion levels measured from heterogeneous tissue samples. The statistical approaches developed for
these studies generally fall into two classes: reference-based and reference-free methods. Reference-
based methods can be utilized for both types of studies described above whereas reference-free
methods are generally only useful for studies attempting to associate tissue-level methylation with
phenotypes of interest.
Reference-based methods use a set of reference samples from homogeneous cell type tissues
corresponding to the cell types thought to be in the heterogeneous tissues. The reference tis-
sue samples serve as the basis for deconvolution. Houseman et al. (2012) proposed the most
widely used method to estimate cell-type composition in blood. The method was designed for the
Infinium R©HumanMethylation27 BeadChip and a set of reference samples was published along with
the statistical methodology. In the publication, the authors identified a subset of probes that were
informative for the white blood cell types and these probes were used in the deconvolution process.
Jaffe and Irizarry (2014) extended the method by augmenting the selected probe set based on the
Infinium R©HumanMethylation450 BeadChip, which is newer and more popular. The Houseman
reference-based method is similar in spirit to a regression calibration method and is based on a
set of three linear models. Following Houseman et al. (2012), the model for the reference cell type
12
tissue methylation levels is
Y0h = β0w0h + 0h
where Y0h is an m× 1 vector of methylation values corresponding to homogeneous cell type tissue
sample h, w0h is a d0 × 1 ANOVA type covariate vector that identifies the cell type to which a
measurement corresponds, β0 is a m×d0 matrix of average methylation values for the d0 cell types
at the m loci, and 0h is a vector of errors. The model for the heterogeneous tissue methylation
levels is
Y1i = β1z1i + 1i
where Y1i is a m× 1 vector of methylation values corresponding to heterogeneous tissue sample i,
z1i is a d1 × 1 covariate vector, β1 is a m× d1 matrix, and 1i is a vector of errors. The surrogacy
model is given by
β1 = 1mγ
T
0 + β0Γ + U
where Γ is a d0 × d1 matrix that summarizes the associations between the rows of β0 and β1, γ0
is a d1 × 1 vector and U is a matrix of errors. The author shows that, under some conditions,
one can estimate the cell type compositions of the heterogeneous tissues from this model. The key
assumption is that E [Y1i | z1i] can be written as
E [Y1i | z1i = z] = ξ(z) +
d0∑
k=1
b0,kω
(z)
k
where β0 = (b0,1, . . . ,b0,d0), ω
(z)
k is the cell type k mixture fraction in the tissue, and ξ
(z) is an
m×1 vector that is orthogonal to the column space of β0. The authors show that the orthogonality
assumption can be verified to some degree through sensitivity analysis but that bias results when it
does not hold. As noted above, the extension of this method by Jaffe and Irizarry (2014) was simply
to select an appropriate set of m probes from the newest Infinium R©BeadChip technology. While
Houseman’s method attempts to account for the fact that reference samples provide estimates of the
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true average cell type methylation levels, it does not produce refined estimates of those methylation
levels by incorporating information from the heterogeneous tissues.
In a study of methylation levels in rheumatoid arthritis patients, Liu et al. (2013) attempted
to adjust for cell type composition using estimates from the Houseman referenced-based method
in a simple linear regression model. Jaffe and Irizarry (2014) demonstrated this may be a poor
approach. Jaffe and Irizarry (2014) also consider a surrogate variables approach, named RUV
(Gagnon-Bartsch and Speed, 2012), that out performed the naive method of adjustment used by
Liu et al. (2013). Application of the RUV method still resulted in significant confounding compared
to a gold standard approach based on FACS. The RUV approach attempts to remove unwanted
variation (hence the name) based on a set of negative control probes. Note that the RUV approach
was not designed to solve the deconvolution problem and so the poor performance is not surprising.
Similar approaches to that used by Liu et al. (2013) have been proposed by others. For example,
Montan˜o et al. (2013) and Guintivano et al. (2013) propose methods specifically for brain tissue
that use data from the CHARM array (Irizarry et al., 2008).
The second class of statistical methods are reference-free. This class of methods has the same
goal as the reference-based methods used by Liu et al. (2013), Montan˜o et al. (2013), and Guinti-
vano et al. (2013) in that they attempt to provide a valid comparison of tissue-level methylation by
adjusting for cell type composition. However, as suggested by their name, reference-free methods
do so without requiring reference samples. Houseman et al. (2014) employ a singular value decom-
position (SVD) to separate cell-composition effects from the effect of interest. Zou et al. (2014) use
a similar approach but the role of dependent and independent variables are reversed. The potential
utility of reference-free methods is obvious. They do not require the potentially burdensome step
of obtaining reference tissue samples. However, reference-free methods cannot provide information
about cell type-specific methylation levels which is ultimately the level of granularity that is of
greatest biological importance. Moreover, the reference-free methods are designed to detect so-
called direct effects which may not fit the biological process under study. Houseman et al. (2014),
propose the model
Y = BXT + MΩT + E
14
Ω = XΓ + Ξ
where Y is an m × n matrix of methylation values, B is an m × p matrix of direct epigenetic
effects, Γ is a p × k coefficient matrix representing cell-proportion effects, X is a n × p matrix of
covariates, M is an m × k matrix of cell type-specific mean methylation values (falling between 0
and 1), Ω is an n× k matrix of of subject-specific cell proportions, E is an m× n matrix of errors,
and Ξ is an n× k matrix of errors. The authors state that in adjusted epigenome-wide association
studies (EWAS), B is of direct interest. These direct affects can be interpreted as covariate effects
that influence methylation levels in all cell types in the heterogeneous tissue equally and hence
are not mediated by cell composition. However, since the covariates may also be associated with
compositional differences, it is important to correct for tissue composition in the analysis. While
such direct affects may indeed exist, we find it more reasonable to posit that covariates (e.g. disease
phenotype) may influence the methylation level for one or more cell types in the tissue. Such cell
type-specific methylation effects are harder to study but may be more biologically meaningful. The
reference-free method proposed by Houseman et al. (2014) was used by Charlton et al. (2014) in
the study of Wilms tumors. Houseman et al. (2015) provide an review-like discussion of DNA
methylation deconvolution using the Infinium R©BeadChip data.
Recently deconvolution using bisulfite sequencing (BS-seq) data has been studied. This type
of data presents unique challenges. For methylation data collected using Infinium R©BeadChip
technology, multiple replicates for reference tissues are typically available (e.g. data from Houseman
et al. (2012) and Reinius et al. (2012)). However, for BS-seq data, reference tissues generally do not
have replication making the method of Houseman et al. (2012) impossible to apply with adaptation.
Sun et al. (2015) use a quadratic programming approach (Van den Meersche et al., 2009) to solve
a simultaneous system of equations constructed using methylation estimates from heterogeneous
tissue samples using 14 reference tissue samples: liver, lungs, esophagus, heart, pancreas, colon,
small intestines, adipose tissues, adrenal glands, brain, T cells, B cells, neutrophils, and placenta.
The majority of these data were collected as a part of the NIH Roadmap Epigenomics project
(Bernstein et al., 2010) and do not have replicates (biological or technical) although some of the
reference tissue samples are pooled from multiple donors. Using these reference tissues the authors
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identified a set of 5,820 genomic regions (500bp in length) that were informative of the 14 reference
tissue types. For each region the methylation level in each of the samples was estimated as the
percentage of all CpGs that were methylated. Then, for heterogeneous tissue sample s = 1, ..., S,
the following linear system was solved
Ys = Mρs
where Ys is a m × 1 vector of estimated methylation levels in heterogeneous tissue sample s at
the m genomic regions, M is the m× k matrix of estimated methylation levels for the k reference
samples considered in a given deconvolution problem (k was generally 5-6, not 14) and ρs was the
unknown k×1 vector of tissue composition fractions that satisfied the constraints that 0 ≤ ρs,j ≤ 1
for j = 1, ..., k and
∑k
j=1 ρs,j = 1. The authors first demonstrated their method was able to recover
the composition fractions of DNA mixture tissues. Then, the authors demonstrated their method
on a real data set comprised of plasma samples from 15 pregnant women (five from each trimester)
and validated their ability to estimates the placental composition in the mother’s blood plasma
using paternally inherited fetal SNP alleles that were not possessed by the mother.
Ziller et al. (2013) use a similar quadratic programming algorithm to deconvolve in silico mix-
tures of HUES64 and hippocampus whole genome bisulfite sequencing (WGBS) libraries (i.e. het-
erogeneous tissues constructed by combining reads from sequenced HUES64 and hippocampus
libraries). The work of Sun et al. (2015) and Ziller et al. (2013) both focus on statistical decon-
volution as a method for estimating the composition of a heterogeneous tissue. The quadratic
programming approaches does not take into account the fact that the reference tissues provide
estimates of average methylation level for a tissue type and so these approach could suffer from
some degree of measurement error bias. The quadratic programming approach used by Sun et al.
(2015) and Ziller et al. (2013) has been previously proposed for gene expression data by Gong et al.
(2011) and others.
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CHAPTER 3: BAYESIAN DESIGN OF A SURVIVAL TRIAL UNDER
A PROPORTIONAL HAZARDS ASSUMPTION USING HISTORICAL DATA
3.1 Introduction
There is a growing demand for principled ways to incorporate knowledge from previously com-
pleted clinical trials in the design and analysis of future trials. Regulatory authorities, such as
the Food and Drug Administration (FDA), are increasingly embracing Bayesian methodology for
this purpose. For example, in 2010 the FDA issued guidance on using Bayesian methods in medi-
cal device clinical trials (Food and Drug Administration, 2010). Recently additional guidance has
been issued that discusses using Bayesian methods to extrapolate information from adult trials to
pediatric populations (Food and Drug Administration, 2016).
We consider Bayesian design of a superiority survival trial in a situation where a previously
completed clinical trial (i.e. a historical trial) is available to inform the design and analysis of the
new trial. During design one must identify appropriate values of the controllable trial characteristics
such as the number of subjects to enroll and the number of events required for analysis. An appro-
priate statistical methodology must also be proposed for hypothesis testing. These choices are made
to ensure the trial design has desirable operating characteristics. For confirmatory trials, the pri-
mary operating characteristics of interest are the type I error rate and statistical power. Currently
the Food and Drug Administration (FDA) requires that all proposed trial designs demonstrate rea-
sonable type I error control. Traditionally, frequentist type I error control has been required. This
is currently the case for the Center for Drug Evaluation and Research but no longer for the Center
for Devices and Radiological Health where fully Bayesian approaches are common. For a design
to exhibit Frequentist type I error control, the type I error rate cannot exceed some pre-specified
threshold for any possible null value of the parameters. The requirement to have frequentist type
I error control is not an issue for objective Bayesian designs (i.e. designs utilizing non-informative
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priors that are designed to yield good frequentist operating characteristics). In contrast, Bayesian
hypothesis testing using informative priors directly conflicts with the frequentist notion of type I
error control. As our empirical results will demonstrate, ensuring frequentist type I error control
necessitates that all prior information be discarded. See Appendix A.1 for a proof of this result in
a sample case.
As a solution to this predicament, we propose a design methodology that yields Bayesian type
I error control. Unlike the traditional frequentist approach, our Bayesian approach controls a
weighted average type I error rate with weights determined by the posterior distribution of the
parameters given the historical data and conditional on the null hypothesis being true. Such an
approach is sensible when one has pertinent information about the null and alternative hypotheses
(in the form of data from a previously completed trial) and when one still wants to protect against
type I errors in a equitable way. The Center for Devices and Radiological Health will consider
designs that control a Bayesian version of type I error when the historical data are of high quality
(Pennello and Thompson, 2007). We demonstrate that in a design that has Bayesian type I error
control, meaningful amounts of prior information can be incorporated into the design and analysis
of the new trial. However, borrowing the prior information is not free. When the historical data are
informative about the parameter being tested, the size of the new trial must be relatively large to
justify borrowing a large fraction of the available information. We also introduce a complementary
Bayesian version of statistical power, defined as a weighted average statistical power with weights
determined by the posterior distribution of the parameters given the historical data and conditional
on the alternative hypothesis being true. We demonstrate that designing a trial to have adequate
Bayesian power can lead to a much more conservative sample size than designing a trial to have
adequate power based on fixed values of the parameters, such as their posterior means given the
historical data.
The trial design methodology we present in this chapter is essentially a Bayesian sample size
determination method. There is a large literature on Bayesian sample size determination methods.
Adcock (1997) gave an early review. More recent contributions include Rahme and Joseph (1998),
Rubin and Stern (1998), Katsis and Toman (1999), Simon (1999), Wang and Gelfand (2002),
Pham-Gia and Turkkan (2003), Spiegelhalter et al. (2004), Inoue et al. (2005), Clarke and Yuan
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(2006), De Santis (2007), M’Lan et al. (2008), Chen et al. (2011), Ibrahim et al. (2012b), Chen
et al. (2014a), and Chen et al. (2014b). Much of this literature focuses on simple models including
one and two sample normal or binomial models, linear regression models, and generalized linear
regression models. Comparatively little has been done with survival models for right-censored
data. Notable exceptions are Ibrahim et al. (2012b), Chen et al. (2014a), and Chen et al. (2014b).
Bayesian designs which control type type I error in some sense have been recently considered by
Chen et al. (2011), Ibrahim et al. (2012b), Chen et al. (2014a), and Chen et al. (2014b). The
approach to type I error control considered by these authors is closely related to frequentist type I
error control and hence, is quite different from the approach that we propose.
Our design methodology utilizes a stratified proportional hazards regression model with a flexi-
ble piecewise constant baseline hazard for each stratum. Information is borrowed from the historical
trial by way of the power prior of Ibrahim and Chen (2000). Bayesian analysis of proportional haz-
ards models using the power prior has been considered in Ibrahim and Chen (1998), Ibrahim et al.
(2001b), and Chen et al. (2002a). However, our work offers key new insights. We obtain a previously
unrecognized closed-form for the posterior distribution of the hazard ratio regression parameters
and establish a new connection between this posterior and the weighted Cox partial likelihood
(Cox, 1975). By virtue of being able to integrate out the baseline hazard analytically, we are able
to develop an efficient simulation-based design methodology that avoids Markov Chain Monte Carlo
(MCMC) methods through an accurate normal approximation to the posterior distribution for the
hazard ratio regression parameters.
The rest of this chapter is organized as follows: In Section 3.2 we develop a general cumulative
hazard model for survival data under a proportional hazards assumption and derive the corre-
sponding likelihood. In Section 3.3 we derive a closed-form for the posterior distribution of the
hazard ratio regression parameters (up to normalizing constant) and we discuss a new connection
between this posterior and the weighted Cox partial likelihood. In Section 3.4 we formally define
our Bayesian versions of type I error and power and discuss the simulation process for determining
an appropriate set of controllable trial characteristics for the future trial. Section 3.5 presents a
detailed example of our methodology using data from a previously published clinical trial. We close
the chapter with some discussion in Section 3.6.
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3.2 The Piecewise Constant Hazard Proportional Hazards Model
We consider a flexible proportional hazards model where the baseline hazard is allowed to vary
across S levels of a stratification variable. The cumulative hazard for subject i of n is given by
Λi (t) = Λ[si] (t) exp
(
γzi + β
Txi
)
(3.2.1)
where si is the stratum to which subject i belongs, Λ[s] (t) is the baseline cumulative hazard for
stratum s, zi is a binary treatment indicator, xi = (xi1, ..., xip) is a p × 1 vector of baseline
covariates, γ is the log hazard ratio for treatment versus control, and β = (β1, ..., βp) is a p × 1
vector of regression coefficients.
Let λ[s] (t) denote the piecewise constant baseline hazard for stratum s. We partition the time
axis into Ks intervals according to the change points 0 = ts,0 < ts,1 < .... < ts,Ks = ∞ and let
λsk > 0 denote the constant hazard value over interval Is,k = (ts,k−1, ts,k]. We denote the set of all
baseline hazard parameters by λ and all model parameters by θ = (λ,β, γ). We refer to this model
in its entirety as the piecewise constant baseline hazard proportional hazards model (PWC-PH)
model. The PWC-PH model is commonly used in Bayesian survival analysis when the proportional
hazards assumption is tenable (Ibrahim et al., 2001b).
Let ti and ci be the time-to-event and time-to-censorship for subject i, respectively. We assume
ci is independent of ti conditional on (zi,xi). For subject i, we define yi = min (ti, ci) to be the
observation time, νi = I [ti ≤ ci] to be the indicator that an event was observed, νik to be the
indicator that the event occurred in interval Isi,k, and rik to be the subject’s time at risk in interval
Isi,k. We denote the set of indices corresponding to subjects from stratum s by Gs. The likelihood
can be written as follows:
L (θ |D) ∝
n∏
i=1
{
λ[si] (yi)φi
}νi exp [−Λ[si] (yi)φi]
∝
S∏
s=1
Ks∏
k=1
λαsksk e
−βskλsk ×
n∏
i=1
φνii (3.2.2)
where αsk =
∑
i∈Gs νik is the total number of events for subjects from stratum s occurring in
20
interval Is,k, φi = exp
(
γzi + β
Txi
)
is the hazard ratio regression function for subject i, βsk =∑
i∈Gs φirik is the sum of scaled risk times for subjects from stratum s in interval Is,k, and D =
{(yi, νi, zi,xi) : i = 1, ..., n} is the observed data. For each stratum we assume the partition of
the time axis is known so that νik and rik are known given yi and νi. Note the factorization
of the likelihood in (3.2.2). The left term is a product of
∑S
s=1Ks independent gamma kernels
(conditional on the hazard ratio regression parameters) and the right term is a function of the
hazard ratio regression parameters that does not depend on the baseline hazard. We will exploit
this factorization to obtain a closed-form marginal distribution for the hazard ratio regression
parameters in Section 3.3.
3.3 The Posterior Distribution under the Basic Power Prior
We consider the case where a single historical trial is available to inform the design and analysis
of the future trial. The basic form of the power prior is as follows:
pi0
(
θ
∣∣D0, a0) ∝ [L(θ|D0)]a0 pi0(θ) (3.3.1)
where 0 ≤ a0 ≤ 1 is a fixed scalar parameter, D0 is the historical data, L(θ|D0) is the likelihood
for θ given the historical data, and pi0(θ) is an initial prior for θ. When a0 = 0 the historical data is
essentially discarded and the power prior reduces to the initial prior. In contrast, when a0 = 1 the
power prior corresponds to the posterior distribution from an analysis of the historical data using
the initial prior. For intermediate values of a0 the weight given to the historical data is diminished
to some degree leading to a prior for the new trial that is more informative than the initial prior
but less informative than using the historical trial posterior as the prior for the new trial.
The power prior is appealing for many reasons, not the least of which is the fact that it provides
a semi-automatic mechanism for transforming historical data into a prior for subsequent analyses.
One only needs to elicit a value for a0 for the prior to be fully specified. Often the value of a0 is
determined a priori to ensure the trial design has some desired operating characteristic. In our case,
we will maximize a0 under the constraint that the trial design has Bayesian type I error control.
For a complete review of the basic power prior and its generalizations see Ibrahim et al. (2015).
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We consider the same PWC-PH model for the historical trial that was given in (3.2.1). For
now, we assume that all parameters are shared. We discuss other scenarios in Appendix A.2. A
default improper initial prior is obtained by taking
pi0 (θ) ∝ pi0 (γ,β)× pi0 (λ)
with pi0 (γ,β) ∝ 1 and pi0 (λ) ∝
∏S
s=1
∏Ks
k=1 λ
−1
sk . The prior for λ, when applied to a simple PWC
hazard model, is the Jeffreys prior (Jeffreys, 1946). The resulting joint posterior is proper as long as
at least one event is observed in every interval for each stratum. A proper alternative is obtained by
taking pi0 (γ,β) ∝ Normal (0,Σ0) with Σ0 = σ20 · I and pi0 (λ) ∝
∏S
s=1
∏Ks
k=1 Gamma (λsk | δ0, δ0).
For the proper priors to be non-informative, one would take σ20 to be large and δ0 to be small
(inverse scale parametrization). In what follows we employ the improper prior, though derivations
are similar for the proper prior.
For subject j of n0 in the historical trial we let sj be the subject’s stratum, νj,0 be the indicator
that an event was observed, νjk,0 be the indicator that the event occurred in interval Isj ,k, and rjk,0
be the subject’s time at risk in interval Isj ,k. We let Gs,0 denote the set of indices corresponding to
historical trial subjects in stratum s. The power prior can be written as follows:
pi (θ |D0, a0) ∝
S∏
s=1
Ks∏
k=1
λ
αsk,0−1
sk e
−βsk,0λsk ×
n0∏
j=1
φ
a0νj,0
j (3.3.2)
where αsk,0 = a0
∑
j∈Gs,0 νjk,0, βsk,0 = a0
∑
j∈Gs,0 φjrjk,0, and D0 is the observed data for the
historical trial. We refer to αsk,0 as the effective number of events borrowed from the historical
trial. Note that the likelihood factorization that was obtained in (3.2.2) is also exhibited by the
power prior.
It is straightforward to show that the posterior distribution has the form
pi (θ |D,D0, a0) ∝ pi (λ | γ,β,D,D0, a0)× pi (γ,β |D,D0, a0)
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where
pi (λ | γ,β,D,D0, a0) ∝
S∏
s=1
Ks∏
k=1
Gamma
(
λsk
∣∣∣∣α∗sk, β∗sk) (3.3.3)
and
pi (γ,β |D,D0, a0) ∝
S∏
s=1
{∏
i∈Gs φ
νi
i
∏
j∈Gs,0 φ
a0νj,0
j∏Ks
k=1
[
β∗sk
]α∗sk
}
(3.3.4)
with α∗sk = αsk+αsk,0 and β
∗
sk = βsk+βsk,0. This result is obtained by combining the gamma kernels
from (3.2.2) and (3.3.2), appropriately normalizing each of the resulting conditionally independent
gamma kernels, and absorbing the counterbalancing reciprocal terms into the marginal posterior
for the hazard ratio regression parameters. The factorization of the joint posterior that we have
uncovered is a desirable feature. If one considers λ a nuisance parameter then they can work directly
with (3.3.4). This is appealing for trial design since the success or failure of the trial depends on
inference for γ after integrating out all other parameters.
3.3.1 A Connection with the Weighted Cox Partial Likelihood
We can make an explicit connection between the marginal posterior for the hazard ratio re-
gression parameters under the PWC-PH model and the weighted Cox partial likelihood. Under
a particular data-dependent partition of the time axis, the marginal posterior in (3.3.4) is equal
to the Breslow approximation of the weighted Cox partial likelihood (Breslow, 1974). For ease of
exposition, we take S = 1 and omit the notation for the stratification variable. Our arguments
trivially extend to the stratified model (S > 1).
We partition the time axis into K intervals where K is the number of unique event times from
the combined studies and take the upper bound tk of each interval Ik to be the k
th ordered event
time. We assume that all subjects not experiencing an event are administratively censored at time
tK and that no other censoring occurs. Thus, all subjects who are at risk in time interval Ik have
risk time equal to tk − tk−1. Without loss of generality, we combine the n + n0 subjects from the
two studies into a single set indexed by i with weight wi equal to 1 for new trial subjects and equal
to a0 for historical trial subjects. Let Dk be the set of indices for the subjects having an event at
time tk and let Rk be the set of indices for the subjects at risk in time interval Ik. Under these
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assumptions, the marginal posterior in (3.3.4) may be reformulated as follows.
pi (γ,β |D,D0, a0) ∝
∏n+n0
i=1 φ
wiνi
i∏K
k=1
(∑n+n0
i=1 wiφirik
)∑n+n0
i=1 wiνik
∝
K∏
k=1
∏
i∈Dk φ
wi
i(∑
i∈Rk wiφi
)∑
i∈Dk wi
(3.3.5)
The reader will note that (3.3.5) is the weighted approximate partial likelihood with event time
multiplicity handled according to Breslow. If the historical trial is ignored altogether (a0 = 0),
the marginal posterior for the hazard ratio parameters is simply the Breslow approximation to the
Cox partial likelihood based on the new trial data. Though we may be the first to point out the
connection between the marginal posterior for the hazard ratio regression parameters in a PWC-PH
model using the power prior to the weighted Cox partial likelihood, the idea that the Cox partial
likelihood has a Bayesian justification is not new (Sinha et al., 2003).
In practice, the conditions that we have assumed for the purposes of our derivation will not be
met exactly. For example, one might partition the time axis using a small to moderate number of
change points rather than one change point per unique event time. In addition, non-administrative
censoring may occur. The impact of the time axis partition and non-administrative censoring on
the degree of agreement between the marginal posterior for the hazard ratio regression parameters
and the weighted Cox partial likelihood is not easy to characterize analytically but our experience
and simulations suggest that the agreement will be strong in most practical cases. Thus, Bayesian
inference using the PWC-PH model with the power prior will be approximately the same as Bayesian
inference using the weighted Cox partial likelihood. We demonstrate this with a simulation study
in Appendix A.3.
3.4 Simulation-Based Bayesian Design of a Superiority Study
The null and alternative hypotheses for a superiority trial are as follows:
H0 : γ ≥ 0 versus H1 : γ < 0
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where γ is the log-hazard ratio for treatment versus control. We accept H1 if
P (γ < 0 |D,D0, a0) = P (H1 |D,D0, a0) (3.4.1)
is at least as large as some critical value ψ. Both ψ and a0 are pre-specified constants. During
design, we examine various possible values for the number of events required in the new trial
(denoted by ν), a0, and ψ in search of a set of values that yield sufficient Bayesian power while
controlling the Bayesian type I error rate at no more than α. We refer to the set of values {ν, a0, ψ}
as the key controllable trial characteristics. We note that increasing of the number of enrolled
subjects n ≥ ν will decrease the time required to complete the trial, but will have virtually no
impact on the operating characteristics of primary interest.
We will set ψ equal to 1− α and attempt to find the maximum value of a0 for a given value of
ν subject to the Bayesian type I error rate restriction. Our choice of ψ is justified by the fact that
the posterior probability P (γ < 0 |D,D0, a0 = 0) will be approximately uniformly distributed in
large samples when γ = 0 and the model is correct. In other words, the posterior probability of
the alternative hypothesis (under no borrowing) has the same asymptotic distribution as a fre-
quentist p-value when the null hypothesis is true. Accordingly, rejecting the null hypothesis when
P (γ < 0 |D,D0, a0 = 0) ≥ ψ = 1 − α should provide frequentist type I error control (asymptot-
ically). Rigorous exposition on the asymptotic distribution of so-called posterior probabilities of
the half-space can be found in Dudley and Haughton (2002). In this light, one can view our design
procedure as starting out with a size α frequentist hypothesis test (based on taking a0 = 0) and
then modifying the test by borrowing increasing amounts of information from the historical trial
until it functions as a size α hypothesis test with respect to the Bayesian type I error rate.
3.4.1 Definition of the Bayesian Type I Error Rate and Power
In order to formally define the Bayesian type I error rate and Bayesian power, we first introduce
the concepts of sampling and fitting priors that were formalized by Wang and Gelfand (2002) and
extended by Chen et al. (2011) to investigate Bayesian type I error and power. Let pi
(s)
0 (θ) and
pi
(s)
1 (θ) be the null and alternative sampling priors and let pi
(f) (θ) be the fitting prior. A sampling
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prior specifies a probability distribution for θ conditional on a particular hypothesis being true.
Hence, the null sampling prior will give zero weight to values of θ having a negative γ component
and the alternative sampling prior will give zero weight to values of θ having a non-negative γ
component. The sampling priors are referred to as such because they are used to sample parameter
values in the simulation-based estimation procedure for the Bayesian type I error rate and power.
This procedure is detailed in Section 3.4.4. The fitting prior pi(f) (θ) is simply the prior used to
analyze the data. In our case pi(f) (θ) is the basic power prior given in (3.3.1).
For a fixed value of θ, define the null hypothesis rejection rate as
r (θ |D0, a0) = E
[
1
{
P
(
γ < 0
∣∣D,D0, a0) ≥ ψ} ∣∣θ,D0, a0]
where 1
{
P
(
γ < 0
∣∣D,D0, a0) ≥ ψ} is an indicator that we accept H1 based on the posterior prob-
ability P
(
γ < 0
∣∣D,D0, a0) determined by the observed data D (generated from p (D | θ)), the
chosen analysis model (which need not be p (D | θ)), and the chosen fitting prior. For null values
of θ the quantity r (θ |D0, a0) is the type I error rate and for alternative values of θ it is power.
For chosen null and alternative sampling priors, the Bayesian type I error rate and Bayesian power,
denoted by α(s) and 1− β(s), are defined as
α(s) = E
pi
(s)
0 (θ)
[r (θ |D0, a0)] (3.4.2)
and
1− β(s) = E
pi
(s)
1 (θ)
[r (θ |D0, a0)] . (3.4.3)
The expectation in (3.4.2) is with respect to the null sampling prior distribution for θ and the
expectation in (3.4.3) is with respect to the alternative prior sampling distribution for θ. We
note that Chen et al. (cf. equation 5) define the Bayesian the type I error rate and power in
terms of the null and alternative prior predictive distribution of the data,
∫
p (D | θ)pi(s)0 (θ) dθ and∫
p (D | θ)pi(s)1 (θ) dθ, respectively. Our presentation here simply changes the order of integration
(D before θ) to highlight the fact that the Bayesian type I error rate and Bayesian power are
weighted averages of the quantities based on fixed values of θ. Our recipe for simulation-based
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estimation of the Bayesian type I error rate and Bayesian power follows closely with the presentation
in Chen et al.
3.4.2 Default Sampling Priors
It should be clear from Section 3.4.1 that the Bayesian type I error rate and power depend
critically on the choice of the null and alternative sampling priors. It is natural that the sampling
priors would reflect one’s belief about the parameters in light of the information available from
the historical trial. Presumably, the historical data will suggest that there is treatment efficacy
but the evidence will not be overwhelming (hence the need for and the desire to conduct another
clinical trial). We propose a set of default sampling priors that are well suited for this scenario.
After collecting the historical data, our posterior belief about the parameters is determined by
pi (θ |D0). If one believes the subjects in the historical and future trials are exchangeable, then the
most logical choices for the null and alternative sampling priors are pi
(s)
0 (θ) = pi (θ |D0, γ ≥ 0) (the
historical posterior given that H0 is true) and pi
(s)
1 (θ) = pi (θ |D0, γ < 0) (the historical posterior
given that H1 true), respectively. Figure 3.1 illustrates the marginal posterior distribution for γ
based on our analysis of the historical trial data used in the example application in Section 3.5 along
with the corresponding default null and alternative marginal sampling priors for γ. Though we have
only plotted the marginal sampling priors for γ, conditioning on the null or alternative hypothesis
obviously induces changes in the entire joint distribution for θ. That is to say, the distribution
for the baseline hazard parameters and other regression parameters can be quite different for the
null and alternative sampling priors. The key point is that by defining the sampling priors as we
have done, we preserve the stochastic relationships between the treatment and nuisance parameters
that are implied by the historical data under the assumption that a particular hypothesis is true.
To make this idea more explicit we contrast it with a commonly used approach that is easier
to implement. Consider a point mass alternative sampling prior with all parameters set to their
posterior means. For the null sampling prior, the value of γ is simply set to zero with other
parameters remaining unchanged. This approach is only sensible when γ is independent of the
remaining parameters in θ given D0. Of course, this is not the case as we will see in Section 3.5.
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Figure 3.1: pi (γ |D0) and corresponding default marginal sampling priors.
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A fundamental challenge in implementing our suggested approach is that the default sampling
priors cannot be directly sampled from due to not having closed-forms. However, this issue is easily
overcome through the following approximation. First, we fit the model to the historical data using
MCMC methods to obtain B samples {θb : b = 1, ..., B} from pi (θ |D0). We can then approximate
sampling from pi
(s)
0 (θ) and pi
(s)
1 (θ) by sampling with replacement from the sets {θb : γb ≥ 0} and
{θb : γb < 0}, respectively. If the number of sample points in each restricted set is large, the discrete
approximations of the sampling priors will be accurate. Obviously the choice of B will depend on
how much mass the historical trial posterior puts in the null region. Since this process only needs to
be completed once, the computational burden of choosing B to be extremely large (e.g. 5, 000, 000)
is quite reasonable.
3.4.3 Modifications to the Default Sampling Priors
The default sampling priors previously described are sensible and automatic. However, there
will be instances where it is desirable to modify the default priors to incorporate subjective external
information. For example, researchers may deem it impossible for the new treatment to cause more
than a 10% increased risk relative to the planned control. In addition, researchers may want
to compute power over a restricted alternative space that rules out implausibly large or clinically
insignificant effect sizes. In this section we introduce intuitive modifications to the default sampling
priors that still preserve the stochastic relationships between the treatment and nuisance parameters
that are implied by the historical data under the assumption that a particular (restricted) hypothesis
is true.
The general null sampling prior is defined as pi
(s)
0 (θ) = pi (θ |D0, 0 ≤ γ ≤ γ0,u) and the general
alternative sampling prior is defined as pi
(s)
1 (θ) = pi (θ |D0, γ1,l ≤ γ < γ1,u). When γ0,u = ∞,
γ1,l = −∞, and γ1,u = 0 the general sampling priors reduce to the default sampling priors. We
note that the procedure developed to sample from the default sampling priors applies to the general
sampling priors as well. As γ0,u → 0, we will see that less and less information can be borrowed
from the historical trial if the Bayesian type I error is to be controlled. Note that for γ0,u = 0, the
Bayesian type I error rate is similar to the frequentist type I error rate. Similarly for γ1,l ≈ γ1,u the
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Bayesian power is similar to the traditional notion of power. The key difference is that the Bayesian
quantities are still averaged with respect to the non-degenerate sampling prior distributions for the
nuisance parameters which are defined with respect to the historical trial posterior distribution.
Thus, even in the case where γ0,u = 0, Bayesian type I error control is still not as strict as frequentist
type I error control (which requires control of type I error for any value of the nuisance parameters).
3.4.4 Estimation of the Bayesian Type I Error Rate and Power
In this section, we describe the simulation process that is used to estimate the Bayesian operating
characteristics of interest. Let B be the number of simulation studies to be performed. To estimate
the Bayesian type I error rate we proceed as follows:
1. Sample θ(b) from the null sampling prior pi
(s)
0 (θ).
2. Given θ(b), simulate the new trial data D(b) based on the assumed model for survival times
as well as other specified distributions for enrollment, censorship, and covariates.
3. Update the fitting prior pi(f) (θ) based on the likelihood for the simulated data L
(
θ |D(b)
)
to
obtain the posterior distribution pi
(
γ,β |D(b),D0, a0
)
and calculate the posterior probability
of the alternative hypothesis P
(
γ < 0
∣∣D(b),D0, a0).
4. Compute the null hypothesis rejection indicator for simulation study b.
r(b) = 1
{
P
(
γ < 0
∣∣D(b),D0, a0) ≥ ψ}
5. Estimate the Bayesian type I error rate with the empirical null hypothesis rejection rate.
α(s) ≈ 1
B
B∑
b=1
r(b)
Steps 1-4 are first repeated for b = 1, ..., B to obtain the outcome for each simulation study and then
step 5 combines the results to estimate the Bayesian type I error rate. The process for estimating
Bayesian power is identical. We simply use the alternative sampling prior in place of the null
sampling prior.
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3.4.5 Efficient Computation of Posterior Quantities
Simulation-based trial design methods can be computationally demanding due to the need to
simulate a large number of datasets and fit models to each one. For Bayesian design problems, the
computational burden is substantial since MCMC methods are typically utilized for inference. To
alleviate this problem, we employ the Laplace approximation (i.e. multivariate normal approxima-
tion) to the marginal posterior for the hazard ratio regression parameters. Using this approximation
obviates the need for MCMC altogether thereby providing considerable speed benefits over even
the most efficient MCMC approach. The approximation is justified by the fact that the marginal
posterior distribution for (γ,β) tends to a multivariate normal as the effective number of events
increases. Namely, we have
(γ,β |D,D0, a0) ·∼ Normal

γˆ
βˆ
 , Σˆ =
σˆ211 Σˆ12
Σˆ12 Σˆ22

 (3.4.4)
where
(
γˆ, βˆ
)
is the posterior mode and Σˆ is the inverse negative Hessian matrix for the logarithm
of posterior evaluated at
(
γˆ, βˆ
)
. Our proposed inference procedure is based on the posterior
probability P (γ < 0 |D,D0, a0). Under (3.4.4), this posterior probability is equal to 1 - Φ (γˆ/σˆ11)
and is readily computed without any sampling once γˆ, βˆ, and Σˆ have been obtained through a
Newton-Raphson type procedure. Thus, we replace the computational burden of MCMC with that
of optimizing a relatively simple objective function.
To assess the accuracy of the Laplace approximation we performed an array of simulation
studies. A discussion of these results can be found in Appendix A.4. The Appendix also contains
a description of our customized approach to fitting the model with MCMC, when desired. In
summary, our results suggest the difference between the posterior probability computed using the
actual marginal posterior for the hazard ratio regression parameters and that computed from the
normal approximation is negligible. Accordingly, we can think of no circumstances where one would
actually need to utilize MCMC in order to perform inference during design with the model we have
considered. We note that when performing the actual analysis, one will generally use MCMC since
it will likely be of interest to characterize the exact posterior distribution for all model parameters
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and since the computation burden of MCMC for a single analysis using the PWC-PH model is
not great. However, if one is content with the accurate Laplace approximation we have discussed,
one can simply draw Monte Carlo samples for (γ,β) from (3.4.4) and then sample (λ | γ,β) from
(3.3.3) to approximate the full posterior. This approach can be combined with rejection sampling
to draw approximate samples from the default sampling priors as well.
3.5 Application: Design of a Superiority Study
The E1684 trial was a randomized controlled trial conducted to assess the utility of Interferon
Alfa-2b (INF) as an adjuvant therapy following surgery for deep primary or regionally metastatic
melanoma. A detailed analysis of the trial was given in Kirkwood et al. (1996). The design
and primary analysis were stratified by disease stage according to four groups: (1) deep primary
melanomas of Breslow depth more than 4 mm; (2) primary melanomas of any tumor stage in the
presence of N1 regional lymph node metastasis detected at elective lymph node dissection with
clinically inapparent regional lymph node metastasis; (3) clinically apparent N1 regional lymph
node involvement synchronous with primary melanoma of T1-4; and (4) regional lymph node
recurrence at any interval after appropriate surgery for primary melanoma of any depth. Subjects
treated with the investigational therapy demonstrated a statistically significant prolongation of
relapse-free survival compared to those receiving the standard of care (SOC) based on stratified
log-rank test (p = 0.0023, one-sided). For the purposes of demonstrating the methodology we have
presented in this manuscript, we restrict our attention to subjects from the fourth stratum. Based
on this group there was evidence of efficacy but the evidence was not overwhelming according to
traditional null hypothesis testing criteria.
The number of positive nodes at lymphadenectomy was found to be highly prognostic for
relapse-free survival in this disease group and so we considered it as a stratification variable for
the future trial (number of positive nodes ≤ 1 (stratum one) versus ≥ 2 (stratum two)). Table
3.1 provides a basic summary of the relapse-free survival data by treatment group and stratum
for the targeted risk group. We make the assumption that a model with a treatment effect and
stratum-specific baseline hazard holds for these data. No other covariates available appeared to
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Table 3.1: Summary survival data for selected E1684 subjects
Treatment Stratum N # Events Risk Time
SOC 1 37 26 88.4
2 47 36 105.8
INF 1 43 21 176.3
2 39 31 81.1
be predictive of relapse-free survival and so we do not include additional covariates in the design
model.
We first analyzed the historical trial data using the PWC-PH model with the number of baseline
hazard components ranging from one to 12 per stratum and selected the best model according
to the deviance information criterion (DIC) (Spiegelhalter et al., 2002). For a given number of
components, the baseline hazard change points were chosen to coincide with observed event times
such that an approximately equal number of events were observed in each time interval.
Table 3.2 presents the posterior mean, the posterior standard deviation (SD), and 95% highest
posterior density (HPD) interval for the treatment effect parameter and for each baseline hazard
parameter using the best model according to DIC. The right end points for the chosen time axis
partition for each stratum are given in the rightmost column. We note the highest posterior density
(HPD) interval for the treatment effect puts mass in both the null region and the alternative region
though the evidence clearly favors treatment efficacy. Thus, it is reasonable to assume that if these
data were collected in one clinical trial, an additional trial might be conducted where this data
could inform the design and analysis. Table 3.3 presents the means and HPDs for all parameters
under the default null and alternative sampling priors. Note the changes in the distribution of
the baseline hazard parameters when we condition on the null hypothesis being true versus the
alternative. This illustrates why it is inappropriate to fix the baseline hazard parameters at, say,
their posterior means and simply vary the value of γ during design.
Broadly speaking, we seek a design that controls the Bayesian type I error rate at no more than
2.5% (α = 0.025) and that has a Bayesian power of approximately 80%. Our primary purpose in
this section is to compare and contrast designs based on different choices of sampling priors. To
illustrate how the choice of null sampling prior impacts the amount of historical information that
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Table 3.2: Posterior summaries for historical trial
Parm. Mean SD HPD tk
γ -0.267 0.1907 (-0.642,0.106) n/a
λ1,1 0.474 0.2172 (0.110,0.906) 0.153
λ1,2 1.217 0.4756 (0.388,2.161) 0.247
λ1,3 1.112 0.4342 (0.362,1.978) 0.356
λ1,4 0.609 0.2562 (0.175,1.122) 0.551
λ1,5 0.288 0.1323 (0.067,0.551) 0.929
λ1,6 0.471 0.2164 (0.109,0.900) 1.189
λ1,7 0.206 0.1056 (0.036,0.415) 1.710
λ1,8 0.212 0.1097 (0.036,0.429) 2.296
λ1,9 0.032 0.0167 (0.005,0.065) ∞
λ2,1 0.874 0.3376 (0.285,1.547) 0.107
λ2,2 2.529 0.9800 (0.828,4.485) 0.148
λ2,3 1.544 0.4837 (0.681,2.516) 0.266
λ2,4 0.914 0.3151 (0.358,1.544) 0.466
λ2,5 1.140 0.4146 (0.413,1.968) 0.633
λ2,6 0.418 0.1624 (0.137,0.742) 1.082
λ2,7 0.262 0.1092 (0.075,0.480) 1.833
λ2,8 0.234 0.0972 (0.068,0.429) 2.874
λ2,9 0.088 0.0365 (0.025,0.161) ∞
Table 3.3: Posterior summaries for default sampling priors
—– Alternative —– ——— Null ———
Parm. Mean HPD Mean HPD
γ -0.298 (-0.590,0.000) 0.086 (0.000 ,0.236)
λ1,1 0.481 (0.116,0.919) 0.395 (0.096,0.749)
λ1,2 1.235 (0.404,2.191) 1.006 (0.331,1.765)
λ1,3 1.129 (0.363,1.990) 0.918 (0.295,1.603)
λ1,4 0.618 (0.175,1.130) 0.501 (0.150,0.911)
λ1,5 0.293 (0.070,0.558) 0.239 (0.059,0.454)
λ1,6 0.478 (0.113,0.912) 0.386 (0.094,0.733)
λ1,7 0.210 (0.036,0.420) 0.168 (0.030,0.334)
λ1,8 0.216 (0.037,0.435) 0.168 (0.030,0.335)
λ1,9 0.033 (0.005,0.066) 0.025 (0.004,0.050)
λ2,1 0.885 (0.295,1.565) 0.750 (0.247,1.312)
λ2,2 2.562 (0.835,4.520) 2.146 (0.732,3.764)
λ2,3 1.565 (0.681,2.522) 1.307 (0.591,2.098)
λ2,4 0.926 (0.362,1.554) 0.772 (0.307,1.288)
λ2,5 1.154 (0.424,1.989) 0.968 (0.351,1.645)
λ2,6 0.424 (0.139,0.748) 0.354 (0.120,0.624)
λ2,7 0.265 (0.077,0.484) 0.222 (0.066,0.405)
λ2,8 0.237 (0.069,0.432) 0.203 (0.061,0.371)
λ2,9 0.089 (0.026,0.162) 0.078 (0.022,0.140)
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can be borrowed, we consider three possibilities: (N1) the null sampling prior obtained by taking
γ0,u = 0, (N2) the null sampling prior obtained by taking γ0,u = log(1.10), and (N3) the default
null sampling prior (γ0,u =∞). To illustrate how the choice of alternative sampling prior impacts
the number of required events to obtain 80% power, we consider two possibilities: (A1) a point
mass alternative sampling prior with parameters set to the posterior means in Table 3.2 and (A2)
the default alternative sampling prior. The first case corresponds to powering the trial to detect
the most likely effect size given the data from the historical trial. Such an approach is commonly
used in practice.
For all simulation studies, the generative baseline hazard model for the new trial used the time
axis partition from Table 3.2. For a targeted number of events ν, we took n = 3ν with no censoring
other than administrative censoring that occurred when the targeted number of events had been
reached. Simulated subjects were allocated to strata in proportions matching the historical trial
(i.e. approximately 48% stratum one) and the randomization was 1:1. The PWC-PH model fit to
the data did not make use of the true time axis partition. Instead, we took the number of baseline
hazard components to be 50 per stratum with change points chosen to coincide with observed event
times such that an approximately equal number of events occurred in each time interval within a
stratum. In general, the number of baseline hazard components used is fairly inconsequential when
interest lies solely in the baseline hazard parameters. We discuss this briefly in Appendix A.3. For
all simulation studies, we utilized the normal approximation discussed in Section 3.4.5 to compute
the required posterior probability.
For a given null sampling prior, the first step in the design process is to find the value of a0 that
yields a Bayesian type I error rate of 2.5% for each value of ν in the set under consideration. To
do this we performed 500, 000 simulations for each ν to estimate the type I error rate over a range
of a0 values, used loess methods to smooth these estimates, and then used linear interpolation to
determine the precise value of a0 that corresponded to the desired error rate.
Figure 3.2 presents loess curves of the Bayesian type I error rate as a function of a0 for all
three null sampling priors for the cases where ν = 350, ν = 450, and ν = 550. It is clear that for
these sample sizes, virtually no information can be borrowed from the historical trial under null
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Figure 3.2: Loess curves and point estimates for the Bayesian type I error rate as a function of a0
for ν = 350 (black), ν = 450 (dark gray), and ν = 550 (light gray). Each curve was estimated from
500, 000 simulation studies performed using values of a0 from 0 to 1 with a step size of 0.05.
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Table 3.4: Bayesian power estimates under various sampling priors
Null Alternative
Sampling Sampling Prior
Prior ν a0 A1 A2
N1 310 0.000 65.0 62.8
350 0.000 70.2 65.5
450 0.000 80.7 70.7
500 0.000 84.7 72.5
550 0.000 87.8 74.3
800 0.000 96.5 79.9
N2 310 0.559 75.6 69.1
350 0.593 80.2 71.5
450 0.717 89.1 76.4
500 0.780 91.9 78.4
550 0.848 94.2 79.9
800 1.000 98.7 84.7
N3 310 0.849 80.6 72.5
350 0.906 84.7 74.7
450 1.000 91.6 78.8
500 1.000 93.5 80.0
550 1.000 95.0 81.1
800 1.000 98.7 84.6
sampling prior N1. In fact, the estimates obtained for a0 under null sampling prior N1 where never
larger than 0.02 and most were approximately zero for every value of ν we considered (ν = 250 to
ν = 800). Based on these results, we set a0 = 0 for the purpose of determining power in all design
simulations using null sampling prior N1. In contrast, we see that when null sampling prior N2 or
N3 is used, we are able to borrow much of and sometimes all of the information in the historical
data without surpassing the threshold for the Bayesian type I error rate. Note that a relatively
large number of events is required for the future trial to justify borrowing all the information from
the historical trial when using the default null sampling prior. Thus, although our Bayesian version
of type I error control is less restrictive than frequentist type I error control, there is still significant
restriction on the amount of information that can be borrowed. The fundamental difference is that
the Bayesian type I error restriction can be overcome by running a future trial of adequate size.
Table 3.4 provides power estimates for each combination of null and alternative sampling priors
and for selected values of ν. Each estimate in the table is based on 500, 000 simulation studies. For
each value of ν and each null sampling prior, the value of a0 that was identified in the first stage
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of design is also provided in the table. For null sampling priors N2 and N3 we see that the general
pattern is that as ν increases, a0 can also be increased while still controlling the Bayesian type I error
rate. If we are permitted to control less restrictive versions of the Bayesian type I error rate (i.e.
using null sampling prior N2 or N3 instead of N1), we obtain a Bayesian power of approximately
80% with approximately 250 to 300 fewer events under the default alternative sampling prior (A2)
and with approximately 100 to 140 fewer events under the point mass alternative sampling prior
(A1).
3.6 Discussion
In this chapter we have developed a Bayesian design methodology for clinical trials with survival
endpoints that makes use of data from a historical trial. We have proposed new Bayesian versions
of type I error and power that are defined with respect to our belief about the model parameters
after observing the historical data. Our results illustrate that if we require frequentist type I error
control, it is not possible to borrow meaningful amounts of information from the historical data.
However, when we relax the design constraints to require Bayesian type I error control using our
default null sampling prior, we are able to borrow substantial amounts of information from the
historical trial but full borrowing only comes with a relatively large number of events in the new
trial. Thus, while Bayesian type I error control is less restrictive than frequentist type I error
control, the former still places significant restrictions on how much information can be borrowed.
We have also demonstrated that powering a trial to have adequate Bayesian power under our default
alternative sampling prior will generally lead to a much larger number of events in the new trial
compared to a point mass alternative sampling prior using the most likely effect size based on the
historical data.
The conflict between Bayesian analysis with informative priors and frequentist type I error
control is a topic of future research for the authors. In this chapter, our case study focuses on
a design application where information is borrowed on the treatment effect as well as nuisance
parameters. In this case the apparent conflict between frequentist type I error control and Bayesian
analysis with an informative prior is undeniable. However, when one borrows information only on
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the nuisance parameters, the conflict is less obvious. This is because the historical trial does not
inform the treatment effect parameter and hence, does not overtly suggest with the null hypothesis
is false. However, since the sampling priors for the nuisance parameters are defined with respect
to the historical data, there is an implicit assumption that the nuisance parameter values in the
generative model for the new study are consistent with the historical trial posterior.
Within the proportional hazards framework, there are potential extensions of our methodology
that can help protect against unanticipated systematic differences between the historical and new
trial subjects beyond what can be addressed by stratification or covariate adjustment (i.e. a lack
of exchangeability). We have considered the case where a0 is determined a priori and fixed to
control the Bayesian type I error rate but one can extend the methodology to the case where a0
is random. When the model includes stratification variables but no covariates, one can implement
the normalized power prior (Duan et al., 2006) without approximation. When the baseline risk is
allowed to differ between the historical and new studies (i.e. the baseline hazard is not shared),
one can also develop a version of the commensurate power prior (Hobbs et al., 2011) through the
accurate normal approximation to the marginal posterior for the hazard ratio regression parameters.
Both of these extensions attempt to dynamically adjust the amount of information borrowed based
on the similarity of the historical and new study data.
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CHAPTER 4: BAYESIAN DESIGN OF A SURVIVAL TRIAL WITH A CURED
FRACTION USING HISTORICAL DATA
4.1 Introduction
Survival models that accommodate a cured fraction in the studied population, commonly re-
ferred to as cure rate models (Ibrahim et al., 2001b), have become popular tools for analyzing
data from cancer clinical trials. These models have been used for modeling time-to-event data for
various types of cancers, including breast cancer (Woods et al., 2009; Tsodikov, 2002), leukemia
(Tsodikov et al., 1998), multiple myeloma (Othus et al., 2012), prostate cancer (Zaider et al., 2001),
and melanoma (Kirkwood et al., 2000). When a survival curve plateaus in the right tail after an
adequate follow-up period, cure rate models can be more advantageous than standard models such
as the Cox proportional hazards model or the piecewise exponential model. The horizontal asymp-
tote associated with the aforementioned plateau, often called a cure rate, is an important quantity
to model in these settings and using a model that explicitly does so often leads to a better fit
compared to standard survival models.
In this paper we develop a Bayesian clinical trial design methodology using the promotion time
cure rate model (Yakovlev et al., 1993; Yakovlev, 1996; Chen et al., 1999) in a scenario where
a previously completed clinical trial (i.e. a historical trial) is available to inform the design and
analysis of the new one. During clinical trial design, one must identify appropriate values of the
controllable trial characteristics such as the number of subjects to enroll in the trial. An appropriate
statistical methodology must also be proposed for hypothesis testing. These choices are made to
ensure the trial design has desirable operating characteristics. For confirmatory trials, the primary
operating characteristics of interest are the type I error rate and statistical power. Currently
the Food and Drug Administration (FDA) requires that all proposed trial designs demonstrate
reasonable type I error control. Traditionally, frequentist type I error control has been required.
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This is currently the case for the Center for Drug Evaluation and Research but no longer for the
Center for Devices and Radiological Health where fully Bayesian designs are becoming common.
For a design to exhibit Frequentist type I error control, the type I error rate cannot exceed some
pre-specified threshold at the value of the parameter defining the boundary between the null and
alternative hypotheses. For unbiased statistical tests, this ensures that the type I error rate is
controlled for every possible null value of the parameter. The requirement to have frequentist type
I error control is not an issue for objective Bayesian designs (i.e. designs utilizing non-informative
priors that are designed to yield good frequentist operating characteristics). In contrast, Bayesian
hypothesis testing using informative priors directly conflicts with the frequentist notion of type I
error control. Ensuring frequentist type I error control necessitates that all prior information be
discarded.
We propose a design methodology that is based on Bayesian type I error control. Unlike the
traditional frequentist approach, the Bayesian approach controls a weighted average type I error
rate with weights determined by the posterior distribution of the parameters given the historical
data and conditional on the null hypothesis being true. This design approach is sensible when
one has pertinent information about the null and alternative hypotheses (i.e. high-quality data
from a previously completed trial) and when one still wants to protect against type I errors in
an equitable way. We demonstrate that in a design that exhibits Bayesian type I error control,
meaningful amounts of prior information can be incorporated into the design and analysis of the new
trial. The Center for Devices and Radiological Health will consider designs that control a Bayesian
version of type I error when the historical data are of high quality (Pennello and Thompson, 2007),
although the design may still be required to control the frequentist type I error rate at an acceptable
level (e.g. twice the nominal Bayesian type I error rate). We also consider designs with this type of
added restriction. To complement the Bayesian type I error rate, we introduce a Bayesian version
of statistical power, defined as a weighted average statistical power with weights determined by the
posterior distribution of the parameters given the historical data and conditional on the alternative
hypothesis being true. We demonstrate that designing a trial to have adequate Bayesian power
can lead to a much larger sample size than designing a trial to have adequate power based on an
optimistic fixed value of the parameters.
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The trial design methodology we present in this paper is essentially a Bayesian sample size
determination method. There is a large literature on Bayesian sample size determination. Much
of it focuses on simple models including one and two sample normal or binomial models, linear
regression models, and generalized linear regression models. Comparatively little has been done
with survival models for right-censored data. Notable exceptions are Ibrahim et al. (2012b); Chen
et al. (2014a,b). Bayesian designs which control type I error in some sense have been recently
considered in Chen et al. (2011); Ibrahim et al. (2012b); Chen et al. (2014a,b). The approach to
type I error control considered by these authors is closely related to frequentist type I error control
and hence is quite different from the approach that we propose here.
For our design methodology, we extend the promotion time cure rate model of Yakovlev et al.
(1993) to allow the distribution for the promotion times to vary across levels of a stratification
variable. Our results demonstrate that this can be more appropriate than covariate adjustments
in the model for the cured fraction which is a more common approach. Information from the
historical trial is borrowed by way of the power prior of Ibrahim and Chen (2000). Bayesian
analysis of univariate cure rate models has been considered in Chen et al. (1999); Ibrahim et al.
(2001a,b); Chen et al. (2002a,b); Tsodikov et al. (2003). Although Bayesian analysis using cure rate
models with the power prior has been previously investigated, the work to date has only focused
on analysis with no attention being paid to clinical trial design. Frequentist trial design using cure
rate models was considered in Bernardo and Ibrahim (2000).
Most Bayesian design methodologies are simulation-based and the model fitting step often
requires Markov Chain Monte Carlo (MCMC) methods that can be extremely time consuming.
Through a connection between Bayesian analysis with the power prior and weighted maximum
likelihood analysis, we develop an asymptotic approximation to the posterior distribution that ob-
viates the need for MCMC in design simulations. By using the approximation, one can simply
perform weighted maximum likelihood analysis and use the corresponding asymptotic p-value to
approximate the relevant posterior probability for Bayesian hypothesis testing. For reasonably
sized trials, this approximation is highly accurate. The positive impact of this very general ap-
proximation tool is two-fold. First, since MCMC-based model fitting is replaced by optimization
of a low-dimensional objective function, the computational burden of the simulation-based design
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procedure is greatly reduced. Second, since standard software is available (e.g. SAS R© or R) for
weighted maximum likelihood analysis, implementing our method does not require extensive custom
programming.
The rest of this article is organized as follows: In Section 4.2 we develop a stratified promotion
time cure rate model, discuss some properties, and derive the corresponding likelihood. In Sec-
tion 4.3 we discuss the basic power prior and the approximation to the posterior that obviates the
need for MCMC. In Section 4.4 we formally define Bayesian versions of type I error and power and
discuss the simulation process for determining an appropriate set of controllable characteristics for
the new trial. In Section 4.5 we present a detailed example design using data from a previously
published clinical trial. We close the paper with some discussion in Section 4.6.
4.2 The Promotion Time Cure Rate Model
We consider a flexible promotion time cure rate model where the promotion time distribution
is allowed to vary over levels of a stratification variable. The unstratified version was proposed
originally by Yakovlev et al. (1993) and a thorough treatment from the Bayesian perspective was
first given in Chen et al. (1999). The model is typically motivated through a latent competing
risks framework. Using notation similar to Ibrahim et al. (2001b), we let Ni denote the number
of metastasis-competent tumor cells for subject i that remain after initial treatment. We assume
that Ni follows a Poisson distribution with parameter θi = exp
(
γzi + x
T
i β
)
where zi is a binary
treatment indicator, xi = (xi1, ..., xip) is a p × 1 vector of baseline covariates that includes an
intercept, γ is the treatment effect, and β = (β1, ..., βp) is a p × 1 vector of regression coefficients
corresponding to the covariates. Further let Zij denote the random time for the j
th metastasis-
competent tumor cell to produce detectable disease in subject i. Hence, one can view Zij as the
“promotion time” for the jth metastasis-competent tumor cell. Conditional on Ni, the Zij are
assumed to be independent and identically distributed according to the cumulative distribution
function F (z | ψsi) = 1 − S (z | ψsi) where si is the stratum to which subject i belongs and ψs
represents the promotion time model parameters for stratum s. The time to detectable cancer
relapse for subject i is given by Yi = min {Zij , 0 ≤ j ≤ Ni} where Zi0 = ∞. Suppressing the
43
notation for covariates, the marginal probability of survival past time y for subject i is given as
follows:
Sp (y | θi,ψsi) = P (Ni = 0 | θi) + P (Yi > y | Ni ≥ 1, θi,ψsi)
= exp(−θi) +
∞∑
k=1
S (y | ψsi)k exp(−θi)
θki
k!
= exp (−θiF (y | ψsi)) (4.2.1)
The quantity in (4.2.1) is a marginal probability in the sense that it is not conditional on the latent
number of metastasis-competent tumor cells or even whether or not the subject is cured. We note
that Sp (∞| θi,ψsi) = P (Ni = 0 | θi) = exp(−θi) > 0 and hence Sp (y | θi,ψsi) is not a proper
survival function. The form in (4.2.1) shows that the time to relapse is influenced by the initial
number of metastasis-competent tumor cells as well as their rate of progression. The subdensity
corresponding to (4.2.1) is given by
fp (y | θi,ψsi) = θif (y | ψsi) exp (−θiF (y | ψsi))
with corresponding subhazard given by
hp (y | θi,ψsi) = θif (y | ψsi) . (4.2.2)
From (4.2.2), it is apparent that the promotion time formulation of the cure rate model leads
to a proportional hazards structure for the subhazard. The probability of survival past time y
conditional on subject i being uncured is given by
S∗ (y | θi,ψsi) = P (Yi > y | Ni ≥ 1, θi,ψsi)
=
Sp (y | θi,ψsi)− exp(−θi)
1− exp(−θi) , (4.2.3)
and the corresponding hazard is
h∗ (y | θi,ψsi) =
1
P (Yi <∞| Yi > y, θi,ψsi)
h (y | θi,ψsi) (4.2.4)
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where
P (Yi <∞| Yi > y, θi,ψsi) =
Sp (y | θi,ψsi)− exp(−θi)
Sp (y | θi,ψsi)
.
We note that S∗ (y | θi,ψsi) is a proper survival function and, accordingly, h∗ (y | θi,ψsi) is a proper
hazard function. Unfortunately (4.2.4) does not have a proportional hazards structure since P (Yi <
∞| Yi > y, θi,ψsi) depends on y. It is straight forward to show that h∗ (y | θi,ψsi) is increasing in
θi which is desirable. This means that increasingly negative values of the regression parameters are
associated with a greater cured fraction and lower hazard in the uncured population.
As pointed out in Chen et al. (1999), the promotion time cure rate model has a connection with
the standard mixture cure rate model of Berkson and Gage (1952). It can be readily seen from
(4.2.3) that
Sp (y | θi,ψsi) = exp(−θi) + (1− exp(−θi))S∗ (y | θi,ψsi) .
Thus, the promotion time cure rate model is a special case of the standard mixture cure rate model.
The promotion time cure rate model may be preferred over the standard mixture cure rate model
for several reasons as noted in Chen et al. (1999). First, the model has the natural biological
motivation described above. Second, the model has a proportional hazards structure leading to
convenient interpretation of covariate effects on the subhazard. The standard cure rate model does
not have a proportional hazards structure when the cured fraction is modeled as a function of
covariates using a logistic regression function. Third, the model can be efficiently sampled with a
Gibbs sampler. Lastly, unlike the standard mixture cure rate model, the promotion time cure rate
model yields a proper posterior distribution under a wide class of non-informative improper priors
for the regression coefficients, including a uniform improper prior.
To complete the specification of the survival model in (4.2.1), we must specify a distribution for
the promotion times. Common choices are the Weibull distribution (fully parametric) and piecewise
exponential distribution (semi-parametric). Analysis with each of these promotion time models is
discussed in detail in Ibrahim et al. (2001b) for the case where a single promotion time model is
shared by all subjects. For the design example in Section 5, we utilize a separate Weibull model
for each level of the stratification variable. We note that our choice to allow stratification in the
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model for the promotion times is uncommon. However, the design model selection results discussed
in Section 5 illustrate that this approach can lead to better fit compared to the more standard
modeling framework.
Following Ibrahim et al. (2001b), the complete data likelihood can be written as follows
L (ξ,N |D) =
n∏
i=1
S (yi | ψsi)Ni−vi (Nif (yi | ψsi))vi
e−θiθNii
Ni!
where ξ = {γ,β,ψs : s = 1, ..., S} is the set of all parameters in the model, ψs = {λs, αs} is the set
of Weibull promotion time model parameters for stratum s, andD = {(yi, vi, zi,xi, si) : i = 1, ..., n}
is the observed data. In the literature, Bayesian analysis of the promotion time cure rate model
has been exclusively performed using the complete data likelihood with the Ni being treated as
missing data and therefore included in the Gibbs sampler with the parameters. This approach was
proposed in Chen et al. (1999) and described in full detail in Ibrahim et al. (2001b). The benefit of
such an approach is that the full conditionals for all parameters are log-concave (based on the priors
discussed in Ibrahim et al. (2001b)) and so the parameters can be easily sampled with rejection
sampling or adaptive rejection sampling methods (W. R. Gilks, 1992). The Ni have closed-form
full conditionals for direct Poisson sampling. Alternatively, one can analytically sum out the latent
Ni variables to obtain the observed data likelihood
L (ξ |D) =
n∏
i=1
[θif (yi | ψsi)]vi exp {−θiF (yi | ψsi)} . (4.2.5)
For MCMC analysis based on the observed data likelihood, the regression parameters still have log-
concave full conditionals and they can be sampled efficiently with the same techniques mentioned
above. Unfortunately the full conditionals for the parameters in the promotion time model will not
necessarily have log-concave full conditionals and so we recommend slice sampling (Neal, 2003) for
those parameters. Even though slice sampling does not directly sample from the full conditionals,
since the sampling procedure using the marginal likelihood does not condition on the Ni quantities,
this approach is likely more efficient than the Gibbs sampler using the complete data likelihood. In
our analyses, when MCMC was used, we fit the model using the observed data likelihood as just
described.
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4.3 The Basic Power Prior and the Posterior Distribution
To simplify our exposition, we focus on a scenario with a single historical trial to be used for
design. The form of the basic power prior (Ibrahim and Chen, 2000) using the observed data
likelihood as given in (4.2.5) is as follows:
pi0
(
ξ
∣∣D0, a0) ∝ [L(ξ|D0)]a0 pi0(ξ) (4.3.1)
where 0 ≤ a0 ≤ 1 is a fixed scalar parameter,D0 = {(yj , vj , zj ,xj , sj) : j = 1, ..., n0} is the historical
data, L(ξ|D0) is the likelihood for the historical data, and pi0(ξ) is an initial non-informative prior.
When a0 = 0 the historical data is essentially discarded and the power prior reduces to the initial
prior. In contrast, when a0 = 1, the power prior corresponds to the posterior distribution from
an analysis of the historical data using the initial prior. For intermediate values of a0, the weight
given to the historical data is diminished to some degree leading to a prior that is more informative
than the initial prior but less informative than using the historical trial posterior as the prior for
the new trial.
The power prior is appealing for many reasons. We mention the two most relevant properties to
our discussion and refer the interested reader to Ibrahim et al. (2015) for a complete review. First,
the basic power prior provides a semi-automatic mechanism for transforming historical data into a
subjective prior for design and analysis of a future trial. One only needs to specify the initial prior
pi0(ξ) and elicit a value for a0 for the prior to be fully specified. In our case, the value of a0 will
be chosen so that the design yields desirable Bayesian power while controlling the Bayesian type I
error rate. As an alternative to searching for a fixed value of a0 that leads to control of the Bayesian
type I error rate, one might model a0 as a random variable in an effort to dynamically adjust the
amount of information borrowed based on the degree of similarity between the historical data and
new trial data at the time of the analysis. Such an approach is a step away from a design-based
solution and a step towards meta-analysis. Several extensions of the basic power prior have been
proposed for this type of approach and all are discussed in Ibrahim et al. (2015) and the references
therein. We only consider the fixed a0 approach in this paper.
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The second appealing characteristic of the basic power prior is that analysis using it with a
non-informative initial prior is closely related to weighted maximum likelihood where historical
trial subjects are given a weight of a0 and new trial subjects are given a weight of one. To see this
connection, note that the logarithm of the posterior (ignoring the normalizing constant) is given
by
log pi (ξ |D,D0, a0) = logL(ξ|D) + a0 log [L(ξ|D0)] + log pi0(ξ)
=
n∑
i=1
wi [vi {log θi + log f (yi | λsi , αsi)} − θiF (yi | λsi , αsi)]
+
n0∑
j=1
w0,j
[
vj
{
log θj + log f
(
yj | λsj , αsj
)}− θjF (yj | λsj , αsj)]
+ log pi0(ξ)
which is approximately equal to the weighted log-likelihood based on the combined studies with
wi = 1 for new trial subject i and w0,j = a0 for historical trial subject j. The only difference
between the logarithm of the posterior distribution and the weighted log-likelihood is the term
log pi0(ξ) which has little influence since pi0(ξ) is non-informative by construction. The Bayesian
central limit theorem assures us that, when the effective sample size for the combined trials is
reasonably large,
pi (γ |D,D0, a0) ·∝ Normal
(
γ | γˆ, σ2γˆ
)
where γˆ is the weighted maximum likelihood estimator (MLE) from a joint analysis of both trials
with weights described above and σ2γˆ is the relevant diagonal element of the inverse of the observed
information matrix for the weighted log-likelihood evaluated at the weighted MLE. Using this
connection we can accurately approximate relevant posterior probabilities for our Bayesian analyses
using results that are readily obtainable from standard software using weighted maximum likelihood
methods. To illustrate this, consider the the null and alternative hypotheses H0 : γ ≥ 0 and
H1 : γ < 0, respectively. We can approximate the posterior probability of the alternative hypothesis
as follows:
P (γ < 0 |D,D0, a0) ≈ P
(
Z ≤ − γˆ
σγˆ
∣∣∣∣D,D0, a0) = 1− Φ( γˆσγˆ
)
, (4.3.2)
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where Z is a standard normal variable. We note that the right hand side of (4.3.2) is one minus the
one-sided p-value that arises from weighted maximum likelihood analysis of the combined studies.
4.4 Simulation-Based Bayesian Design of a Superiority Trial
The null and alternative hypotheses for a superiority trial are H0 : γ ≥ 0 and H1 : γ < 0,
respectively. We will accept H1 if P (γ < 0 |D,D0, a0) is at least as large as some critical value
ψ. During design, one examines various possible values for the number of subjects enrolled in the
new trial (n), the duration of the new trial (T ), a0, and ψ in search of a set of values that yield
sufficient Bayesian power while controlling the Bayesian type I error rate at no more than α. We
refer to the set of values {n, T, a0, ψ} as the key controllable trial characteristics.
In general, T should be at least as large as the duration of time it is expected to take for the
survival curves to plateau. Thus, it is natural to fix T for design purposes based on the time
when the survival curves approximately leveled off in the historical trial. This is the approach we
suggest in practice and the approach taken in our example in Section 4.5. We further restrict the
search space for the key controllable trial characteristics by fixing ψ = 1 − α. This choice of ψ is
justified by the fact that the posterior probability P (γ < 0 |D,D0, a0 = 0) (based on an analysis
of the new trial without incorporating historical data) will be asymptotically uniformly distributed
when γ = 0 and the model is correct. In other words, the posterior probability of the alternative
hypothesis has the same asymptotic behavior as a frequentist p-value when the null hypothesis is
true. Accordingly, rejecting the null hypothesis when P (γ < 0 |D,D0, a0 = 0) ≥ ψ = 1−α should
provide frequentist type I error control (asymptotically). A heuristic justification for these ideas
follows directly from the relationship in (4.3.2) but more rigorous exposition on the connection
between so called posterior probabilities of the half-space and frequentist p-values can be found
in Dudley and Haughton (2002). In this light, one can view our design procedure as starting out
with a size α frequentist hypothesis test (based on taking a0 = 0) and then modifying the test by
borrowing increasing amounts of information from the historical trial until it functions as a size α
hypothesis test with respect to the Bayesian type I error rate.
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4.4.1 Definition of the Bayesian Type I Error Rate and Power
In order to formally define the Bayesian type I error rate and Bayesian power, we first introduce
the concepts of sampling and fitting priors that were formalized in Wang and Gelfand (2002) and
extended in Chen et al. (2011) to investigate Bayesian type I error and power. Let pi
(s)
0 (ξ) and
pi
(s)
1 (ξ) be the null and alternative sampling priors and let pi
(f) (ξ) be the fitting prior. A sampling
prior specifies a probability distribution for the model parameters conditional on a particular hy-
pothesis being true. The null sampling prior will give zero weight to values of ξ having a negative
γ component and the alternative sampling prior will give zero weight to values of ξ having a non-
negative γ component. The sampling priors are referred to as such because they are used to sample
parameter values in the simulation-based estimation procedure for the Bayesian type I error rate
and power. This procedure is detailed in Section 4.4.4. The fitting prior pi(f) (ξ) is simply the prior
used to analyze the data. In our case pi(f) (ξ) is the basic power prior given in (4.3.1).
For a fixed value of ξ, define the null hypothesis rejection rate as
r (ξ |D0, a0) = E [1 {P (γ < 0 |D,D0, a0) ≥ ψ} | ξ,D0, a0]
where 1 {P (γ < 0 |D,D0, a0) ≥ ψ} is an indicator that we accept H1 based on the posterior prob-
ability P (γ < 0 |D,D0, a0) determined by the observed data D. For null values of ξ, the quantity
r (ξ |D0, a0) is the type I error rate and, for alternative values of ξ, it is power. For chosen null
and alternative sampling priors, the Bayesian type I error rate α(s) and Bayesian power 1 − β(s)
are defined as
α(s) = E
pi
(s)
0 (ξ)
[r (ξ |D0, a0)] (4.4.1)
and
1− β(s) = E
pi
(s)
1 (ξ)
[r (ξ |D0, a0)] . (4.4.2)
The expectation in (4.4.1) is with respect to the null sampling prior distribution for ξ and the ex-
pectation in (4.4.2) is with respect to the alternative prior sampling distribution for ξ. We note that
in Chen et al. (2011) (cf. equation 5) the authors define the Bayesian type I error rate and power in
terms of the null and alternative prior predictive distribution of the data,
∫
p (D | ξ)pi(s)0 (ξ) dξ and
50
∫
p (D | ξ)pi(s)1 (ξ) dξ, respectively. Our presentation here simply changes the order of integration to
highlight the fact that the Bayesian type I error rate and Bayesian power are weighted averages of
the quantities based on fixed values of ξ. Our recipe for simulation-based estimation of the Bayesian
type I error rate and Bayesian power follows closely the presentation in Chen et al. (2011).
4.4.2 Default Sampling Priors
It should be clear from Section 4.4.1 that the Bayesian type I error rate and power depend
critically on the choice of the null and alternative sampling priors. It is natural that the sampling
priors would reflect one’s belief about the parameters in light of the information available from the
historical trial. Presumably, the historical trial data will suggest that there is treatment efficacy
but the evidence will not be overwhelming (hence the desire to conduct another trial). We propose
a set of default sampling priors that are well suited for this scenario. After collecting the historical
data, one’s belief about the parameters is determined by pi (ξ |D0). If one believes the historical
and future trial patients are exchangeable (within levels of the covariates), then reasonable choices
for the null and alternative sampling priors are pi
(s)
0 (ξ) = pi (ξ |D0, γ ≥ 0) (the historical posterior
given that H0 is true) and pi
(s)
1 (ξ) = pi (ξ |D0, γ < 0) (the historical posterior given that H1 is
true).
Figure 4.1 illustrates the marginal posterior distribution for γ based on our analysis of the
historical trial data used in the example application in Section 4.5 along with the corresponding
default null and alternative marginal sampling priors for γ. Though we have only plotted the
marginal sampling priors for γ, conditioning on the null or alternative hypothesis obviously induces
changes in the entire joint distribution for ξ. The distribution for the promotion time model
parameters and other regression parameters can be quite different for the null and alternative
sampling priors. The key point is that by defining the sampling priors as we have, we preserve the
stochastic relationships between the treatment and nuisance parameters that are implied by the
historical data under the assumption that a particular hypothesis is true. To make this idea more
explicit, we contrast it with a commonly used approach that is easier to implement. Consider a
point mass alternative sampling prior with all parameters set to their posterior means. For the null
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Figure 4.1: pi (γ |D0) and corresponding default marginal sampling priors.
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sampling prior, the value of γ is simply set to zero with other parameters remaining unchanged.
This approach is only sensible when γ is independent of the remaining parameters in ξ given D0.
Of course, this is never the case.
A fundamental challenge in using the proposed sampling priors is that they cannot be di-
rectly sampled from since they do not have closed-forms. However, this issue is easily overcome
through the following approximation. First, we fit the model to the historical trial data using
MCMC methods to obtain B samples {ξb : b = 1, ..., B} from pi (ξ |D0). We can then approximate
sampling from pi
(s)
0 (ξ) and pi
(s)
1 (ξ) by sampling with replacement from the sets {ξb : γb ≥ 0} and
{ξb : γb < 0}, respectively. If the number of sample points in each restricted set is large, the discrete
approximations of the sampling priors will be accurate. Obviously the choice of B will depend on
how much mass the historical trial posterior puts in the null region. Since this process only needs to
be completed once, the computational burden of choosing B to be extremely large (e.g. 5, 000, 000)
is quite feasible.
4.4.3 Alternatives to the Default Sampling Priors
The default sampling priors previously described are sensible and automatic. However, there
will be instances where it is desirable to modify the default priors. For example, researchers may
deem it impossible for the new treatment to decrease the cure fraction by more than a certain
amount relative to the planned control. In addition, researchers may want to compute power over
a restricted alternative space that rules out implausibly large or clinically insignificant effect sizes.
In this section, we introduce intuitive modifications to the default sampling priors that still preserve
the stochastic relationships between the treatment and nuisance parameters that are implied by
the historical data under the assumption that a particular hypothesis is true. We note that the
procedure discussed in Section 4.4.2 for sampling from the default sampling priors applies to the
modified versions discussed in this section.
The general null sampling prior is defined as pi
(s)
0 (ξ) = pi (ξ |D0, 0 ≤ γ ≤ γ0,u). As γ0,u → 0,
less and less information can be borrowed from the historical data if the Bayesian type I error
rate is to be controlled. For γ0,u = 0, Bayesian type I error control is similar to frequentist type I
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error control. The difference is that Bayesian type I error control implicitly assumes the nuisance
parameters in the sampling model for the new trial are consistent with the posterior distribution
for the historical trial (based on the reduced model without a treatment effect). In order to have
Frequentist type I error control, the design methodology would have to be robust to differences
between the nuisance parameters in the generative model for the new trial and the historical trial
posterior. In the example application in Section 4.5, we consider designs based on the default null
sampling prior and the most restrictive general null sampling prior defined by taking γ0,u = 0.
We will see that no information can be borrowed from the historical trial in the latter case. By
extension, this implies that information borrowing is impossible if the design is required to have
frequentist type I error control.
The general alternative sampling prior is defined as pi
(s)
1 (ξ) = pi (ξ |D0, γ1,l ≤ γ < γ1,u). Re-
searchers will often be content with a trial design that does not lead to detection of small effect
sizes with high probability. Thus, we expect that γ1,u will be chosen to be less than zero in most
applications. Another option to be considered in lieu of the default alternative sampling prior is
the point mass alternative sampling prior
pi
(s)
1 (ξ) = 1 {ξ = E [ξ |D0, γ < 0]} (4.4.3)
which sets the parameter values equal to their posterior means given the historical data and con-
ditional on the alternative hypothesis being true. Figure 4.2 illustrates the marginal posterior
distribution for γ based on the default alternative sampling prior and the restricted alternative
sampling prior obtained by setting γ1,l and γ1,u equal to the limits of a 50% HPD interval for
the treatment effect parameter based on the analysis of the historical trial used in the example
application in Section 4.5. In that section, we contrast the power of designs based on the default
alternative sampling prior, the restricted alternative sampling prior defined by choosing γ1,l and
γ1,u as just described, and the point-mass sampling prior in (4.4.3).
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Figure 4.2: Alternative marginal sampling priors for γ.
4.4.4 Estimation of the Bayesian Type I Error Rate and Power
In this section, we describe the simulation process that is used to estimate the Bayesian type
I error rate and power. Let B be the number of simulation studies to be performed. To estimate
the Bayesian type I error rate, we proceed as follows:
1. Sample ξ(b) from the null sampling prior pi
(s)
0 (ξ).
2. Given ξ(b), simulate the new trial data D(b). This can be done using the following steps (for
each subject):
i. Simulate xi, zi, and si based on the chosen randomization fraction, distribution for the
covariates, and distribution for the stratification variable.
ii. Calculate θi = exp
(
γzi + x
T
i β
)
and simulate Ni ∼ Poisson (θi).
iii. Simulate Zij ∼ F (z | ψsi) independently for j = 1, ..., Ni and calculate zi = min (Zij : j = 0, ..., Ni)
with Zi0 = T .
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iv. Simulate the time-to-censorship, denoted as ci, according to the chosen distribution. If
only administrative censoring is entertained, then set ci = T .
iv. If zi < ci then set yi = zi and vi = 1, otherwise set yi = ci and vi = 0.
3. Update the fitting prior pi(f) (ξ) based on the likelihood for the simulated data L
(
ξ |D(b)
)
to
obtain the posterior distribution pi
(
ξ |D(b),D0, a0
)
and calculate the posterior probability
of the alternative hypothesis P
(
γ < 0
∣∣D(b),D0, a0).
4. Compute the null hypothesis rejection indicator for simulated trial b:
r(b) = 1
{
P
(
γ < 0
∣∣D(b),D0, a0) ≥ ψ}
5. Approximate the Bayesian type I error rate with the empirical null hypothesis rejection rate:
α(s) ≈ 1
B
B∑
b=1
r(b)
Steps 1-4 are first repeated for b = 1, ..., B to obtain the outcome for each simulated trial and then
step 5 combines the results to estimate the Bayesian type I error rate. The process for estimating
Bayesian power is identical. One simply needs to use the alternative sampling prior in place of the
null sampling prior in the algorithm above.
4.5 Bayesian Design of a Superiority Trial in High-Risk Melanoma
The E1690 trial was conducted to assess the utility of Interferon Alfa-2b (INF) as an adjuvant
therapy following surgery for deep primary or regionally metastatic melanoma. A detailed report
on the trial was given in Kirkwood et al. (2000). Briefly, E1690 was a prospective, randomized,
three-arm clinical trial designed to evaluate the efficacy of high-dose IFN for one year and low-dose
IFN for two years relative to observation (OBS) in high-risk melanoma patients using relapse-free
survival (RFS) and overall survival endpoints. We restrict our attention to the high-dose IFN
regimen and consider the design of a follow-up RFS trial to confirm the efficacy of IFN.
Patients enrolled in the E1690 trial had histologically proven American Joint Committee on
56
0 1 2 3 4 5 6 7
time (yrs)
0.0
0.2
0.4
0.6
0.8
1.0
Su
rv
iv
al
 P
ro
ba
bi
lit
y
OBSHigh-dose IFN+ Censored
Su
rv
iv
al
 P
ro
ba
bi
lit
y
Figure 4.3: Kaplan-Meier curves for the high-dose INF and OBS groups.
Cancer (AJCC) stage IIB or stage III primary or recurrent regional nodal involvement from cu-
taneous melanoma without evidence of systemic metastatic disease (disease stages 1: T4cN0, 2:
T1-4pN1cN0, 3: T1-4cN1, and 4: T1-4N1 recurrent). The randomization and primary analysis
were stratified by disease stage and the number of positive nodes at lymphadenectomy. The pri-
mary analysis was based on a stratified log-rank test and the two-sided p-value was 0.054. There
were 215 subjects and 114 relapses observed in the high-dose IFN group and 211 subjects and 126
relapses observed in the OBS group. Among the set of subjects who did not experience relapse,
the median observation time was over four years. Figure 4.3 presents the Kaplan-Meier estimator
for the survival curves for the high-dose IFN and OBS groups. Note the clear plateau appearing
at approximately 4 years. This suggests a cure rate model is reasonable for these data. Overall
the data from E1690 suggests a treatment benefit for RFS but the evidence is not overwhelming
by traditional statistical criteria.
In the E1690 trial, disease stage and the number of positive nodes at lymphadenectomy were
highly prognostic for RFS and so we consider these characteristics for inclusion in the design model
to help ensure exchangeability of subjects across the two studies. To formally choose the design
model, we compared a variety of promotion time cure rate models that adjusted for these covariates
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Table 4.1: DIC for six best candidate design models
Stratification Variables Cured Fraction Model Covariates Weibull DIC Exponential DIC
Stages 1-2 and 3-4 Treatment, 2-3 nodes, ≥ 4 nodes 1011.317 1011.557
Stages 1,2,3 and 4 Treatment, 2-3 nodes, ≥ 4 nodes 1014.234 1015.368
Stages 1-2 and 3-4 Treatment, ≥ 2 nodes 1017.845 1017.530
Table 4.2: Posterior summaries for the historical trial and default sampling priors
— Posterior — — Default Alternative — — Default Null —
Parm Mean (SD) HPD Mean (SD) HPD Mean (SD) HPD
γ -0.26 (0.130) (-0.51,0.00) -0.26 (0.121) (-0.49,-0.03) 0.05 (0.044) ( 0.00, 0.14)
β1 -0.10 (0.122) (-0.34,0.14) -0.09 (0.120) (-0.32, 0.15) -0.25 (0.107) (-0.46,-0.04)
β2 0.23 (0.172) (-0.11,0.57) 0.23 (0.172) (-0.11, 0.56) 0.21 (0.172) (-0.12, 0.55)
β3 0.77 (0.158) ( 0.46,1.08) 0.77 (0.157) ( 0.46, 1.08) 0.77 (0.156) ( 0.46, 1.08)
λ1 0.48 (0.088) ( 0.31,0.65) 0.48 (0.088) ( 0.31, 0.65) 0.49 (0.086) ( 0.32, 0.66)
α1 1.20 (0.134) ( 0.94,1.47) 1.20 (0.135) ( 0.94, 1.47) 1.21 (0.133) ( 0.95, 1.47)
λ2 0.67 (0.077) ( 0.51,0.82) 0.67 (0.077) ( 0.51, 0.82) 0.67 (0.078) ( 0.51, 0.82)
α2 1.06 (0.072) ( 0.92,1.21) 1.06 (0.073) ( 0.92, 1.21) 1.06 (0.073) ( 0.92, 1.21)
in the model for the cured fraction and/or stratified by them in the model for the promotion times.
Table 4.1 lists the six best fitting models according to the deviance information criterion (DIC)
(Spiegelhalter et al., 2002). The DIC values were computed based on 50, 000 MCMC samples from
an analysis using a uniform improper prior on the regression parameters and a Gamma (0.001, 0.001)
prior on each of the parameters in the promotion time model. It is shown in Ibrahim et al. (2001b)
(cf. Theorem 5.2.1) that the resulting posterior is proper under mild conditions which are met by
the E1690 data. In addition to the six models shown in Table 4.1, a variety of other models were
considered including models that adjusted for disease stage in the model for the cured fraction and
models that stratified by treatment and/or the number of positive nodes at lymphadenectomy in
the promotion time model. We selected the model having the best fit according to DIC for design.
Thus, the design model had separate Weibull promotion time distributions for disease stages 1-2
and for disease stages 3-4. The model for the cured fraction included an intercept, a treatment
indicator, an indicator for having 2-3 positive nodes, and an indicator for having ≥ 4 positive nodes.
Table 4.2 presents the posterior mean, the posterior standard deviation (SD), and 95% highest
posterior density (HPD) interval for all parameters based on an analysis of the historical E1690
data as well as for the default sampling priors. We note the highest posterior density (HPD)
interval for the treatment effect puts a non-negligible amount of mass in both the null region and
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the alternative region though the evidence clearly favors treatment efficacy (about 97.5% of the
mass is in the alternative region). Note the dramatic change in the posterior mean for β1 (the
intercept) when we condition on the null hypothesis being true versus the alternative. If the null is
true, the data imply the cured fraction in the untreated group is much higher than if the alternative
is true (approximately 46% compared to 40%, for subjects with stage 1 or 2 cancer having ≤ 1
positive node at lymphadenectomy). This illustrates why it is inappropriate to fix the nuisance
parameters at, say, their posterior means and simply vary the value of γ during design (unless one
is purposefully considering sampling priors that are inconsistent with the historical data).
Our primary purpose in this section is to compare and contrast designs based on different
choices of sampling priors. To illustrate how the choice of null sampling prior impacts the amount
of information that can be borrowed from the historical trial, we consider two possibilities: the
frequentist-like null sampling prior obtained by taking γ0,u = 0 and the default null sampling
prior obtained by taking (γ0,u = ∞). To illustrate how the choice of alternative sampling prior
impacts power, we consider three possibilities: the point mass alternative sampling prior with
parameters set to the posterior means in Table 4.2 (for the default alternative sampling prior), the
restricted alternative sampling prior with γ1,l = −0.343 and γ1,u = −0.169 which are the limits
of the 50% HPD interval for γ based on the historical trial posterior, and the default alternative
sampling prior. The point mass alternative sampling prior corresponds to a difference in the cured
fraction of approximately 9.3% in subjects with stage 1 or 2 cancer having ≤ 1 positive node at
lymphadenectomy. For design simulations, we assumed uniform enrollment over a period of 4 years
and a trial duration of T = 6.5 years. The only censoring was administrative at trial completion.
Moreover, the distribution for cancer stage and the number of positive nodes at lymphadenectomy
was taken to match the observed distribution from E1690 and the randomization was 1:1.
For a chosen null sampling prior, the first step in the design process is to find the largest value
of a0 that leads to control of the Bayesian type I error rate for each sample size being considered.
To do this, we performed 200, 000 simulations studies for n = 550 to n = 800 with a step size of 25
over a range of values for a0 and estimated the Bayesian type I error rate for each combination of n
and a0. Next, we used degree-two polynomial regression to smooth estimates of the Bayesian type I
error rate for each sample size and interpolated the correct choice of a0. For these regression curve
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Figure 4.4: Regression curves and point estimates of the Bayesian type I error rate for n = 550,
n = 650, and n = 750 based on the Frequentist-like null sampling prior (light gray) and the default
null sampling prior (black). Each point estimate was based on 200, 000 simulation studies.
fits, the smallest R2 value was 0.994 indicating a near perfect fit. Figure 4.4 presents estimates of
the Bayesian type I error rate as a function of a0 for both null sampling priors for sample sizes
n = 550, n = 650, and n = 750. Lastly, we smoothed the chosen values of a0 based on a simple
linear regression model using sample size as the regressor. For the linear regression curve fits, the
smallest R2 value was 0.974 indicating near perfect fit. Figure 4.5 presents the estimated curves
for a0 as a function of sample size that lead to control of the Bayesian type I error rate at 2.5% for
the default null sampling prior and at 5.0% for the frequentist-like null sampling prior.
It is clear from Figure 4.4 that virtually no information can be borrowed from the historical
trial when the frequentist-like null sampling prior is used and when the Bayesian type I error rate is
to be controlled at 2.5%. In fact, the estimates obtained for a0 when using that null sampling prior
were less than 0.005 for every value of n we considered. Based on these results, we set a0 = 0 for
the purpose of determining power in all design simulations using the frequentist-like null sampling
prior (when the Bayesian type I error rate was to be controlled at 2.5%). In contrast, we see
that when using the default null sampling prior, we are able to borrow a meaningful amount of
information from the historical trial without surpassing the 2.5% Bayesian type I error threshold.
As illustrated in Figure 4.5, we can borrow approximately 33% of the historical trial information
when n = 550 and approximately 40% when n = 800. Note that due to the informativeness of the
historical trial, it is impossible to borrow all of the historical trial information unless the future
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Figure 4.5: Regression curves and point estimates for a0 as a function of sample size for designs
that control of the Bayesian Type I error rate at 2.5% based on the default null sampling prior
(black) and at level 2× 2.5 = 5.0% based on the frequentist-like null sampling prior (light gray).
trial is unrealistically large. Thus, although the Bayesian version of type I error control (based on
the default null sampling prior) is less restrictive than the frequentist-like type I error control, there
is still significant restriction on the amount of information that can be borrowed. The fundamental
difference is that when using the default null sampling prior, the restriction can be overcome by
increasing the size of the future trial. It is also apparent from Figure 4.5 that controlling the
Bayesian type I error rate at 2.5% based on the default null sampling prior does not meet the
added restriction of controlling the Bayesian type I error rate at 5.0% based on the frequentist-like
null sampling prior.
We estimated power using each of the three alternative sampling priors discussed in Section
4.4.3 for sample sizes from n = 550 to n = 800 using a step size of 25 and 200,000 simulations in
each case. For each sample size and alternative sampling prior, we considered values of a0 satisfying
three possible criteria for type I error control: values that control the Bayesian type I error rate
at 2.5% when using the default null sampling prior (DN2.5), values that control the Bayesian type
I error rate at 2.5% when using the Frequentist-like null sampling prior (FN2.5), and values that
control the Bayesian type I error rate at no more than 2.5% when using the default null sampling
prior and at no more than 5.0% when using the Frequentist-like null sampling prior (FN5.0). The
latter approach may be appealing to regulatory bodies since it ensures a reasonable upper bound
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Figure 4.6: Quadratic regression curves and point estimates for Bayesian power as a function of
sample size when the value of a0 is chosen to control the Bayesian type I error rate at 2.5% when
using the default null sampling prior (solid black line), to control the Bayesian type I error rate
at 2.5% when using the Frequentist-like null sampling prior (solid gray line), and to control the
Bayesian type I error rate at no more than 2.5% when using the default null sampling prior and at
no more than 5.0% when using the Frequentist-like null sampling prior (dashed black line).
on the frequentist-like type I error rate for the design. Using degree-two polynomial regression
model, we interpolated the power for intermediate samples sizes. For these regression curve fits,
the smallest R2 value was 0.998, indicating a near perfect fit. Figure 4.6 presents estimates of
Bayesian power as a function of sample size for each criteria for choosing a0. Table 4.3 includes
the power estimates and associated values of a0 for select sample sizes to faciliate more direct
comparison. Using the point mass alternative sampling prior (PM), we obtain 80% power with
sample sizes of approximately 590, 600, and 760 for Bayesian type I error criteria DN2.5, FN2.5,
and FN5.0, respectively. Using the more conservative restricted alternative sampling prior (RA),
we obtain 80% power with sample sizes of approximately 670 and 690 for Bayesian type I error
criteria DN2.5 and FN5.0, respectively. At the maximum sample size considered, the power only
reaches approximately 76.5% when the frequentist-like type I error rate is controlled at 2.5%. Using
the default alternative sampling prior (DA), which is the most conservative with respect to power,
we do not reach 80% power even when the sample size is 800 for any of the three Bayesian type I
error rate criteria. We expect very few trials will be powered using the default alternative sampling
prior. Nonetheless, this sampling prior can provide a realistic estimate of power for the trial design
based on what is deemed plausible given the historical data.
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Table 4.3: Power estimates for select sample sizes
————– DN2.5 ————– ————– FN5.0 ————– ——— FN2.5 ———
n a0 DA RA PM a0 DA RA PM DA RA PM
550 0.328 0.687 0.731 0.775 0.317 0.684 0.728 0.771 0.604 0.623 0.663
560 0.331 0.692 0.737 0.782 0.318 0.689 0.734 0.778 0.609 0.630 0.671
570 0.334 0.696 0.743 0.788 0.319 0.693 0.739 0.784 0.614 0.636 0.679
580 0.337 0.700 0.750 0.795 0.320 0.697 0.745 0.790 0.618 0.643 0.686
590 0.340 0.705 0.756 0.801 0.321 0.701 0.750 0.796 0.623 0.650 0.694
600 0.343 0.709 0.761 0.807 0.322 0.704 0.756 0.802 0.627 0.656 0.701
610 0.346 0.713 0.767 0.813 0.323 0.708 0.761 0.807 0.632 0.663 0.708
620 0.349 0.717 0.773 0.819 0.324 0.712 0.766 0.813 0.636 0.669 0.715
630 0.352 0.721 0.778 0.825 0.325 0.715 0.771 0.818 0.640 0.675 0.722
640 0.355 0.725 0.784 0.830 0.327 0.719 0.776 0.823 0.644 0.681 0.729
650 0.358 0.728 0.789 0.836 0.328 0.722 0.781 0.829 0.648 0.687 0.735
660 0.361 0.732 0.794 0.841 0.329 0.726 0.786 0.834 0.652 0.693 0.742
670 0.364 0.736 0.799 0.846 0.330 0.729 0.791 0.838 0.656 0.699 0.748
680 0.367 0.739 0.804 0.851 0.331 0.732 0.795 0.843 0.660 0.705 0.754
690 0.370 0.742 0.809 0.856 0.332 0.735 0.800 0.848 0.664 0.710 0.761
700 0.374 0.746 0.813 0.861 0.333 0.739 0.804 0.852 0.668 0.716 0.766
710 0.377 0.749 0.818 0.866 0.334 0.741 0.808 0.857 0.671 0.721 0.772
720 0.380 0.752 0.822 0.870 0.335 0.744 0.812 0.861 0.675 0.726 0.778
730 0.383 0.755 0.827 0.875 0.337 0.747 0.816 0.865 0.678 0.731 0.783
740 0.386 0.758 0.831 0.879 0.338 0.750 0.820 0.869 0.682 0.737 0.789
750 0.389 0.761 0.835 0.883 0.339 0.753 0.824 0.873 0.685 0.742 0.794
760 0.392 0.764 0.839 0.887 0.340 0.755 0.828 0.877 0.688 0.746 0.799
770 0.395 0.767 0.842 0.891 0.341 0.758 0.832 0.880 0.691 0.751 0.804
780 0.398 0.770 0.846 0.895 0.342 0.760 0.835 0.884 0.694 0.756 0.809
790 0.401 0.772 0.849 0.898 0.343 0.762 0.839 0.887 0.697 0.761 0.814
800 0.404 0.775 0.853 0.902 0.344 0.765 0.842 0.890 0.700 0.765 0.818
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4.6 Discussion
In this paper, we have developed a Bayesian design methodology for time-to-event clinical trials
with a cured fraction that makes use of data from a previously completed clinical trial. We have
proposed Bayesian versions of type I error and power that are defined with respect to one’s belief
about the model parameters after observing the historical study data. Our results illustrate that
if one requires the design to exhibit frequentist type I error control, it is not possible to borrow
any information from the historical data. However, when one relaxes the design constraints to
require Bayesian type I error control using our default null sampling prior, we are able to borrow
substantial amounts of information from the historical study. Depending on the informativeness
of the historical data, one may only be able to borrow a fraction of the available information.
Thus, while Bayesian type I error control is less restrictive than frequentist type I error control,
the former still places significant restrictions on how much information can be borrowed. We have
also demonstrated that powering a study to have adequate Bayesian power under a non-degenerate
alternative sampling prior will generally lead to a much larger study compared to a point mass
alternative sampling prior using the most likely effect size based on the historical study posterior.
The conflict between Bayesian analysis with informative priors and frequentist type I error
control is a topic of future research for the authors. In this paper, our case study focuses on a design
application where information is borrowed on the treatment effect as well as nuisance parameters.
In this case, the apparent conflict between frequentist type I error control and Bayesian analysis
with an informative prior is undeniable. However, when one borrows information only on the
nuisance parameters, the conflict is less obvious. This is because the historical study does not
inform the treatment effect parameter and hence, does not overtly suggest the null hypothesis is
false. However, since the sampling priors for the nuisance parameters are defined with respect
to the historical study data, there is an implicit assumption that the nuisance parameter values
in the generative model for the new study are consistent with the historical study posterior. In
future work, we plan to consider designs that borrow information on the control group only, giving
practical advice on defining and using default null and alternative sampling priors in this setting.
All design computations were performed using the weighted maximum likelihood approximation
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to the posterior distribution as described in Section 4.3 and using the KillDevil computing cluster
at the University of North Carolina at Chapel Hill. Weighted maximum likelihood analysis was per-
formed using SAS/STAT R© software, specifically the NLP procedure. The accuracy of the weighted
maximum likelihood approximation is demonstrated via simulation in Appendix B.1. Data simu-
lations and MCMC-based model fitting (to obtain discrete approximations of the sampling priors)
was performed using custom C++ programming that was written by the authors.
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CHAPTER 5: BAYESIAN DESIGN OF A CARDIOVASCULAR
OUTCOMES TRIAL
5.1 Introduction
In December of 2008, the US Food and Drug Administration (FDA) issued a guidance for
industry effectively establishing a two-stage framework for the assessment of cardiovascular risk
in all new therapeutic agents intended for the treatment of Type 2 Diabetes Mellitus (T2DM)
(Food and Drug Administration, 2008). The guidance specifies that the stage one data should rule
out an 80% increase in cardiovascular risk for treated subjects compared to controls. If the stage
one data do not also rule out a 30% increase in cardiovascular risk, and the overall risk-benefit
analysis supports approval, a randomized controlled trial will generally be required to ultimately
rule out a 30% increase in stage two. Thus, the stage one objective is to rule out a 80% increase in
cardiovascular risk and the stage two objective is to further rule out a 30% increase in cardiovascular
risk. In practice, the hazard ratio estimated from a Cox proportional hazards model is used
as the basis for cardiovascular risk assessment and so stages one and two might equivalently be
characterized as having to rule out hazard ratios of 1.8 and 1.3, respectively. The values 1.8 and
1.3 are commonly referred to as the stage one and stage two risk margins.
Various design strategies have been proposed and utilized for the evaluation of cardiovascular
risk to satisfy the two-stage framework described above. These approaches and their relative
merits are discussed in Geiger et al. (2015) and Marchenko et al. (2015). Strategies for ruling out
the stage one risk margin include performing a meta-analysis of phase II and phase III trials with
or without interim data from an ongoing cardiovascular outcome trial (CVOT) and conducting a
CVOT designed and powered to ultimately rule out the stage two risk margin. At this time, it is
expected that the stage two risk margin will be ruled out using data from a CVOT. The required
number of subjects that must be recruited to enable timely completion of a CVOT designed to
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rule out the stage two risk margin is substantial. This is because, even in the high risk T2DM
population, cardiovascular events are relatively rare. In several published CVOTs the observed
annualized event rate for major adverse cardiac events (MACE), the primary endpoint used to
evaluate cardiovascular risk in these trials, was as low as 2%-3% (The ADVANCE Collaborative
Group, 2008; The ACCORD Study Group, 2011; Scirica et al., 2013). Not surprisingly, there is
considerable interest in reducing the size of these large trials. As more and more CVOTs complete,
it is becoming increasingly apparent that the pool of completed CVOTs could be a valuable source
of information to be used in the design and analysis of future CVOTs. Koch (2015) noted that
Bayesian methods might be used to borrow information for the placebo control group leading to a
new CVOT that might complete more quickly.
In this chapter, we develop two Bayesian adaptive design strategies based on assumed availability
of subject-level placebo control data from a previously completed CVOT (i.e. a historical CVOT).
Our focus is ruling out the stage two risk margin of 1.3 using information from the CVOT being
planned as well as control information from a selected historical CVOT which is to be incorporated
through an informative Bayesian prior. Ibrahim et al. (2012b) and Chen et al. (2014a) have
previously developed Bayesian meta-design methods for CVOTs using trial-level covariate data
with a goal of controlling the type I error rate in the traditional frequentist sense. Their results
show that little to no information was borrowable under that constraint. The constraint that a
design must control the type I error rate in the traditional sense forces one to discard all prior
information (Berry et al. (2010), cf Chapter 5).
We take an approach that differs from Ibrahim et al. (2012b) in two key respects. First, we will
not attempt to control the type I error rate in the traditional sense for the reasons described above.
Instead, we propose adaptive designs that ensure the maximum type I error rate has a reasonable
upper bound (e.g. twice the targeted level) and the minimum statistical power has a reasonable
lower bound (i.e. 10% less than the targeted amount) over a range of possible parameter values for
the generative model in the planned CVOT. Second, rather than relying on trial-level covariates
(which may be extracted from publications), we propose methodology that requires subject-level
data since covariate adjustment at that level is, in our opinion, critically important for justifiable
information borrowing in a single arm of a multi-arm trial.
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We propose and evaluate two novel strategies one might take for borrowing information from
a historical CVOT. The first approach, which we call the all-or-nothing adaptive design, uses the
basic power prior (Ibrahim and Chen, 2000). The basic power prior is a traditional prior in the
sense that it allows a fixed amount of information to be borrowed from the historical CVOT. The
amount of information to be borrowed would be negotiated with the pertinent regulatory body
during the planning stages of the new CVOT. For example, one might target borrowing 25% of the
events needed to have a desired power for the new CVOT. At a pre-planned interim analysis, which
should occur after a reasonable number of events have been accrued in the new CVOT, one assesses
the degree of conflict between the prior information and the new CVOT data using a likelihood
ratio statistic where large values indicate a lack of agreement between the two data sources and
hence a potential lack of exchangeability of the enrolled subjects (beyond what is addressed by
covariate adjustment). If the likelihood ratio statistic is sufficiently large, the study continues to
the final analysis where the data are analyzed with an objective Bayesian prior (i.e. no borrowing).
Otherwise, the study is stopped at the interim analysis and the analysis is performed using the basic
power prior constructed to yield the desired amount of borrowing. One determines what qualifies as
a “sufficiently large” likelihood ratio statistic through a simulation-based procedure that evaluates
the type I error rate and statistical power of the design over a range of possible parameter values
for the generative model in the new CVOT.
For the second approach, which we call the dynamic borrowing adaptive design, one allows
the amount of information borrowed from the historical CVOT to be dynamically adjusted using
a novel extension of the joint power prior (Ibrahim and Chen, 2000) which we call the restricted
maximal borrowing power prior. In this framework, the fraction of information borrowed from
the historical CVOT is treated as a random variable (denoted by a0). The restricted maximal
borrowing power prior is constructed so that one obtains a desirable posterior distribution for a0
when the observed data in the new CVOT and historical CVOT are perfectly homogeneous. Thus,
when using this formulation of the power prior, one essentially specifies an upper bound posterior
distribution governing the amount of information that can be borrowed in a best case scenario.
At a pre-planned interim analysis, which should occur after a reasonable number of events have
been accrued in the new CVOT, the posterior mean of a0 (or an alternative posterior functional) is
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examined to determine whether or not sufficient information is being borrowed from the historical
CVOT. If it is determined that too little information is being borrowed relative to the desired
amount, the study continues to the final analysis. Otherwise, the study is stopped at the interim
analysis. In either case, the formal analysis utilizes the restricted maximal borrowing power prior
to borrow the amount of information that is supported by the level of agreement between the data
from the new and historical CVOTs at the time of the analysis. One determines the minimal amount
of information borrowing that must take place in order to stop the CVOT at the interim analysis
using a simulation-based design procedure that evaluates the type I error rate and statistical power
of the design over a range of possible parameter values for the generative model in the new CVOT.
The rest of this chapter is organized as follows: In Section 5.2 we discuss historical CVOT selec-
tion, practical considerations for specifying the sampling model, and practical design considerations
for the new CVOT so as to justify borrowing information from a selected historical CVOT. In sec-
tion 5.3 we develop the general proportional hazards model that we use as the sampling model for
both adaptive designs. In Section 5.4.1 we formalize the all-or-nothing adaptive design framework.
In Section 5.4.2 we formalize the dynamic borrowing adaptive design framework. In Section 5.5 we
discuss choosing the number of events at which to perform the interim and final analyses, possible
choices for the randomization ratio, and the simulation-based procedure for identifying a reason-
able criteria for stopping the trial at the pre-planned interim analysis. In Section 5.6 we present
and compare detailed example designs using both adaptive design methods using the SAVOR trial
(Scirica et al., 2011, 2013) as the historical CVOT. In Section 5.7 we close the chapter with some
discussion.
5.2 Practical Design Considerations
The set of CVOTs that have been initiated to date reflect a high degree of variability in vir-
tually all aspects of the targeted patient populations. There are differences in basic demographic
characteristics (e.g. age ranges), differences in the required level of glycemic control (i.e. ranges for
hemoglobin A1c), and differences in definitions of qualifying cardiovascular disease history. To il-
lustrate this, we compare select characteristics of the target patient populations for three completed
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CVOTs: the SAVOR, EXAMINE, and TECOS trials. The SAVOR trial serves as the historical
CVOT in our example design applications to follow.
This SAVOR trial (Scirica et al., 2011, 2013) was a multi-center, randomized, double-blind,
placebo-controlled CVOT designed to evaluate the effect of saxagliptin on the incidence of major
adverse cardiovascular events (MACE), which is the required primary endpoint for ruling out the
stage two risk margin in all CVOTs. In common with all other CVOTs, the target population
for the SAVOR trial was enriched to include subjects that were at comparatively high risk for
cardiovascular events. Enrolled subjects were required to be at least 40 years of age and to have a
hemoglobin A1c (HbA1c) value of at least 6.5% but also less than 12.0%. In addition to age and
glycemic control criteria, subjects enrolled in the SAVOR trial were required to have a history of
cardiovascular disease or to present with multiple risk factors that included renal failure. The set of
qualifying events defining a history of cardiovascular disease were ischemic heart disease, peripheral
arterial disease (PAD), and/or ischemic stroke. Acceptable risk factors for cardiovascular disease
included dyslipidemia, hypertension, and being a smoker at enrollment. Subjects were excluded
from the SAVOR trial if they had an acute cardiovascular event in the two month period before
enrollment, if they were severely obese (BMI>50), had severe dyslipidemia, or severe hypertension.
The EXAMINE trial (White et al., 2011, 2013) was a multi-center, randomized, double-blind,
placebo-controlled CVOT designed to evaluate the effect of alogliptin on MACE events. Subjects
were required to be at least 18 years of age. Those subjects not being treated with insulin at
enrollment were required to have a HbA1c value of at least 6.5% but also less than 11.0%. Subject
being treated with insulin at enrollment were required to have a HbA1c value of at least 7.0% but
also less than 11.0%. Unlike the SAVOR trial, the EXAMINE trial enrolled only those subjects that
presented with acute coronary syndrome (ACS) (acute myocardial infarction or unstable angina
requiring hospitalization) between 15 and 90 days prior to enrollment. Subjects were excluded from
the EXAMINE trial if they had one of several hemodynamically unstable cardiovascular disorders
(NYHA class 4 heart failure, refractory angina, uncontrolled arrhythmia, critical valvular heart
disease, or severe hypertension). Due to the requirement that enrolled subjects have ACS, the
target population in the EXAMINE trial had fundamentally higher cardiovascular risk than the
population targeted by SAVOR (at least in the period immediately following enrollment). Since an
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inclusion criteria in the EXAMINE trial was essentially an exclusion criteria for the SAVOR trial,
it should be clear that no amount of covariate adjustment could justify designing a future CVOT
in the image of EXAMINE while targeting a SAVOR-like trial for information borrowing.
The TECOS trial (Green et al., 2013, 2015) was a multi-center, randomized, double-blind,
placebo-controlled CVOT designed to evaluate the effect of sitagliptin on MACE events. The
TECOS trial did not specifically target subjects who had acute coronary events (although it appears
these subjects were not specifically excluded either). Like the SAVOR trial, the TECOS trial
enrolled subjects with chronic conditions that are associated with increased cardiovascular risk.
TECOS subjects were required to have a history of cardiovascular disease defined as having coronary
artery disease, ischemic cerebrovascular disease (e.g. ischemic stroke), or peripheral arterial disease.
These criteria would suggest the target population for TECOS was at least qualitatively similar
to SAVOR (with respect to cardiovascular disease). However, unlike in the SAVOR trial, TECOS
subjects were required to be at least 50 years old and to have a HbA1c value of at least 6.5%
and but also less than 8.0% resulting in a target population that was somewhat older but had
better glycemic control compared to the SAVOR and EXAMINE trials. Moreover, the TECOS
trial excluded subjects in renal failure.
At this point we would like to make two important observations. First, it is quite obvious
that no two CVOTs are the same in terms of their target populations (at least not yet). The
fact is most CVOTs appear to be systematically different in this respect. Thus, the assumption of
exchangeability of trials that is often made to justify the use of hierarchical models for information
borrowing across multiple historical trials seems untenable. For this reason, we suggest borrowing
information from a single historical CVOT that was selected and used, as much as possible, as a
blue print for the design of the new CVOT. By this we mean that, on paper the historical CVOT
and the new CVOT should be as similar as possible. Basic inclusion and exclusion criteria related
to age, level of glycemic control, cardiovascular disease history, and other known prognostic factors
for MACE events should be nearly identical.
The second point is that no matter what one does from a design perspective, it is not reasonable
to assume that all subjects in the historical and new CVOTs are exchangeable so as to justify
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performing the primary analysis using a very simple survival model as is commonly done in a
single randomized controlled trial. It will be necessary to adjust for a reasonable set of prognostic
factors to help better ensure exchangeability of subjects across trials. In our experience there are
a multitude of characteristics (i.e. potential covariates) that are associated with increased risk
for MACE events but only a few that are captured in clinical databases with the level of clarity
and consistency that makes them useful across CVOTs. For example, history of percutaneous
coronary intervention (PCI) is commonly collected in medical history but the information is often
incomplete. Knowing whether the procedure was elective or performed to resolve an acute life-
threatening event would be valuable as would knowing the date that the procedure was performed.
Presumably, procedures from the distant past may not be relevant. The true relationship between
a subject’s history of PCI and their underlying cardiovascular risk is likely too complicated to be
useful in a statistical analysis. In contrast, characteristics like age, duration of diabetes, baseline
HbA1c, and estimated glomerular filtration rate (eGFR) provide clear and concrete information
about the overall health of the subject and about cardiovascular risk (even if these characteristics
represent surrogates for true underlying risk factors that are not clearly captured in the available
data). We suggest one focus on adjusting for the latter type of characteristics in the statistical
model and hope that the similarity of the study designs does an adequate job of addressing the
former. This approach is admittedly imperfect and it speaks to the need for one to evaluate the
assumption of exchangeability of subjects (conditional on covariates) to determine if information
borrowing from the historical CVOT seems reasonable once some data is collected in the new
CVOT.
5.3 The Piecewise Constant Hazard Proportional Hazards Model
In this section we present the sampling model used for analysis. We consider a flexible propor-
tional hazards model where the baseline hazard is allowed to vary across S levels of a stratification
variable. The cumulative hazard for subject i in the new CVOT is given by
Λi (t) = Λ[si] (t) exp
(
γzi + β
Txi
)
(5.3.1)
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where si is the stratum to which subject i belongs, Λ[s] (t) is the baseline cumulative hazard for
stratum s, zi is a binary treatment indicator, xi = (xi1, ..., xip) is a p × 1 vector of baseline
covariates, γ is the log hazard ratio for treatment versus control, and β = (β1, ..., βp) is a p × 1
vector of regression coefficients corresponding to the covariates.
Let λ[s] (t) denote the piecewise constant baseline hazard for stratum s. We partition the time
axis into Ks intervals according to the change points 0 = ts,0 < ts,1 < .... < ts,Ks = ∞ and let
λsk > 0 denote the constant hazard value over interval Is,k = (ts,k−1, ts,k]. We denote the set of all
baseline hazard parameters by λ and all model parameters by θ = (γ,β,λ). We refer to this model
in its entirety as the piecewise constant baseline hazard proportional hazards model (PWC-PH)
model. The PWC-PH model is commonly used in Bayesian survival analysis when the proportional
hazards assumption is tenable (Ibrahim et al., 2001b).
5.4 Adaptive Design Strategies
We assume the new CVOT will be an event-driven trial with J = 2 analyses and that analysis
j will be performed when a pre-planned number of events νj have been accrued. We refer to the
first analysis as the interim analysis and the second analysis as the final analysis. Throughout our
discussion, we represent the observed data for the new CVOT at the time of analysis j by Dj
and we represent the historical CVOT data by D0. Our goal is to develop a design that exhibits
reasonable type I error control and that
(1) stops early at the interim analysis, resulting in an adequately powered analysis by virtue of
borrowing control events from the historical CVOT, or
(2) stops at the final analysis, resulting in a adequately powered analysis by accruing a sufficient
number of events in the new CVOT regardless of whether or not any events are borrowed
from the historical CVOT.
In Section 5.4.1 we provide an overview of the all-or-nothing adaptive design approach and in
Section 5.4.2 we provide an overview of the dynamic borrowing adaptive design approach. As
noted previously, we consider information borrowing through historical CVOT control subjects
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only. The data from the treated subjects in the historical CVOT would be discarded. Information
from the historical CVOT is borrowed through the nuisance parameters β and λ which are common
to the sampling models for the two CVOTs.
5.4.1 All-or-Nothing Adaptive Design
The all-or-nothing adaptive design is based on the basic power prior (Ibrahim and Chen, 2000).
In this setting, the basic power prior can be written as follows:
pi0
(
θ
∣∣D0, a0) ∝ [L(β,λ|D0)]a0 × pi0(γ,β,λ) (5.4.1)
where 0 ≤ a0 ≤ 1 is a fixed scalar parameter, D0 is the historical data, L(β,λ|D0) is the likelihood
for β and λ given the historical data, and pi0(γ,β,λ) is an initial objective prior. We consider the
initial prior
pi0(γ,β,λ) ∝ pi0 (γ,β)× pi0 (λ) ∝ 1×
S∏
s=1
Ks∏
k=1
λ−1sk .
When a0 = 0 the historical CVOT data is essentially discarded and the power prior reduces to the
initial prior. In contrast, when a0 = 1 the power prior corresponds to the posterior distribution
from an analysis of the historical CVOT using the initial prior. For intermediate values of a0 the
weight given to the historical CVOT is diminished to some degree leading to a prior that is more
informative than the initial prior but less informative than using the historical CVOT posterior as
the prior for the new CVOT.
Definition of the Interim Stoppage Criteria
For the all-or-nothing adaptive design, one fixes a0 at some target value representing the desired
fraction of the ν0 control events that are to be borrowed from the historical CVOT. Generally, a0
would be chosen to ensure that the effective number of control events at the interim analysis
is sufficient to have adequate power under the assumption of no treatment effect and that the
historical CVOT provides unbiased information about the generative model parameters in the new
CVOT. The effective number of control events at the interim analysis is simply the number of
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control events in the new CVOT plus the fraction borrowed from the historical CVOT, a0ν0. At
the interim analysis one evaluates the log-likelihood for the new CVOT data at the maximum a
posteriori (MAP) estimates θˆ0 based on no borrowing and at θˆa0 based on the pre-planned amount
of borrowing. If the log-likelihood ratio statistic
logL(θˆ0|D1)− logL(θˆa0 |D1) (5.4.2)
is large, this suggests that the underlying generative models for the historical and new CVOTs
may be different (i.e. subjects are not exchangeable) and that information borrowing may not be
justified. If it happens that
0 < logL(θˆ0|D1)− logL(θˆa0 |D1) ≤ ∆ (a0)
for chosen ∆ (a0), then the study is stopped and the data are analyzed using the pre-planned
amount of borrowing. If the inequality does not hold, the study continues to the final analysis and
the data are analyzed using the initial prior (i.e. a0 = 0).
The value of ∆ (a0) must be determined through simulation to ensure that the type I error rate
and power for the design are reasonable under various generative models for the new CVOT. In
particular, we propose choosing ∆ (a0) so that the statistical power does not drop by more than
10% when the baseline hazard in the generative model for the new CVOT is moderately less than
the MAP estimate from historical CVOT (in every stratum). In addition, we require that the choice
of ∆ (a0) results in a type I error rate that is less than double the targeted rate when the baseline
hazard in the generative model for the new CVOT is moderately more than the MAP estimate
from historical CVOT (in every stratum). We discuss how to formally identify an acceptable value
for ∆ (a0) in Section 5.5.1.
We note that there are an infinite number of ways in which the historical study MAP estimates
could differ from the generative model parameters in the new CVOT. Clearly, it is impossible to
investigate all possibilities. We choose to focus on equal multiplicative perturbations in all baseline
hazard parameters since this type of modification has the intuitive interpretation of systematically
shifting the baseline cardiovascular risk in the target population of the new CVOT up or down
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relative to the historical CVOT. In practice, if there is concern about a particular covariate effect, it
would make sense to consider perturbations of the corresponding hazard ratio regression parameter
as well.
5.4.2 Dynamic Borrowing Adaptive Design
The joint power prior (Ibrahim and Chen, 2000) generalizes the basic power prior by treating
the a0 parameter as a random variable and giving it a prior distribution. For control group only
borrowing using model (5.3.1), the form of the joint power prior is as follows:
pi0
(
θ, a0
∣∣D0) ∝ [L(β,λ|D0)]a0 × pi0(β,λ)× pi0(γ)× pi0(a0) (5.4.3)
where pi0(a0) is an initial prior for a0 and other quantities are the same as in (5.4.1). The joint
power prior allows the level of agreement between the observed data in the historical and new trial
to influence the amount of information that is borrowed.
Several authors have made arguments in favor of alternative generalizations of the basic power
prior. In particular, Duan et al. (2006) advocate the normalized power prior which can be viewed
a special case of the joint power prior that is obtained by dividing (5.4.3) by
∫
{L(β,λ|D0)a0 × pi0(β,λ)} d (β,λ)
and thus changing the initial prior on a0. The primary argument in favor of the normalized power
prior is that it obeys the likelihood principle whereas the joint power prior does not. That is, in the
normalized power prior one can replace L(β,λ|D0) with c ·L(β,λ|D0) for c > 0 and the resulting
inference will not change. In the case of the normalized power prior, pi0(a0) represents the marginal
prior distribution for a0 whereas in (5.4.3) it does not. These properties of the normalized power
prior would be compelling if the initial prior for pi0(a0) represented ones belief about the parameter
a0. However, in practice, the a0 parameter is simply modeled as random to facilitate data-driven
information borrowing. Accordingly, we view pi0(a0) as nothing more than a characteristic of the
statistical model that one can manipulate to control the operational characteristics of the design.
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From this point of view, it should be obvious that the choice to use the normalized power prior or
joint power prior is arbitrary.
Another generalization of the basic power prior is the commensurate power prior (Hobbs et al.,
2011, 2012). When the data are not normally distributed, the commensurate power prior cannot be
applied without likelihood approximation (e.g. Laplace approximation) which will be potentially
inaccurate for baseline hazard parameters. Moreover, the baseline hazard can be integrated out
when using the joint power prior and this greatly simplifies MCMC sampling during design (since
estimating the baseline hazard is irrelevant in design simulations). The same integration could not
be done analytically when a commensurate prior is placed on the baseline hazard and, as a result,
the computational burden of model fitting would be much greater. For these reasons we did not
consider a version of the commensurate power prior.
Choosing the Initial Prior pi0(a0)
As previously discussed, we view the initial prior pi0(a0) as a characteristic of the statistical
model that can and should be manipulated to ensure the design has reasonable operating charac-
teristics. The form of the initial prior that yields good operating characteristics will depend on a
variety of things including the size of the historical study (e.g. number of events) and the model
complexity. As a general rule, as the ratio of the number of parameters to total information (e.g.
number of events) increases, so to will the amount of information borrowed from the historical
CVOT even if the most likely parameter values determined by the two likelihoods are quite differ-
ent. This is because, as the number of parameters increases, the likelihoods will be increasingly flat
and, hence, relatively consistent with one another. Failing to acknowledge this property can result
in poor type I error control.
In light of these observations it would seem ideal that we specify the initial prior for a0 in a
way that takes into account the complexity of the chosen sampling model and the total number of
events in the historical CVOT and new CVOT at the time of the interim analysis. To that end,
we propose the restricted maximal borrowing power prior which has the same form as (5.4.3) with
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initial prior
pi0(a0) ∝ pi
∗(a0)∫ {L(β,λ|D0)a0+δpi0(β,λ)} d (β,λ) (5.4.4)
where δ is the ratio of events in the new CVOT at the interim analysis to the number of events in the
historical CVOT controls. This formulation of the joint power prior has the property that, in the
idealized scenario where the new CVOT data and historical CVOT data are perfectly homogeneous,
the posterior distribution pi(a0 |D1,D0) is equal to pi∗(a0). By perfectly homogeneous we mean
that the likelihood for the new CVOT is identical to the likelihood for the historical CVOT apart
from being scaled by the power δ which accounts for differing numbers of events in the two trials.
Details on the calculation of the denominator in (5.4.4) can be found in Appendix C.1.
By specifying the prior in this way, one essentially places an upper bound on the amount
of information that can be borrowed from the historical CVOT. Not only does this approach
ensure that model complexity does not unduly influence the amount of information borrowing,
it also provides a very intuitive frame of reference for how much information might be borrowed
in the analysis. In practice we propose a beta distribution for pi∗(a0). When specifying the mean
parameter and dispersion parameter, it is important to note that obtaining the amount of borrowing
implied by pi∗(a0) is essentially impossible. Thus, the mean parameter should be larger than the
fixed value of a0 that is used in the all-or-nothing approach. Regardless of what distribution
is chosen for pi∗(a0), several choices for the parameters governing the mean and spread of the
distribution will likely need to be explored in order to ensure that the amount of borrowing actually
obtained (on average) is reasonable when the historical CVOT provides unbiased information about
the parameters in the generative model for the new CVOT.
Definition of the Interim Stoppage Criteria
At the interim analysis, one computes the effective number of events being borrowed
E [a0 |D1,D0]× ν0
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and compares that value to a pre-identified minimum acceptable number of events δ0. If it happens
that
E [a0 |D1,D0]× ν0 < δ0
then the study will continue to the final analysis. Otherwise, the study will be stopped at the
interim analysis. In either case, the formal analysis will incorporate whatever amount of information
is supported by the historical and new CVOT data at the time of the formal analysis.
5.5 The Simulation-Based Design Strategy
The null and alternative hypotheses for ruling out the stage two risk margin are as follows:
H0 : e
γ ≥ 1.3 versus H1 : eγ < 1.3
where γ is the log-hazard ratio for treatment versus control. We accept H1 if the posterior prob-
ability of the alternative hypothesis is at least as large as some critical value ψ. To decrease the
search space for the number of study characteristics that are manipulated in design simulations,
we recommend fixing ψ = 1 − α where α is the targeted type I error rate for the design. One
needs to select the number of events ν1 and ν2 at which the interim and final analyses will take
place. Traditionally, the final analysis for a CVOT is performed when approximately 612 events
have accrued. This will result in approximately 90% power to rule out the stage two risk margin
under the assumption of no treatment effect (i.e γ = 0) and 1:1 randomization. Since the worst case
scenario for both the all-or-nothing adaptive design and the dynamic borrowing adaptive design
is no borrowing, it makes sense to take ν2 = 612 for both approaches. The choice of ν1 is more
challenging. If the interim analysis is very early, a large fraction of the total events will need come
from the historical CVOT and there may not be enough events in the new CVOT to fully evaluate
whether information borrowing is reasonable. For example, one would want to ensure a reasonable
amount of observation time in each time interval defined by the baseline hazard model. A very late
interim analysis will require less borrowing from the historical CVOT but will also result in less
efficiency gain over the traditional CVOT (i.e. little decrease in the average trial duration compared
79
to the traditional CVOT). For our discussion, we plan the interim analysis at ν1 = 612×0.75 = 459
events which should error on the side of having accrued sufficient events in the new CVOT to allow
legitimate evaluation of the comparability of the data from the two trials.
The number of events that must be borrowed from the historical CVOT will depend on the ran-
domization strategy that is implemented. There are two reasonable choices for allocating subjects
to the treatment arms in the new CVOT. First, one could implement unbalanced randomization
(i.e. 2:1 allocation) which should result in an approximately equal effective number of events in
the two arms at the interim analysis in the situations where the CVOT actually stops at the in-
terim. In this case, the unbalanced randomization will result in the formal analysis having optimal
power (under the assumption of no treatment effect). In contrast, balanced randomization (i.e. 1:1
allocation) would be preferred if the study proceeds to the final analysis (since there will be little
or no borrowing in this case). Our simulation studies suggest that the performance of balanced
randomization is superior to unbalanced randomization and so we recommend using that allocation
strategy regardless of the adaptive design strategy taken. This means that slightly more than 153
events will need to be borrowed from the historical CVOT in order to have 90% power at the
interim analysis.
Having decided on the number of events at which to perform the interim and final analyses as
well as the treatment allocation ratio, what remains is to determine a reasonable criteria for when
the trial should be stopped at the interim analysis. This requires a large scale simulation study
using a range of possible parameter values for the new CVOT generative model. The parameter
values should range from being in complete agreement with the historical CVOT MAP estimates
to being in strong disagreement with them.
Let θ0,1,...,θ0,M represent the collection of null parameter values considered and θ1,1,...,θ1,M
represent the corresponding alternative parameter values. We assume θ0,m = θ1,m apart from
the value of γ which will be zero for alternative cases and log(1.3) for null cases. For hypothesis
h = 0, 1 and parameter value m = 1, ...,M , one must simulate the data at the time of the final
analysis for B hypothetical new CVOTs, denoted by D
(1)
hm,2, ...,D
(B)
hm,2, and then back calculate the
interim analysis data, denoted by D
(1)
hm,1, ...,D
(B)
hm,1. Next one computes the posterior probability
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of the alternative hypothesis and determines whether or not to reject the null hypothesis for each
simulated CVOT at each analysis. Let r
(b)
hm,j be the indicator that one rejects the null hypothesis
based on the observed data at analysis j for simulation study b using generative model parameter
value θh,m. Using the set of rejection indicators
{
r
(b)
hm,j : h = 0, 1;m = 1, ...,M ; b = 1, ..., B
}
along
with corresponding the interim analysis log-likelihood ratio statistic from (5.4.2) (for the all-or-
nothing adaptive design) or posterior mean for a0 (for the dynamic borrowing adaptive design),
one can determine an acceptable criteria for when the study should be stopped at the interim
analysis.
5.5.1 Stoppage Criteria for All-or-Nothing Adaptive Designs
Let `
(b)
hm denote the interim analysis log-likelihood ratio statistic for simulation study b based
on generative model parameter value θh,m. We identify a reasonable value of ∆ (a0) by examining
an array of possible values beginning at zero and ending at a value just larger than the maximum
likelihood log-likelihood ratio statistic observed over all simulation studies. If ∆ (a0) = 0 then the
CVOT will always continue to the final analysis resulting in a design that mirrors the traditional
CVOT approach. If ∆ (a0) is larger than the maximum log-likelihood ratio statistic observed in the
simulation studies, the CVOT will always stop at the interim analysis and the pre-planned amount
of information will always be borrowed. To determine the subset of choices for ∆ (a0) that yield
acceptable designs, we proceed in the following way. Let ∆ represent a potential cutoff value for the
log-likelihood ratio statistic. One computes the empirical null hypothesis rejection rate rˆh,m (∆)
defined as
rˆh,m (∆) =
1
B
B∑
b=1
[
r
(b)
hm,1 · 1
(
`
(b)
hm ≤ ∆
)
+ r
(b)
hm,2 · 1
(
`
(b)
hm > ∆
)]
(5.5.1)
for each generative model parameter value θh,m. For h = 0 the empirical null hypothesis rejection
is an estimate of the type I error rate and for h = 1 it is an estimate of power. If the maximum
estimated type I error rate over all M null parameter values is less than an acceptable upper bound
(e.g. 5.0%, twice the targeted type I error rate) and the minimum power is more than an acceptable
lower bound (e.g. 80%, 10% less than the targeted power), then the value of ∆ yields an acceptable
design for the chosen value of a0. Among the set of values that yield an acceptable design, one
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would set ∆ (a0) equal to the value that results in the the maximum estimated probability of early
stoppage.
5.5.2 Stoppage Criteria for Dynamic Borrowing Adaptive Designs
The approach for choosing when the effective number of events being borrowed from the his-
torical study is too low to justify stopping the CVOT at the interim analysis is similar to the
above procedure for the all-or-nothing design. We consider an array of possible cutoff values for
the effective number of events being borrowed ranging from 0 the mean parameter for pi∗(a0). For
each potential cutoff δ, one computes the empirical null hypothesis rejection rate rˆh,m (δ) defined
as
rˆh,m (δ) =
1
B
B∑
b=1
[
r
(b)
hm,1 · 1 (E [a0 |D1,D0]× ν0 ≥ δ) + r(b)hm,2 · 1 (E [a0 |D1,D0]× ν0 < δ)
]
(5.5.2)
for each generative model parameter value θh,m. If the maximum estimated type I error rate over
all M null parameter values is less than an acceptable upper bound (e.g. 5.0%, twice the targeted
type I error rate) and the minimum power is more than an acceptable lower bound (e.g. 80%, 10%
less than the targeted power), then the value of δ yields an acceptable design for the given choice
of pi∗(a0). Among the set of values that yield an acceptable design over all choices for pi∗(a0), one
would set δ0 equal to the value that results in the the maximum estimated probability of early
stoppage.
5.6 Designing a CVOT to Borrow from the SAVOR Trial
In this section we compare the all-or-nothing adaptive design and the dynamic borrowing adap-
tive design. For this exercise, we utilize the SAVOR trial as the historical CVOT. As noted in
Section 5.2, the SAVOR trial was a multi-center, randomized, double-blind, placebo-controlled
CVOT designed to evaluate the effect of saxagliptin on the incidence of major adverse cardiovas-
cular events (MACE). The rationale for the SAVOR trial was discussed in Scirica et al. (2011) and
the study results are discussed in Scirica et al. (2013).
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We included the following characteristics in the sampling model: age, duration of diabetes,
baseline HBA1c, baseline eGFR, gender, history of MI, and history of stroke. Each of these char-
acteristics had strong association with the MACE endpoint in the SAVOR trial and it was felt
that these characteristics could be consistently measured across trials. Binary data for many other
medical history characteristics (e.g. history of PCI, history of PAD, history of hypertension) were
available and could be evaluated for potential inclusion in the sampling model. Most medical his-
tory provides imprecise information about underlying cardiovascular risk. For example, the date
of a previous MI and the underlying reason for a PCI procedure are clearly important, but both
were essentially unavailable. Our decision to include a particular characteristic in the sampling
model reflected a balance between the apparent statistical significance of the characteristic in the
SAVOR trial and the clarity of the information provided by the characteristic as judged by subject
matter experts. Building a “best” model for borrowing from the SAVOR trial is beyond the scope
of this work. Our goal here is to simply illustrate the two approaches we have developed using a
reasonable sample model.
Due to the computational complexity of the dynamic borrowing adaptive design, we were forced
to dichotomize duration of diabetes (> 10 years), baseline HbA1c (> 8%), and baseline eGFR
(< 60 mL/min). For the PWC-PH model, the data can be reduced to one observation per unique
value of the covariates. When the covariates are all discrete, this leads to a tremendous speed
up in model fitting via MCMC. For the dynamic borrowing adaptive design, MCMC cannot be
avoided. However, this is not the case for the all-or-nothing adaptive design. With virtually no
approximation error, the all-or-nothing adaptive design can be performed by exploiting a connection
between the PWC-PH model and a weighted Poisson regression model. The asymptotic p-value
from a maximum likelihood analysis of the weighted Poisson regression model is essentially equal to
the required posterior probability for Bayesian inference using the PWC-PH model with the basic
power prior. Thus, one can get what is needed for the simulation-based design without fitting the
model with MCMC. However, to facilitate comparison between the two design approaches, we used
the dichotomized covariates for both.
The sampling model was stratified by age using three stratum (≤ 60 years, > 60 years and
≤ 70 years, and > 70 years). A constant hazard was assumed for the first two strata and a three
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Table 5.1: Posterior summaries for SAVOR trial
Parameter Characteristic MAP Mean SD HPD
β1 Male 0.3666 0.3682 0.0930 (0.1887,0.5539)
β2 History of Stroke 0.6844 0.8606 0.1038 (0.4731,0.8800)
β3 History of MI 0.4864 0.4869 0.0829 (0.3233,0.6477)
β4 Diabetic > 10 years 0.2782 0.2796 0.0873 (0.1069,0.4469)
β5 HBA1c > 8.0% 0.4049 0.4043 0.0841 (0.2338,0.5627)
β6 eGFR < 60 mL/min 0.6057 0.6052 0.0861 (0.4353,0.7710)
λ1,1 Age ≤ 60 0.0104 0.0104 0.0014 (0.0078,0.0132)
λ2,1 60 < Age ≤ 70 0.0118 0.0118 0.0014 (0.0091,0.0146)
λ3,1 Age > 70 0.0121 0.0121 0.0020 (0.0084,0.0159)
λ3,2 0.0149 0.0149 0.0025 (0.0104,0.0200)
λ3,3 0.0208 0.0208 0.0033 (0.0146,0.0274)
component model was assumed for the age > 70 years stratum. The change points were fixed at
0.85 years and 1.50 years which lead to an even number of events in each time interval. The choice
to stratify by age was made due to a potential violation of the proportional hazards assumption.
There were 8145 SAVOR control subjects with complete data for each of the characteristics
that were included in the sampling model. Of those 8145 subjects, 605 experienced a MACE event.
Table 5.1 presents posterior summaries from an analysis of the SAVOR data using the objective
prior described in Section 5.4.1. Posterior summaries are based on 25,000 MCMC samples. For all
parameter estimates, the MAP estimates were essentially equal to the posterior mean.
When simulating data for the new CVOT, we used the MAP estimates from Table 5.1 for the
hazard ratio regression parameters. For the baseline hazard parameters, we considered generative
model parameters that differed from the MAP estimates in Table 5.1 by 0%, 10%, 20%, and 30%.
We considered increases and decreases to the baseline hazard parameters. The covariates and
stratification variable were simulated to match that observed marginal distribution for each based
on the SAVOR trial. Enrollment was simulated to be uniform over a two year period and no
dropout was assumed. For each possible value of the generative model parameters, we simulated
100,000 CVOTs to evaluate the all-or-nothing adaptive design and 40,000 CVOTs to evaluate the
dynamic borrowing adaptive design. The difference in the number of simulation studies was a
result of the computational burden of MCMC model fitting for the dynamic borrowing adaptive
design and the need to investigate multiple possible choices for pi∗(a0). For the all-or-nothing
84
borrowing approach, we took a0 = 0.263 resulting in a target of 159 events being borrowed from
the SAVOR trial (ν2 − ν1 = 153). For the dynamic borrowing approach, we consider nine possible
beta distributions for pi∗(a0) corresponding to mean parameters 0.45, 0.50, and 0.55 and strength
parameters 1.5, 2.0, and 2.5. For the all-or-nothing adaptive design and for each choice of pi∗(a0)
in the dynamic borrowing adaptive design, we determined a reasonable interim stoppage criteria
using the procedures described in Sections 5.5.1 and 5.5.2, respectively.
Table 5.2 presents characteristics of the optimal all-or-nothing adaptive design and the optimal
dynamic borrowing adaptive design. The optimal all-or-nothing adaptive design is based on stop-
ping at the interim analysis if the log-likelihood ratio statistic in (5.4.2) is no more than log(1.8).
The optimal dynamic borrowing adaptive design is based on stopping at the interim analysis if
the effective number of events being borrowed is at least 121 and based on a beta distribution for
pi∗(a0) with mean parameter 0.55 and strength parameter 2. For this choice, the average posterior
mean for a0 at the interim analysis across all simulations was approximately 0.28 in the situation
where the historical CVOT MAP estimates were unbiased with respect to the generative model
parameters in the new CVOT. The mean decrease in CVOT duration and percent change in CVOT
duration are computed with respect to a CVOT that always proceeds to the final analysis.
The two optimal designs are quite similar in terms of the probabilities for early stoppage and
reduction in the duration of the average CVOT. The designs are also similar in terms of power and
type I error control (by construction). One key property of both designs is that when the baseline
hazard in the generative model for the new CVOT is at least 30% different from the historical
CVOT MAP estimates, the new CVOT nearly always proceeds to the final analysis leading to
adequate type I error control and high power. This highly desirable property is what allows us to
avoid considering more extreme differences between the baseline hazard in the generative model
for the new CVOT and the historical CVOT MAP estimates. If we did not observe this behavior
with a 30% difference, we would need to consider larger differences.
It is apparent that the type I error rate is most inflated when the baseline hazard in the
generative model for the new CVOT is modestly lower than the historical CVOT MAP estimates.
Similarly, the power reduction is greatest when the baseline hazard in the generative model for
85
Table 5.2: Optimal adaptive designs
True New CVOT Early Estimated Mean Mean Percent
Hazard BL. Hazard Stoppage Power/Type I Duration Decrease Change
Ratio Scale Factor Probability Error Rate (years) in Duration in Duration
————————– Optimal All-or-Nothing Adaptive Design ———————–—
1.0 0.7 0.001 0.900 5.69 0.00 0.01
0.8 0.070 0.898 5.06 0.07 1.42
0.9 0.513 0.911 4.22 0.48 10.18
1.0 0.796 0.900 3.68 0.67 15.34
1.1 0.541 0.821 3.65 0.41 10.15
1.2 0.153 0.842 3.72 0.11 2.80
1.3 0.018 0.892 3.62 0.01 0.32
1.3 0.7 0.001 0.025 5.11 0.00 0.02
0.8 0.077 0.051 4.56 0.07 1.52
0.9 0.514 0.050 3.83 0.42 9.82
1.0 0.790 0.020 3.37 0.58 14.66
1.1 0.537 0.024 3.34 0.36 9.72
1.2 0.164 0.025 3.39 0.10 2.90
1.3 0.022 0.024 3.30 0.01 0.38
———————– Optimal Dynamic Borrowing Adaptive Design ——————–—
1.0 0.7 0.001 0.901 5.68 0.00 0.03
0.8 0.118 0.900 5.00 0.12 2.40
0.9 0.595 0.906 4.14 0.55 11.80
1.0 0.811 0.886 3.67 0.68 15.63
1.1 0.646 0.814 3.57 0.49 12.13
1.2 0.284 0.801 3.63 0.20 5.21
1.3 0.061 0.874 3.59 0.04 1.09
1.3 0.7 0.002 0.027 5.11 0.00 0.04
0.8 0.149 0.049 4.49 0.14 2.93
0.9 0.608 0.044 3.75 0.49 11.63
1.0 0.804 0.021 3.35 0.59 14.93
1.1 0.654 0.021 3.26 0.44 11.84
1.2 0.315 0.026 3.30 0.19 5.57
1.3 0.081 0.025 3.27 0.05 1.41
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the new CVOT is modestly higher than the historical CVOT MAP estimates. When the historical
CVOT MAP estimates are unbiased with respect to the generative model parameters in the new
CVOT, we are able stop the study early approximately 80% of the time leading to a decrease in the
mean duration of the new CVOT by more than half a year (for either design method). Even when
the historical CVOT MAP estimates are off by as much as 10% relative to the baseline hazard in
the generative model for the new CVOT, we are still able to stop the new CVOT over 50% of the
time using the all-or-nothing design and even more often using the dynamic borrowing design.
They key differences in the two optimal designs are that the dynamic borrowing design tended
to stop the new CVOT earlier leading to a slightly greater decrease in the average CVOT duration.
However, the fixed borrowing design had higher minimum power when the bias of the historical
CVOT MAP estimates was in the direction that compromised power. When discussing differences
between the two designs we must point out the major caveat that the dynamic borrowing design
characteristics are estimated with significantly lower precision than the all-or-nothing design char-
acteristics. Moreover, the dynamic borrowing adaptive design is only optimal over the choices for
pi∗(a0) that we considered. Other choices for pi∗(a0) may perform better.
5.7 Discussion
In this chapter we have developed two Bayesian adaptive design methodologies that allow
one to borrow control events from a previously completed CVOT as a means to increase the
efficiency of future CVOTs. We developed the all-or-nothing adaptive design which seeks to borrow
a prespecified amount of events from the historical CVOT and that uses an interim analysis to
evaluate whether borrowing is reasonable. As an alternative, we developed the dynamic borrowing
adaptive design which allows the observed data to determine the amount of events that are borrowed
from the historical CVOT and that uses the interim analysis to assess if enough events are being
borrowed to justify stopping the study. For both designs, our simulation studies demonstrated
that, when information borrowing is justifiable, the adaptive designs lead to future CVOTs that
can be significantly shorter in duration. Our methods require subject-level data and we devoted
significant discussion to the practical reasons why that is the case. We hope that our work can foster
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discussion on subject-level data sharing, standardization of data collection, and (where reasonable)
standardization of the disease populations that are targeted for recruitment into CVOTs.
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CHAPTER 6: DNA METHYLATION DECONVOLUTION USING
BISULFITE SEQUENCING DATA
6.1 Introduction
DNA methylation is the most widely studied epigenetic marker in mammals and a growing num-
ber of human diseases, including cancer, are associated with aberrant DNA methylation patterns
(Robertson, 2005; Kulis and Esteller, 2010). In addition to its implications in human disease, DNA
methylation has an important role in mammalian development (Jones and Takai, 2001) and has
been shown to uniquely characterize functionally different cell and tissue types with high fidelity
(Baron et al., 2006; Reinius et al., 2012; Varley et al., 2013).
Methylation data are usually collected from heterogeneous tissue samples, such as blood, which
can be harvested in a cost effective manner. The tissue samples are heterogeneous in the sense that
they are comprised of several (possibly many) functionally distinct cell types with each having a
potentially distinct DNA methylation signature. For example, blood contains many different types
of white blood cells, including neutrophils, basophils, eosinophils, lymphocytes, and monocytes. In
addition to white blood cells, organs such as the liver can contribute significantly to the circulating
pool of DNA in blood (Lo et al., 1998). Presumably, each cell type represented in a heterogeneous
tissue sample contributes DNA for methylation analysis in accordance with its relative abundance
in the tissue sample.
Methylation data collected from heterogeneous tissues is used in predominantly two ways: (1)
to test for differential methylation or (2) to estimate the composition of the heterogeneous tissues
using supplemental methylation data from reference tissue samples. Reference tissue samples are
comprised predominately of one cell type though they are generally not perfectly homogeneous
(Reinius et al. (2012), Supplemental Table 2).
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When testing for differential methylation, if the cell types comprising the set of heterogeneous
tissue samples have functionally distinct methylation signatures, as they do in blood (Reinius
et al., 2012; Houseman et al., 2012), it is important to control for tissue composition in analyses
performed at the tissue level. It has been argued that many purported associations between age
and DNA methylation can be attributed to tissue composition bias that was poorly addressed
in the analysis (Jaffe and Irizarry, 2014). One could argue that the far more relevant biological
question is whether differential methylation exists in one or more of the constituent cell types in the
heterogeneous tissue samples. However, no existing methods attempt to estimate cell type-specific
methylation signatures for the purposes of associating phenotypes of interest with cell type-specific
differential methylation. The method we develop herein is a first step towards filling this need.
Since our goal is to estimate cell type-specific methylation levels using reference samples, it is
quite natural to simultaneously estimate tissue composition. Quadratic programming approaches
are commonly applied to estimate tissue composition using data from high-throughput sequencing
experiments. This technique has been recently applied by Sun et al. (2015) and Ziller et al. (2013).
Quadratic programming techniques treat the reference tissue methylation levels as the known aver-
age methylation levels for the constituent cell types. Houseman et al. (2012) proposed an alternative
method designed for the Infinium R©HumanMethylation27 BeadChip that acknowledges that refer-
ence tissues only provide an estimate of average methylation levels for the constituent cell types
but this method requires reference tissue replication, making it impractical for high-throughput se-
quencing data. None of these methods produced updated estimates of cell type-specific methylation
levels.
In this chapter we develop a reference-based statistical deconvolution approach for DNA methy-
lation that is ideally suited for data from high-throughput bisfulfite sequencing experiments. By
positing a joint model for the heterogeneous tissue sample data as well as the reference tissue
sample data, our approach allows simultaneous estimation of both tissue composition and cell-type
specific methylation levels. The rest of this chapter is organized as follows: In Section 6.2, we
present a simple deconvolution model and discuss model fitting. We also discuss extensions of the
simple deconvolution model to accommodate overdispersion in the cell type-specific methylation
levels and discuss why using the more complicated model may be unnecessary in practice. In Sec-
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tion 6.3, we use real data from DNA mixture experiments to demonstrate that estimates of tissue
composition based on the proposed deconvolution model are superior to those from the typical
quadratic programming approach and from an overdispersed deconvolution model. In Section 6.4
we use simulation studies to demonstrate that estimates of cell type-specific methylation levels can
be significantly improved through deconvolution. We close the chapter with some discussion in
Section 6.5.
6.2 A Simple Deconvolution Model
In this section we develop a reference-based deconvolution model that facilitates simultaneous
estimation of heterogeneous tissue composition and average cell type-specific methylation. We
note that the term “cell type” may be replaced with “homogenous tissue type” without any loss
of generality (e.g. liver cell versus liver tissue). In many cases the latter term may be more
appropriate. We assume that G loci are available for analysis and that a subset of K cell types
comprise each heterogeneous tissue. We use locus as a generic term that may refer to a single CpG
dinucleotide or a specified genomic region. We propose a deconvolution model for the individual
DNA molecules on which methylation is measured. The model is comprised of two components: (1)
a sample-specific latent multinomial allocation distribution that identifies the cell type of origin for
each DNA molecule and (2) a locus and cell type-specific binomial methylation distribution that
identifies whether or not each DNA molecule is methylated conditional on its cell type of origin.
Let k index cell type, g index locus, n index the heterogeneous tissue sample, and d index the
DNA molecule. The latent multinomial cell type allocation model is given by
p (zngd,1, ..., zngd,K | θn) ∝ θzngd,1n,1 · · · θzngd,Kn,K
where zngd,k is an indicator that the d
th DNA molecule covering locus g from heterogeneous tissue
sample n originated from a type k cell and θn = [θn,1, . . . , θn,K ] is aK×1 vector of tissue composition
fractions that are non-negative and sum to one. The cell type allocation model arises naturally from
the assumption that the cell type of origin for each DNA molecule is determined by the relative
abundance of the cell type in the heterogeneous tissue. The binomial methylation model is given
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by
p (yngd | zngd,1, ..., zngd,K) ∝
K∏
k=1
[
pi
yngd
g,k (1− pig,k)1−yngd
]zngd,k
where yngd is an indicator that the DNA molecule is methylated and pig,k is the methylation prob-
ability for type k cells at locus g. The complete data log-likelihood for the heterogeneous tissue
samples is given by
` (pi,θ1, ...,θN , z1, ..., zN | y1, ...,yN )
=
N∑
n=1
G∑
g=1
Dng∑
d=1
K∑
k=1
(zngd,k [log (θn,k) + yngd log (pig,k) + (1− yngd) log (1− pig,k)])
(6.2.1)
where N is the total number of heterogeneous tissue samples, Dng is the total number of DNA
molecules covering locus g in heterogeneous tissue sample n, yn = {yngd : ∀(g, d)}, zn = {zngd,k : ∀(g, d, k)},
and pi = {pig,k : ∀(g, k)}.
For the reference tissue samples, the cell type of origin for each DNA molecule is known (by
assumption) and so only the binomial methylation model is relevant for these samples. In many
cases the sequencing depth in the reference tissue samples will be much greater than in the het-
erogeneous tissue samples. We have found it to be useful to down weight the reference samples so
they do not dominate estimation of the cell type-specific methylation probabilities. The weighted
log-likelihood for the reference tissue samples is given by
`
(
pi
∣∣∣∣ {ykn : ∀(n, k)}) = K∑
k=1
Nk∑
n=1
G∑
g=1
ωkng
Dkng∑
d=1
ykngd log (pig,k) + (1− ykngd) log (1− pig,k)
 (6.2.2)
where Nk is the total number of reference tissue samples comprised of type k cells, D
k
ng is the total
number of DNA molecules covering locus g in cell type k reference tissue sample n, ωkng is the
weight given to the set of DNA molecules covering locus g, ykngd is an indicator that DNA molecule
d is methylated, and ykn =
{
ykngd : ∀(g, d)
}
.
One combines (6.2.1) and (6.2.2) to form the full complete data log-likelihood. Unfortunately,
since the variables z1, ..., zN are not observed, the likelihood cannot be directly maximized. How-
ever, one can derive a simple expectation-maximization (EM) algorithm (Dempster et al., 1977)
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to optimize the associated observed data likelihood, which would theoretically be obtained by
summing out z1, ..., zN .
6.2.1 Model Fitting via the EM Algorithm
The EM algorithm is comprised of two steps that are completed in an iterative loop: the E-
step and the M-step. To complete the E-step, one needs to compute the expectation of (6.2.1)
with respect to the conditional distribution of zn given yn using the estimates of the parameters
at the current iteration of the algorithm. This is equivalent to replacing zngd,k in (6.2.1) with its
conditional expectation given yngd. It is not difficult to show that
E
[
zngd,k
∣∣yngd = 1,θ(t)n ,pi(t)g ] = ψ(t)ngk,1 = θ(t)n,kpi(t)g,k∑K
k′=1 θ
(t)
n,k′
pi
(t)
g,k′
(6.2.3)
and
E
[
zngd,k
∣∣yngd = 0,θ(t)n ,pi(t)g ] = ψ(t)ngk,0 = θ
(t)
n,k
(
1− pi(t)g,k
)
∑K
k′=1 θ
(t)
n,k′
(
1− pi(t)
g,k′
) (6.2.4)
where θ
(t)
n is the current estimate of the tissue composition fractions for heterogeneous tissue sample
n and pi
(t)
g represents the current estimates for the methylation probabilities for the K cell types
at locus g.
The M-step maximizes the expected full complete data likelihood. One can obtain closed-form
updates for both sets of parameters. The update for the cell type k tissue composition fraction in
heterogeneous tissue sample n is given by
θ
(t+1)
n,k =
∑G
g=1Dng ×
(
ψ
(t)
ngk,1 + ψ
(t)
ngk,0
)
∑K
k′=1
∑G
g=1Dng ×
(
ψ
(t)
ngk
′
,1
+ ψ
(t)
ngk′ ,0
)
and the update for the methylation probability for type k cells at locus g is given by
pi
(t+1)
g,k =
∑N
n=1
(
ψ
(t)
ngk,1
∑Dng
d=1 yngd
)
+
∑Nk
n=1
(
ωkng
∑Dng
d=1 y
k
ngd
)
∑N
n=1
(
ψ
(t)
ngk,1
∑Dng
d=1 yngd + ψ
(t)
ngk,0
[
Dng −
∑Dng
d=1 yngd
])
+
∑Nk
n=1 ω
k
ngD
k
ng
.
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The EM algorithm is guaranteed to find a locally optimal solution but can be sensitive to the
initial values for the parameters when the observed data likelihood is multimodal. In practice, we
initialize the methylation probability for type k cells at locus g to the value
pi
(0)
g,k =
∑Nk
n=1 ω
k
ng
∑Dkng
d=1 y
k
ngd∑Nk
n=1 ω
k
ngD
k
ng
and all tissue composition fractions to 1/K. We have found the algorithm to be quite robust to
the initial values used for the tissue composition fractions.
6.2.2 On Overdispersion in the Cell Type-Specific Methylation Model
Modeling overdispersion is a staple in the analysis of methylation data from bisulfite sequencing
experiments in situations where tissue composition is ignored (Hebestreit et al., 2013; Dolzhenko
and Smith, 2014; Feng et al., 2014; Sun et al., 2014). It is reasonable to assume that the presence
of overdispersion in these cases is at least partially attributable to ignoring tissue composition
but it is also highly plausible that overdispersion exists for other reasons. Initially we sought to
accommodate overdispersion in our deconvolution model. This was done by using a beta-binomial
model for the cell type-specific methylation levels instead of a binomial model.
Fitting the overdispersed deconvolution model cannot be done with a simple EM algorithm.
To fit the overdispersed deconvolution model, we implemented a variational EM algorithm similar
to that proposed by Blei et al. (2003) for estimation of the latent Dirichlet allocation model. The
variational EM algorithm does not maximize the observed data likelihood but instead maximizes
a tractable lower bound on the observed data likelihood. In simulation studies we observed that,
unless the number of replicates for the reference samples were large (which will never be the case),
it was impossible to estimate the overdispersion parameters with any reliability. The dispersion
parameter estimates obtained from the variation EM algorithm were consistent with a binomial
assumption even when the data were simulated from highly overdispersed beta-binomial distribu-
tions. Moreover, we observed that the estimates of the cell type-specific methylation probabilities
were no better than those produced by fitting the simple deconvolution model described above. In
light of these findings, we elected to pursue the simplified deconvolution model. The computational
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complexity of fitting the overdispersed deconvolution model using a variational EM algorithm is
orders of magnitude greater than fitting the simple deconvolution model using an EM algorithm.
The results we present in Sections 6.3 and 6.4 provide evidence that fitting the overdispersed de-
convolution model with a variational EM algorithm leads to inferior estimates compared to those
from the simple deconvolution model we have proposed (even when the overdispersed deconvolution
model is correct).
6.3 Estimation of Tissue Composition in DNA Mixture Experiments
In this section we present results from an analysis of a set of heterogeneous tissues that were
created by Sun et al. (2015) by mixing known quantities of DNA from several cell types. Sun
et al. (2015) constructed 18 DNA mixture tissues using buffy coat DNA (i.e. white blood cells),
placental DNA, and liver DNA. The buffy coat DNA was obtained from a 40 year old, non-pregnant
woman. The placental DNA was obtained immediately following the delivery of a healthy female
baby having a gestational age of 38 weeks. The liver DNA was obtained from the non-neoplastic
liver tissue of a 57 year old female subject during resection of a hepatocellular carcinoma.
We obtained unprocessed bisulfite sequencing data for the DNA mixture tissues from Sun et al.
(2015), unprocessed bisulfite sequencing data for a reference placental tissue from Lun et al. (2013),
unprocessed bisulfite sequencing data for a reference liver tissue from the NCBI Gene Expression
Omnibus (GSM1058027), and unprocessed bisulfite sequencing data for a reference B cell tissue and
a reference neutrophil tissue from Hodges et al. (2011). We obtained processed methylation calls
for CD4+T cells and CD8+T cells from Ziller et al. (2013). Unfortunately, unprocessed bisulfite
sequencing data are not publicly available for the T cell data. All unprocessed bisulfite sequencing
data were then uniformly processed using Bismark (Krueger and Andrews, 2011) version 0.14.4
and aligned to the hg19/GRCh37 reference assembly, which matched the reference assembly used
by Ziller et al. (2013).
We restricted our attention to methylation calls for 5,820 genomic loci that were identified by
Sun et al. (2015) as being informative for one or more of 14 reference cell types (which include
the cell types used to construct the DNA mixture tissues). Each locus corresponded to a genomic
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region that was 500bp in length. Complete details on the genomic location of each region can be
found in Supplemental Table 1 from Sun et al. (2015). We combined the number of methylated
calls and the number of unmethylated calls over all CpGs in a region to form the observed data.
The average sequencing depth was 67 for the 18 heterogeneous tissues, 184 for the B cell reference
tissue, 330 for the neutrophil reference tissue, 2028 for the CD4+T cell reference tissue, 2118 for the
CD8+T cell reference tissue, 1039 for the placenta reference tissue, and 1096 for the liver reference
tissue. We excluded 103 loci that were not covered in all 18 DNA mixture tissues and/or that had
extremely high or low sequencing depth compared to the average depth in the 18 heterogeneous
tissues. This resulted in 5717 loci that were used for analysis.
For the weighted EM algorithm (used to fit the simple deconvolution model), the weight given
to a particular reference sample at a given locus was equal to the ratio of the average sequencing
depth from the 18 DNA mixture tissues to the sequencing depth in the reference tissue. We also
considered an unweighted approach but observed superior performance when using weights (data
not known). The EM algorithm was terminated when the maximum change in all parameters was
less than 10−5. We implemented the quadratic programming approach using the SAS System (v9.4,
OPTMODEL Procedure) using the most stringent convergence criteria. Following Sun et al. (2015),
the proportion of all calls in a region that were methylated was used as the response in the linear
system of equations. We also fit the overdispersed deconvolution model using a variational EM
algorithm. The overdispersed deconvolution model assumed a separate overdispersion parameter
for each cell type and locus. The algorithm was terminated after 15,000 iterations and all parameter
estimates were stable except for the dispersion parameters. Estimates of the dispersion parameters
were all very large (large values imply no overdispersion).
Figure 6.1 presents a plot of the estimated versus the true cell type composition fractions
and corresponding linear regression curves for white blood cells, liver, and placenta in the 18
DNA mixture tissues. Each point on the figure corresponds to the estimate from one of the
18 samples. The true composition fractions were assumed to equal the DNA fraction used in
the mixtures as reported by Sun et al. (2015). The quadratic programming approach resulted in
consistent over estimation of the white blood cell fraction in cases where the true fraction was small.
Correspondingly, there was consistent under estimation of the liver fraction when the true fraction
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Figure 6.1: Estimated cell type composition in 18 DNA mixture tissues
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Table 6.1: DNA Mixture tissue composition fraction estimate quality
Quadratic Overdispersed Simple
Programming Deconvolution Model Deconvolution Model
Cell Type MAD Ratio MAD Ratio MAD
White Blood Cells 0.042 2.341 0.023 1.272 0.018
Liver 0.060 1.864 0.033 1.025 0.032
Placenta 0.033 1.914 0.043 2.452 0.017
was large. Results from the simple deconvolution model and the overdispersed deconvolution model
(to a lesser extent), corrected this bias.
To provide a more quantitative assessment of the relative quality of the estimates provided by
the simple deconvolution model, we computed the mean absolute deviation (MAD) for the esti-
mated composition fraction for each cell type relative to the true composition fraction using each
of the three approaches discussed. Table 6.1 provides the mean absolute deviations as well as the
ratio of the mean absolute deviations for the other two methods to the mean absolute deviation
from the simple deconvolution model. We see that estimates based on the simple deconvolution
model are more accurate on average than those from the other two approaches. The mean absolute
deviation from the quadratic programming approach is approximately twice that from the simple
deconvolution model for each cell type. The mean absolute deviation for the overdispersed decon-
volution model is nearly the same as that from the the simple deconvolution model for liver cells
but is worse than both other methods for placenta cells.
6.4 Estimation of Tissue Composition and Cell Type-Specific Methylation in
Simulation Studies
In the DNA mixture example from Section 6.3, we were not able to assess the relative quality
of the simple deconvolution model estimates for the cell type-specific methylation probabilities. In
this section we use simulation studies to demonstrate that the estimates for this set of parameters
(and composition fractions) can improve significantly when one incorporates information from het-
erogeneous tissues through deconvolution. To accomplish this, we compare the quality of estimates
based on the simple deconvolution model to those obtained from the overdispersed deconvolution
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model and from quadratic programming. Note that all three methods allow estimation of the tissue
composition fractions but the quadratic programming approach does not produce estimates of the
cell type-specific methylation probabilities. Thus, for these parameters, we compare estimates from
the two deconvolution methods to the proportion of methylated calls in the reference samples.
We simulated bisulfite sequencing data for 25 independent studies, each with G = 1000 loci and
N = 30 heterogeneous tissue samples. The heterogeneous tissues were simulated to have neutrophil,
B cell, CD4+T cell, CD8+T cell, and placenta fractions. The composition of the heterogeneous
tissues was simulated so that the tissues were 40% neutrophils, 30% placenta, 10% B cells, 10%
CD4+T cells, and 10% CD8+T cells, on average. This composition is roughly consistent with blood
samples taken from pregnant females. The 1,000 loci were randomly selected from the set of 5,280
loci identified by Sun et al. (2015). Using the reference tissue samples discussed in Section 6.3,
we set the cell-type specific methylation probabilities at each locus equal to the proportion of
methylated calls at the locus in the reference tissue sample. For each simulated heterogeneous
tissue sample, the sequencing depth at each locus was randomly drawn from a Poisson distribution
having mean parameter equal to the average sequencing depth at the locus from the DNA mixture
tissues discussed in Section 6.3. The sequencing depth in each simulated reference tissue sample
was set to the sequencing depth in the actual reference tissue sample discussed in Section 6.3. A
single reference sample was simulated for each cell type (independently for each simulation study).
The methylation calls for the set of DNA molecules covering a locus (from a given cell type) were
simulated using a beta-binomial model having an overdispersion parameter value of 30 (larger values
mean less variability). The chosen value of the dispersion parameter corresponds to a relatively
large but realistic amount of overdispersion (Feng et al., 2014).
For the weighted EM algorithm, we weighted each reference sample as described in Section 6.3.
The quadratic programming approach was implemented as described in Section 6.3 (to estimate
composition fractions). In these simulations, data were generated from the overdispersed deconvo-
lution model. Thus, if there is a benefit to fitting that model using a variational EM algorithm,
we would expect to observe better estimates compared to the simple deconvolution model. We will
see that is not the case.
99
Estimated Composition Fraction
Tr
ue
 C
om
po
si
tio
n 
Fr
ac
tio
n
0.00 0.750.00 0.750.00 0.750.00 0.750.00 0.75
0.00
0.75
0.00
0.75
0.00
0.75
PlacentaCD8 + T cellsCD4 + T cellsB cellsNeutrophils
W
ei
gh
te
d 
EM
Va
ria
tio
na
l E
M
Q
ua
d.
 P
ro
g.
Figure 6.2: Estimated cell type composition in simulated heterogeneous tissues
Figure 6.2 presents a plot of the estimated versus true cell type composition fractions and
corresponding linear regression curves for a randomly selected subset of 250 (out of 750) simulated
heterogeneous tissues. Each point on the figure corresponds to the estimated composition fraction
for a particular cell type for one of the selected samples. While estimates from all three methods
appear qualitatively similar for every cell type, one can clearly see that the estimates from the simple
deconvolution model have less bias than the estimates from the other two methods for the neutrophil
fraction. The other obvious observation is that none of the three methods do well at estimating the
fraction of CD4+T cells and CD8+T cells. This is not surprising since the methylation signatures
for these two cell types are highly similar (Reinius et al., 2012). This suggests that including
reference samples for cell types that do not have unique methylation signatures may not adversely
100
Table 6.2: Tissue composition fraction estimate quality
Quadratic Overdispersed Simple
Programming Deconvolution Model Deconvolution Model
Cell Type MAD Ratio MAD Ratio MAD
Neutrophils 0.031 2.083 0.039 2.595 0.015
B cells 0.017 1.607 0.030 2.804 0.011
CD4+T cells 0.031 1.061 0.027 0.928 0.029
CD8+T cells 0.025 1.006 0.023 0.943 0.025
Placenta 0.011 1.957 0.010 1.697 0.006
Table 6.3: Cell type-specific methylation estimate quality
Overdispersed Simple
Reference Only Deconvolution Model Deconvolution Model
Cell Type MAD Ratio MAD Ratio MAD
Neutrophils 0.0017 1.434 0.0014 1.197 0.0012
B cells 0.0020 1.045 0.0020 1.034 0.0019
CD4+T cells 0.0020 1.048 0.0020 1.070 0.0019
CD8+T cells 0.0021 1.035 0.0022 1.106 0.0020
Placenta 0.0023 1.433 0.0016 1.159 0.0016
effect parameter estimates for cell types that do. In cases where it is of interest to study methylation
from a solid tissue (e.g. placenta or liver) using blood samples, this property is quite appealing.
Table 6.2 provides the average mean absolute deviation of the composition fraction estimates
for each cell type and deconvolution method. The average was computed over the 25 simulation
studies using all simulated heterogeneous tissue samples. For the quadratic programming and
overdispersed deconvolution model approaches, the ratio of the average mean absolute deviation to
the corresponding average mean absolute deviation from the simple deconvolution model is provided
as well. For neutrophils, B cells, and placenta, the composition fraction estimates based on the
simple deconvolution model are appreciably better (on average) than those from the other two
methods. For CD4+T cells and CD8+T cells, the estimates from all three deconvolution methods
are comparable.
Table 6.3 provides similar information for the cell type-specific methylation probability estimates
for each deconvolution method. For neutrophils and placenta, on average the estimates based on
the simple deconvolution model are appreciably better than those based entirely on the reference
samples and modestly better than those from the overdispersed deconvolution model. The fact
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that the simple deconvolution model improves estimates for neutrophils and placenta methylation
probabilities more than for the other cell types is expected. Since, B cells, CD4+T cells, and
CD8+T cells each only represent 10% of the heterogeneous tissue samples, one should not expect
the same level of improvement as seen in neutrophils and placenta, which represented 40% and
30% of the heterogeneous tissue samples, respectively. There is simply less information in the
heterogeneous tissue samples about methylation levels in B cells, CD4+T cells, and CD8+T cells.
6.5 Discussion
In this chapter we developed a reference-based deconvolution model for DNA methylation data
and proposed an easy-to-implement EM algorithm that can be used to fit the model. Using real and
simulated data, we compared the quality of the tissue composition fraction estimates based on the
proposed deconvolution model to those based on a quadratic programming approach and based on
an overdispersed deconvolution model. Using simulated data, we also compared the quality of the
cell-type specific methylation probability estimates based on the proposed deconvolution model to
those based on the overdispersed deconvolution model and to those based only on reference samples.
We observed that the estimates produced by our deconvolution model were seemingly always better
than those produced by the other approaches considered. These results suggest that the proposed
deconvolution model could be a valuable alternative to quadratic programming techniques for tissue
composition estimation.
In our results from Section 6.4 we noted that all methods considered were unable to estimate
the composition of CD4+T cells and CD8+T cells and we posited that this is because of the
similarity of the methylation signatures for these cell types. It is clear that incorporation of both
those cell types in the deconvolution model did not adversely effect composition estimation (or
methylation probability estimation) for neutrophils or placenta which both are known to have
unique methylation signatures and which both represented larger fractions of the heterogeneous
tissues. This suggests that one might choose a conservative set of blood cell references (e.g. B cells,
T cells, neutrophils, monocytes, eosinophils, etc.) to include in the deconvolution model when the
goal is to estimate the blood composition fraction or methylation levels of a tissue like placenta
102
or liver whose DNA can be found in blood in reasonable amounts. For example, if the goal of a
hypothetical study is to associate a fetal disease phenotype with differential placental methylation,
it would seem possible to do this with the proposed deconvolution model using a set of blood
cell reference tissues, one reference placenta tissue for a case, one reference placenta tissue for a
control, and then a larger number of heterogeneous blood tissue samples from pregnant mothers.
A hypothesis testing framework for this type of problem is a topic of future work.
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CHAPTER 7: FUTURE WORK
7.1 Bayesian Clinical Trial Design
There are a variety of ways that the methods we have developed for Bayesian clinical trial design
can be extended. First, there is the obvious extension of the methodology developed in Chapters
3 and 4 to other, more advanced types of historical data. Our work thus far has focused on basic
time-to-event data but there is significant interest in recurrent events data with a terminating death
event (Rondeau, 2010) and data with a survival and non-survival component (Ibrahim et al., 2010).
Each of these types of data is associated with a more complicated statistical model than what we
considered in Chapters 3 and 4. Due to this added complexity, customized approaches are needed
to make Bayesian design computationally feasible.
The adaptive design methodology that we developed in Chapter 5 can also be extended to
accommodate more advanced data types (at least in the case of the all-or-nothing adaptive design).
In addition to extending the proposed adaptive design methods to other data types, one might also
consider alternative criteria for when the study should be stopped. One promising idea is to use
the prior predictive distribution for the data to assess prior-data conflict (Evans et al., 2006). This
approach would seem more Bayesian than what we have proposed but its application has not been
considered outside of very simple models.
The all-or-nothing adaptive design would seem widely applicable in situations where a single
historical study is available. While the notion of using an informative prior and checking the
exchangeability assumption at an interim analysis is intuitive, it has not been widely adopted. Our
adaptive design results demonstrate that such an approach may be as effective as more complicated
procedures that attempt dynamic information borrowing. In our opinion there is much that can be
done within the framework of the all-or-nothing adaptive design due to relative simplicity of that
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approach.
7.2 DNA Methylation Deconvolution
Our work to date on the DNA methylation deconvolution problem serves as a proof-of-concept
for the idea that one can learn about cell type-specific methylation levels through the process of
deconvolution beyond what is known from reference samples. Our long-term goal is to develop a
hypothesis testing framework that can be used to identify differential cell type-specific methylation
for one or more conditions under study using heterogeneous tissue samples. Exploring the extent
to which this type of approach requires reference samples for each condition under study is an
important intermediate goal. If reference samples are required for each condition, the practicality
of such a method may be limited. However, if under reasonable assumptions it is sufficient to have
reference tissue samples for only the healthy condition, a method of this type could prove valuable.
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APPENDIX A: CHAPTER 3 SUPPLEMENTAL MATERIALS
A.1 Type I Error Control with Informative Priors
For this example we suppose data D = {xi, i = 1, ..., Nx} from Nx subjects are available for
the new study and that Xi ∼ Normal
(
µ, σ2
)
for i = 1, ..., Nx with σ
2 known. We consider testing
the interval null hypothesis as H0 : µ ≤ 0 versus alternative H1 : µ > 0. Further suppose historical
data D0 = {yi, i = 1, ..., Ny} are available form subjects assumed to be exchangeable with those
from the new study. Based on assuming the objective initial prior pi0 (µ) ∝ 1, the basic power prior
has the form
pi0
(
µ
∣∣D0, a0) ∼ Normal(Y¯ , σ2
Nya0
)
(A.1.1)
where Y¯ is the sample mean based on the historical study subjects. Thus, the value of a0 has the
interpretation as the fraction of information (i.e. Fisher Information) that is borrowed from the
historical study. The corresponding posterior distribution is straight forward to derive and is given
as follows:
pi (µ |D,D0, a0) ∝ Normal
(
µ∗, σ2∗
)
with
σ2∗ =
1
Nx
σ2
+
Nya0
σ2
and
µ2∗ = σ
2
∗
(
Nx
σ2
· X¯ + Nya0
σ2
· Y¯
)
where X¯ is the sample mean from new study. We will accept the alternative hypothesis when
P (µ > 0 |D,D0, a0) ≥ φa0
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where φa0 is the posterior probability critical value associated with the chosen value of a0. We
want to compare the statistical power associated with different values of a0 when the posterior
probability critical values are chosen to provide a test procedure that controls the frequentist type
I error rate at level α. First, we consider the case where no information is borrow so that we are
effectively performing an objective Bayesian analysis of the new data. We show that the Bayesian
test is equivalent to the frequentist uniformly most powerful (UMP) test.
Lemma A.1.1. Inference based on the Bayesian rejection rule
P (µ > 0 |D,D0, a0 = 0) ≡ P (µ > 0 |D) ≥ φ0
is identical to the frequentist one-sided, level α UMP test when φ0 is 1− α.
Proof. In this setting we view the posterior probability as a test statistic in the sense that it is
simply a random function of the data. The type I error rate of the test is
E [1 {P (µ > 0 |D) ≥ φ0} | µtrue = 0] (A.1.2)
where the expectation is with respect to the data D. We want to find φ0 so that (A.1.2) is equal
to α. To do this we manipulate the quantity inside the indicator to show that it is equivalent to
the frequentist UMP rejection criteria. Note that in the posterior probability, the data are fixed
and not random. We have that
P (µ > 0 |D) ≥ φ0 ⇐⇒ P
(
µ− X¯
σ√
Nx
>
−X¯
σ√
Nx
∣∣∣∣D
)
≥ φ0
⇐⇒ P
(
Z1 >
−X¯
σ√
Nx
∣∣∣∣D
)
≥ φ0
⇐⇒ P
(
Z2 <
X¯
σ√
Nx
∣∣∣∣D
)
≥ φ0
⇐⇒ Φ
(
X¯
σ√
Nx
)
≥ φ0
⇐⇒ X¯ − 0σ√
Nx
≥ Φ−1 (φ0) (A.1.3)
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where Z1 and Z2 are standard normal random variables. The expression in (A.1.3) is precisely
the rejection rule for the one-sided normal UMP test. Thus, the optimal choice of φ0 satisfies
Φ−1 (φ0) = Z1−α which implies φ0 = 1− α.
We have shown that for a0 = 0 the most powerful (unbiased) Bayesian test procedure requires
φ0 = 1 − α. It should be intuitive that for a0 > 0 we must then have φa0 > 1 − α in order to
maintain control type I error (when Y¯ > 0). We show this now.
Lemma A.1.2. In order for inference based on the Bayesian rejection rule
P (µ > 0 |D,D0, a0) ≥ φa0
to control type I error at level α when the true mean is zero, we must have
φa0 = Φ
[(
Φ−1(1− α)
σ√
Nx
+
Y¯
σ2
Ny ·a0
)
σ∗
]
> 1− α. (A.1.4)
Proof. We must solve the equation
E [1 {P (µ > 0 |D,D0, a0) ≥ φa0} | µtrue = 0,D0, a0] = α
for φa0 . Just as before, we manipulate the posterior probability. We have the following:
P (µ > 0 |D,D0, a0) ≥ φa0 ⇐⇒ P
(
µ− µ∗
σ∗
>
−µ∗
σ∗
∣∣∣∣D,D0, a0) ≥ φa0
⇐⇒ P
(
Z1 >
−µ∗
σ∗
∣∣∣∣D,D0, a0) ≥ φa0
⇐⇒ P
(
Z2 <
µ∗
σ∗
∣∣∣∣D,D0, a0) ≥ φa0
⇐⇒ Φ
(
µ∗
σ∗
)
≥ φa0
⇐⇒ X¯
σ2
Nx
+
Y¯
σ2
Ny ·a0
≥ Φ
−1 (φa0)
σ∗
⇐⇒ X¯ − 0σ√
Nx
≥ σ√
Nx
(
Φ−1 (φa0)
σ∗
− Y¯
σ2
Ny ·a0
)
(A.1.5)
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The expression in (A.1.5) is precisely the rejection rule for the one-sided frequentist UMP test.
Thus, for the Bayesian decision rule to be optimal, φa0 must satisfy the following equation.
Z1−α = Φ−1 (1− α) = σ√
Nx
(
Φ−1 (φa0)
σ∗
− Y¯
σ2
Ny ·a0
)
(A.1.6)
To obtain the equality in (A.1.4), one must simply solve (A.1.6) for φa0 . To show that φa0 > 1−α,
we reformulate the expression given in (A.1.4) as follows.
φa0 = Φ
[(
Φ−1(1− α)
σ√
Nx
+
Y¯
σ2
Ny ·a0
)
σ∗
]
= Φ
[
Φ−1(1− α)
(
1
σ√
Nx
+
Y¯
σ2
Ny ·a0 · Φ−1(1− α)
)√
1
Nx
σ2
+
Ny ·a0
σ2
]
= Φ
[
Φ−1(1− α) · h (a0)
]
It is enough to show that h(a0) is increasing in a0 and that lima0→0 h(a0) = 1 for fixed Y¯ > 0.
Doing so is straightforward and is omitted for brevity.
Thus far we have shown that incorporating any amount of prior information that favors the
alternative hypothesis will inflate the type I error of the test procedure unless we increase the
posterior probability critical value to the quantity defined by φa0 . Now we show that by using the
correct posterior probability critical value to control type I error we effectively discard all prior
information resulting in a power function identical to that obtained by the Bayesian analysis with
a0 = 0.
Theorem 0.1. The power functions for the set of Bayesian hypothesis tests based on the rejection
rules {P (µ > 0 |D,D0, a0) ≥ φa0 : a0 ∈ [0, 1]} are identical. Hence, all prior information is effec-
tively discarded when the rejection rule based on a0 > 0 is calibrated to ensure frequentist I error
control.
Proof. The power function associated with a fixed value of a0 and corresponding posterior proba-
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bility critical value φa0 is given as follows:
E [1 {P (µ > 0 |D,D0, a0) ≥ φa0} |D0, a0, µtrue] (A.1.7)
where the expectation is taken with respect to the distribution for the new data D. To show
equality of the power functions for all a0, it is enough to show that the power function for an
arbitrary a0 is the same as the power function for a0 = 0. Further, it is enough to show equality of
the corresponding events in the indicator functions since the expectations are with respect to the
same distribution for the data.
P (µ > 0 |D,D0, a0) ≥ φa0 ⇐⇒ Φ
(
µ∗
σ∗
)
≥ Φ
[(
Φ−1(1− α)
σ√
Nx
+
Y¯
σ2
Ny ·a0
)
σ∗
]
⇐⇒ µ
∗
σ∗
≥
(
Φ−1(1− α)
σ√
Nx
+
Y¯
σ2
Ny ·a0
)
σ∗
⇐⇒ X¯
σ2
Nx
+
Y¯
σ2
Ny ·a0
≥ Φ
−1(1− α)
σ√
Nx
+
Y¯
σ2
Ny ·a0
⇐⇒ X¯ − 0σ√
Nx
≥ Φ−1(1− α)
⇐⇒ P (µ > 0 |D) ≥ φ0
We have shown in a simple case that when an informative prior is used in a Bayesian analysis
where the decision rule is calibrated to control type I error in the frequentist sense, all prior
information is effectively discarded resulting in a test procedure that is identical to Bayesian analysis
with a objective prior, or in this case, the frequentist UMP test. Although the results derived are
for a very simple model, it is likely the behavior holds in all cases for which a level α hypothesis
test is available.
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A.2 Bayesian Design with Unshared Parameters
In this appendix we derived the marginal posterior for the hazard ratio regression parameters
for the scenario where the historical study model and the new study model have an identical set of
parameters. We refer to this scenario as the identical model scenario (IM). This will not always be
the case. In this section, we derive the marginal posterior for the hazard ratio regression parameters
in two additional scenarios that may be of interest to practitioners.
In the first scenario, we assume that the baseline hazard differs between the historical study and
the new study so that only the hazard ratio regression parameters are shared between the models.
We refer to this scenario as the shared hazard ratio scenario (SHR). This scenario might arise when
one wishes to provide a mechanism for the historical and new studies to differ systematically in
terms of baseline risk yet still allow information borrowing through the hazard ratio regression
parameters where it is reasonable to assume a common effect across studies. For example, one may
choose to stratify by geographic region in an effort to account for temporal changes in baseline
risk and adjust for more concrete biomarkers in the hazard ratio regression model. In the second
scenario we assume that only information about the baseline hazard (i.e. control group) is to be
borrowed. We refer to this scenario as the shared baseline hazard scenario (SBH). This scenario
might arise when the historical study targeted the same disease population that is to be targeted
in the new study and when the investigational therapies are not the same. In both the SHR and
SBH scenarios we will see that the marginal posterior for the hazard ratio regression parameters
is of the same form as that obtained in the IM scenario. Thus, from a software implementation
standpoint, a tool that can be used to perform Bayesian design for the IM scenario can address all
other design scenarios one might want to consider.
The SHR Scenario
In this scenario we assume the baseline hazard for the historical study is allowed to vary across
S0 levels of a stratification variable. We partition the time axis into Ks,0 intervals for stratum s.
Denote the baseline hazard parameters for the historical study model by λ0 and let θ0 = (λ0, γ,β)
be the complete set of parameters in that model. The power prior is simply the marginal posterior
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for the hazard ratio regression parameters based on the exponentiated historical study likelihood
multiplied by the initial prior for the new study baseline hazard.
pi0
(
λ, γ,β
∣∣D0, α0) ∝ pi0 (γ,β∣∣D0, α0)× pi0 (λ)
∝
S0∏
s=1
{ ∏
j∈Gs,0 φ
α0νj,0
j∏Ks,0
k=1 [βsk,0]
αsk,0
}
× pi0 (λ)
It follows that the marginal posterior distribution for the hazard ratio regression parameters after
observing observing new data is as follows:
pi (γ,β |D,D0, α0) ∝
S∏
s=1
{ ∏
i∈Gs φ
νi,0
i∏Ks
k=1 [βsk]
αsk
}
×
S0∏
s=1
{ ∏
j∈Gs,0 φ
α0νj,0
j∏Ks,0
k=1 [βsk,0]
αsk,0
}
.
This result is identical in form to that obtained for the IM scenario when we imagine there being a
single stratification variable having S + S0 levels. Thus, we might equivalently consider this an IM
scenario with parameter vector θ = (λ,λ0, γ,β) where not every parameter is informed by both
studies.
The SBH Scenario
In this case we assume that the hazard ratio regression function φ only consists of a treatment
effect (i.e. φi = e
γ or φi = 1 for all i). The historical study dataset can be reduced to the set of
subjects that belong to the control group. The marginal posterior for γ is as follows:
pi (γ |D,D0, α0) ∝
S∏
s=1
{ ∏
i∈Gs φ
νi
i∏Ks
k=1
[
β∗sk
]α∗sk
}
where α∗sk = αsk + α0
∑
j∈Gs,0 νjk,0 and β
∗
sk = βsk + α0
∑
j∈Gs,0 rjk,0 with Gs,0 now representing the
set of indices for the historical control subjects from stratum s. As with the SHR scenario, the
form of the posterior distribution in the SBH scenario is of the same family as the IM scenario.
One important consideration for the SBH scenario is that by only borrowing information on the
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control group, we may create imbalances in risk factors between the treated and control subjects.
That is to say, by incorporating historical control subjects that were not randomized alongside new
study subjects, the benefit of randomization in the new study is lost and it becomes important to
account for known risk factors in the statistical analysis. Thus, choosing risk factors for stratification
(or covariate adjustment) is critically important in the SBH scenario.
A.3 A Simulation Study Comparing Inference Based on the PWC-PH model
with Inference Based on the Weighted Cox Partial Likelihood
For the simulation studies in this appendix we used the same historical dataset that was used
in the example application from Section 6 of the primary text. The number of baseline hazard
components and the change points for the analysis model where taken from the best historical
study model determined by DIC. The parameter values for the new study model were fixed at the
posterior means reported in Table 2 of the primary text. The following characteristics were varied
in the stimulation studies:
1. Number of new events ν = 100, 300, and 500 with n = 3ν enrolled subjects
2. Ks = 3, 10, and 50 for both s = 1 and s = 2
3. a0 = 0.0, 0.5, and 1.0
Enrollment was assumed to be uniform over a 2 year period. Censorship times were simulated from
a scaled beta distribution with shape parameters equal to 3 and 1 with support on the interval
(0, 10). Administrative censoring occurred at the time when the targeted number of events had
been reached. Thus, there was a substantial amount of censoring in the simulated datasets. We
performed B = 1, 000 simulation studies at each of the 27 combinations of the characteristics being
varied and computed two summaries of agreement. First, we computed the R2 value based on
regressing the log
[
P
(
γ < 0
∣∣D(b),D0, a0)] values computed using the normal approximation to
the PWC-PH posterior onto the corresponding quantities computed using the weighted Cox partial
likelihood. Second, we computed the percentage of study decisions that were concordant between
the two approaches. Study decisions were concordant if 1
{
P
(
γ < 0
∣∣D(b),D0, a0) ≥ ψ} was equal
113
Table A.1: Summary of inference agreement using the PWC-PH model and the weighted Cox
partial likelihood
—– Ks = 3 —– —– Ks = 10 —– —– Ks = 50 —–
ν a0 R
2 % Concordant R2 % Concordant R2 % Concordant
100 0.0 0.98907 96.7 0.99725 98.7 0.99855 99.2
100 0.5 0.99060 96.7 0.99435 97.0 0.99474 96.9
100 1.0 0.97206 94.1 0.97506 94.2 0.97519 94.2
300 0.0 0.98663 96.8 0.99767 98.8 0.99957 99.4
300 0.5 0.99493 97.4 0.99871 98.6 0.99928 98.6
300 1.0 0.98399 97.9 0.98939 98.6 0.98924 98.5
500 0.0 0.99289 98.3 0.99932 99.5 0.99985 99.9
500 0.5 0.99214 99.1 0.99775 99.3 0.99887 99.7
500 1.0 0.98792 99.2 0.99461 98.9 0.99500 99.2
for both approaches. Analysis using the weighted Cox partial likelihood were performed using the
SAS PHREG Procedure (v9.4). Appendix Table A.1 presents the results of our simulation studies.
We see that there is strong agreement in the posterior probabilities used for inference despite the
the fact that the assumptions used to establish the connection between the PWC-PH model and the
weighted Cox partial likelihood do not hold for the simulation studies. We note a slight decrease in
both metrics of agreement as a0 increases for the case where ν = 100. This is likely attributable to
the fact that these analyses include more historical data than new study data and the fact that the
historical data is not perfectly consistent with a proportional hazards assumption. It is clear that
when the proportional hazards assumption holds definitively (a0 = 0) and the number of baseline
hazard components is large, there is near perfect agreement between the methods at all samples
sizes considered.
Lastly, since there is strong agreement between inference based on the PWC-PH model and the
weighted Cox partial likelihood for both large and small K, one can infer that inference on the
hazard ratio regression parameters is robust to the model for the baseline hazard.This suggests that
even a fairly coarse partition of the time axis will suffice when one in not concerned with estimating
the baseline hazard (such as in the design phase of a trial).
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A.4 A Simulation Study Comparing Exact Bayesian Inference Through MCMC
with the Laplace Approximation
This appendix is divided into two sections. In the first section we describe our procedure for
analysis of the PWC-PH model using MCMC methods. Our approach attempts to make the model
fitting step as efficient as possible for scenarios where using MCMC might be preferred in design.
Our MCMC implementation also serves as a tool to fit a model to historical data in order to obtain
samples from the posterior that can be used to create discrete approximations of the sampling
priors. In the second section we provide results from our simulation studies comparing analyses
using MCMC to analyses using the proposed normal approximation to the marginal posterior of
the hazard ratio parameters.
A.4.1 High Throughput Model Fitting with MCMC
In this section we discuss a reformulation of the marginal posterior for the hazard ratio pa-
rameters that is beneficial for MCMC model fitting when the design variables (treatment indicator
and covariates) are binary and few in number. This will commonly be the case during design of
a clinical trial. In this case, one can write the posterior distribution as a function of a relatively
small set of sufficient statistics to which the simulated subject level data can be reduced prior to
model fitting.
Let d index the set of D distinct values of the design variables observed in the combined
historical study and new study datasets. Write φd = exp
(
γz∗d + β
Tx∗d
)
, where (z∗d,x
∗
d) are the
particular values of the design variables identified by d. Let νskd and rskd be the number of events
and total time at risk in interval k for the set of new study subjects in stratum s that had design
variable values identified by d. Let νskd,0 and rskd,0 be the analogous quantities for the historical
study. The marginal posterior (3.3.4) reduces to
pi (γ,β |D,D0, a0) ∝
∏D
d=1 φ
ν∗d
d∏S
s=1
∏Ks
k=1
[
β∗sk
]α∗sk (A.4.1)
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where
ν∗d =
S∑
s=1
Ks∑
k=1
(νskd + a0νskd,0) ,
α∗sk =
D∑
d=1
(νskd + a0νskd,0) , and
β∗sk =
D∑
d=1
φd (rskd + a0rskd,0) .
Thus, one only needs the set of sufficient statistics {(νskd, rskd, νskd,0, rskd,0) : ∀s, k, d} and {(z∗d,x∗d) : ∀d}
in order to evaluate the marginal posterior for MCMC sampling. When D  n+ n0, an approach
using the sufficient statistics is far superior to the straight forward approach using subject level
data. In our implementation we first reduce each simulated dataset to the sufficient statistics and
the perform MCMC model fitting using (A.4.1). Our implementation supports an arbitrary number
of binary covariates.
When the covariates are restricted to be binary it is straight forward to show that the full
conditional distribution for each of the hazard ratio parameters is log-concave. Thus, one can
use rejection sampling or adaptive rejection sampling (W. R. Gilks, 1992) to sample from the full
conditionals. In our implementation we utilize a simple Newton-Raphson algorithm to locate the
mode of the full conditional and then construct a three-part envelope function centered about the
mode for rejection sampling. We use the optimal envelope under the assumption of normality for
the full conditional. Since we only need to draw one sample at each Gibbs step and since so few
samples actually get rejected, we find that it is not necessary to adapt the envelope.
A.4.2 A Comparison of MCMC Analysis Results with Results based on the
Laplace Approximation
For the simulation studies in this section we used the same historical data set as was used in
the example application in Section 3.5. The number of baseline hazard components and the change
points for the new study model where taken from the best historical study model determined by
DIC. The parameter values for the new study model were fixed at the posterior means reported in
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Table A.2: Summary of inference agreement using MCMC and the Laplace approximation
—– K = 3 —– —– K = 10 —– —– K = 25 —–
ν a0 R
2 % Concordant R2 % Concordant R2 % Concordant
40 0.0 0.9996 99.4 0.9995 99.1 0.9995 99.2
40 0.5 0.9999 98.4 0.9999 98.6 0.9999 99.6
40 1.0 0.9999 98.5 0.9998 99.2 0.9998 99.4
80 0.0 0.9999 99.3 0.9998 99.3 0.9999 99.1
80 0.5 0.9999 99.5 0.9999 99.4 0.9999 98.9
80 1.0 0.9999 99.2 0.9999 99.4 0.9999 99.2
120 0.0 0.9999 99.5 0.9999 99.7 0.9999 99.3
120 0.5 0.9999 99.3 0.9999 99.6 0.9999 99.1
120 1.0 0.9999 99.3 0.9999 99.6 0.9999 99.4
Table 3.2. The following parameters were varied in the stimulation studies:
1. Number of new events ν = 40, 80, and 120 with n = 3ν enrolled subjects
2. Ks = 3, 10, and 25 for both s = 1 and s = 2
3. a0 = 0.0, 0.5, and 1.0
Enrollment was assumed to be uniform over a 2 year period. Administrative censoring occurred
at the time when the targeted number of events had been reached. No other censoring mechanism
was simulated. We performed B = 1, 000 simulation studies at each of the 27 combinations of the
parameters being varied and computed two summaries of agreement. First, we computed the R2
value based on regressing the log
[
P
(
γ < 0
∣∣D(b),D0, a0)] values computed using the normal ap-
proximation onto the corresponding quantities computed using MCMC (based on 100, 000 MCMC
samples). Second, we computed the percentage of study decisions that were concordant between
the two approaches. Study decisions were concordant if 1
{
P
(
γ < 0
∣∣D(b),D0, a0) ≥ ψ} was equal
for both approaches. Appendix Table A.2 presents the results of our simulation studies. For a0 = 0,
the analysis does not use any of the historical data and so the case where ν = 40 and a0 = 0 gives
good insight into small sample performance. It appears the normal approximation is valid even
when the sample size is much smaller than what will be encountered in an adequately powered
clinical trial. For all cases the R2 value was near 1.0 and the concordance between the methods
was never below 98%.
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APPENDIX B: CHAPTER 4 SUPPLEMENTAL MATERIALS
B.1 A Simulation Study Comparing Bayesian Inference using MCMC with the
Weighted Maximum Likelihood Approximation
For the simulation studies in this appendix, we used the same historical data set that was used
in the example application from Section 4.5 of the paper. Inference using MCMC methods was
based on 50,000 samples with a 1,000 sample tuning phase for the slice sampler and a post-tuning
burn-in phase of 100 samples. A uniform improper prior was used for the regression parameters
and a Gamma (0.001, 0.001) prior was used for each of the parameters in the promotion time model.
Note that in the weighted maximum likelihood (ML) approximation, the prior is not incorporated.
The following characteristics were varied in the simulation studies: sampling prior (default null
and default alternative), a0 (0.0 and 1.0), and n (550 and 800). All other characteristics of the
simulations (e.g. enrollment distribution) matched that described in the paper. We performed
B = 1, 000 simulation studies at each of the 8 combinations of the characteristics being varied and
computed two summaries of agreement. First, we computed the R2 value based on regressing the
P
(
γ < 0
∣∣D(b),D0, a0) values computed using the weighted maximum likelihood approximation
onto the corresponding quantities computed using MCMC. Second, we computed the percentage of
study decisions that were concordant between the two approaches. Study decisions were concordant
if 1
{
P
(
γ < 0
∣∣D(b),D0, a0) ≥ ψ} was equal for both approaches. Appendix Table B.1 presents
the results of our simulation studies. We see that there is near exact agreement between the
posterior probabilities as well as the simulated outcomes. This suggests that the weighted maximum
Table B.1: Summary of inference agreement using MCMC and the weighted maximum likelihood
approximation
– Default Alternative – – Default Null –
n a0 % Concordant R
2 % Concordant R2
550 0.0 99.5 0.999894 99.9 0.999884
550 1.0 99.6 0.999721 99.9 0.999840
800 0.0 99.4 0.999929 99.9 0.999902
800 1.0 99.8 0.999830 99.9 0.999879
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likelihood approximation is justified for the sample sizes considered in this paper.
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APPENDIX C: CHAPTER 5 SUPPLEMENTAL MATERIALS
C.1 Integral Computation for the Restricted Maximal Borrowing Power Prior
In this appendix we develop a highly accurate approximation for the integral in (5.4.4) which
is given by ∫
[L(β,λ|D0)]a0 [L(β,λ|D0)]δ pi0(β,λ)d (β,λ)
where [L(β,λ|D0)]δ is the likelihood for the new CVOT under the assumption of perfect homogene-
ity with the historical CVOT. For this derivation we take pi0(β,λ) = pi0(β)×pi0(λ) with pi0(β) ∝ 1
and pi0(λ) ∝
∏S
s=1
∏Ks
k=1 λ
−1
sk . Using notation similar to (3.2.2), the integrand can be written as
follows:
[L(β,λ|D0)]a0+δ pi0(β,λ) ∝
S∏
s=1
Ks∏
k=1
λ
(a0+δ)αsk,0−1
sk e
−(a0+δ)βsk,0λsk ×
(
n0∏
i=1
φνi0i
)(a0+δ)
(C.1.1)
where αsk,0 =
∑
i∈Gs ν
k
i0 is the total number of events for historical CVOT subjects from stratum s
occurring in interval Is,k, φi = exp
(
γzi + β
Txi
)
is the hazard ratio regression function for historical
CVOT subject i, βsk,0 =
∑
i∈Gs φir
k
i0, and D0 = {(yi0, νi0, zi,xi) : i = 1, ..., n} is the observed data
from the historical CVOT. It is straight forward to integrate out the baseline hazard in (C.1.1) and
doing so yields the expression
S∏
s=1
Ks∏
k=1
Γ ((a0 + δ)αsk,0)
(a0 + δ)
(a0+δ)αsk,0
× f (β∣∣a0,D,D0) (C.1.2)
where
f
(
β
∣∣a0,D,D0) = ( ∏n0i=1 φνi0i∏S
s=1
∏Ks
k=1 β
αsk,0
sk,0
)a0+δ
.
When the number of combined events in the CVOTs are not very small, the term being ex-
ponentiated in f
(
β
∣∣a0,D,D0) is proportional to a multivariate normal density with mean βˆ and
covariance matrix of Σˆ that only depend on D0. It follows that f
(
β
∣∣a0,D,D0) is proportional to
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a multivariate normal density with the same mean and covariance matrix Σˆa0+δ . Thus,
p
(
β
∣∣a0,D,D0) = f (β∣∣a0,D,D0)
f
(
βˆ
∣∣a0,D,D0)
∣∣∣Σˆ∣∣∣−1/2 (a0 + δ)p/2 (2pi)−p/2
is approximately a multivariate normal density. Based on this, one can easily integrate β out of
(C.1.2) to obtain the following expression which discards any term that does not depend on a0.
∫
[L(β,λ|D0)]a0 [L(β,λ|D0)]δ pi0(β,λ)d (β,λ) ∝
S∏
s=1
Ks∏
k=1
Γ ((a0 + δ)αsk,0)
(a0 + δ)
(a0+δ)αsk,0
f
(
βˆ
∣∣a0,D,D0)
(a0 + δ)
p/2
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